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"Nuclear Magnetic Resonance for the Characterisation of Hot-Melt
Extruded Pharmaceutical Amorphous Solid Dispersions"
Elena Pisa Chen
Low aqueous solubility of active pharmaceutical ingredients (APIs) presents one the
greatest and most frequent challenges to formulation scientists. An estimated 75% of
pharmaceutical compounds under development suffer from poor solubility. The formulation
of drug/polymer amorphous solid dispersions (ASDs) is one of the most successful strategies
for improving the oral bioavailability of poorly soluble APIs. Hot-melt extrusion (HME) is
one method for preparing ASDs that is growing in importance in the pharmaceutical industry.
HME involves the combination of an API and a polymer, which are heated and intensively
mixed to yield a homogeneous product.
Despite the growth in the application of HME to drug development, there are still sub-
stantial gaps in our understanding regarding the dynamics of drug dissolution and dispersion
in viscous polymers as well as physical stability (phase separation and API recrystallization).
Computational models have been built in order to predict optimal processing conditions (e.g.
temperature, residence time, drug loading), but they are limited by the lack of supporting
data for key mass transport parameters. A key omission is the lack of experimental data on
the API diffusion coefficient at conditions relevant to HME.
This dissertation reports the first measurements of API diffusion in pharmaceutical
polymer melts at temperatures relevant to the HME process, by means of high-temperature
PFG NMR. These measurements were performed in the absence of any solvents, for a range
of drug loadings, temperatures, polymer systems and drug species. The mechanism of the
diffusion process and its relationship to viscosity was explored with the Stokes-Einstein
and Arrhenius models. Viscosity plots obtained from the rheology experiments uncovered
the possibility of HME processing at significantly lower temperatures to reduce the risk of
thermal degradation. Additional characterisation of extrudates prepared 30◦C below the
drug’s melting point concluded that satisfactory ASDs were produced.
Furthermore, this dissertation includes 1H solid-state NMR relaxometry measurements as
an insight into physical state, phase separation and API/polymer interactions in extruded
formulations. HME products were found to have formed successful ASDs, with no evidence
viii
of crystalline drug remains or of phase separation. This was not the case for a physical
mixture that had been heated up, but not actively mixed; meaning that extrusion is indeed
required (and not just high temperatures) to achieve ASDs. Chemical shift changes suggested
intermolecular associations between the drug and the polymer. These interactions were
studied in greater detail through a range of novel solid-state and molten-state 2D NMR
experiments. The results not only corroborated the existence of drug-polymer H-bonding,
but also the presence of Van der Waals interactions between the two species.
Finally, several theoretical models were applied to predict solubility and dissolution rate
of a drug in a polymer melt. This involved the calculation of the interaction parameter
and the construction of a miscibility-solubility phase diagram. A simple static spherical
particle dissolution model was fitted with the diffusion coefficient parameters measured in
previous sections and the results were in agreement with experimentally obtained time-to-
dissolution observations. This positive result highlighted the value of measuring the diffusion
coefficient of drugs in polymer mixtures for predicting system behaviour and optimising
process parameters.
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Low aqueous solubility of active pharmaceutical ingredients (APIs) presents one of the
greatest and most frequent challenges to formulation scientists [1–3] and it is becoming more
prevalent with the use of high throughput screening in drug discovery and the targeting of
hydrophobic receptors [4]. The formulation of drug/polymer amorphous solid dispersions
(ASDs) via hot-melt extrusion (HME) is one of the most successful strategies for improving
the oral bioavailability of poorly soluble APIs [5–7]. Despite the growth in the application of
HME to drug development, there are still substantial gaps in our understanding regarding
the dynamics of drug dissolution and dispersion in viscous polymers as well as the physical
stability of the final formulations [8].
The aim of this chapter is to provide a brief overview of the challenges posed by poorly
soluble drugs and the approaches to overcome them, and in particular of products formulated
via HME, which is the focus of this thesis. The analytical techniques commonly employed to
characterise products prepared by HME have been reviewed, with an emphasis on nuclear
magnetic resonance (NMR), since it is the main technique used in this thesis. Mathematical
models, both empirical and mechanistic, of drug dissolution and of the HME process are also
introduced.
1.1 Outline of thesis chapters
Chapter 1 presents the motivation of the work, and a background into amorphous
solid dispersions and hot-melt extrusion. In addition, a discussion on the use of NMR
and MRI techniques in the characterisation of pharmaceutical formulations is provided.
Chapter 2 introduces basic NMR concepts, with a focus on the theory behind the
experiments used throughout this thesis. These include: diffusometry, relaxometry,
solid-state NMR and 2D NMR.
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Chapter 3 reports quantitative measurements of the diffusion coefficient of molten
paracetamol and in mixtures with copovidone at a range of industrially relevant
temperatures and drug loadings. Additionally, a rheological study to examine the
relationship between diffusion coefficient and viscosity is presented.
Chapter 4 discusses the use of solid state NMR spectroscopy and relaxometry and
its application to a variety of paracetamol/copovidone systems. An extruded system
is compared to a sample that was exposed to high temperature and demonstrates the
need for active mixing to obtain homogeneous and amorphous preparations.
Chapter 5 examines intermolecular associations between paracetamol and copovidone
in ASD formulations to identify the type of bonds present and the nuclei involved.
Several noteworthy experimental techniques were used such as high-field fast-MAS
multiple quantum coherence NMR or molten-state COSY NMR.
Chapter 6 applies NMR techniques validated in previous chapters on alternative
formulations such as an industrially relevant drug. A design of experiments run
investigates the effect of processing parameter on mass transport coefficients and sample
micro-structure.
Chapter 7 describes a simple dissolution model that is fitted with parameters calculated
in this thesis. The results from the model are validated experimentally. Additionally, a
temperature-composition phase diagram is constructed for the paracetamol/copovidone
system.
Chapter 8 summarises and discusses the key conclusions drawn from the experimental
and numerical work performed in this thesis and explores the scope for future work.
1.2 Drug solubility issues and improvement techniques
The solid dosage oral formulation is the prevailing method for drug delivery; the main
advantages being the ease of administration, high patient compliance and flexibility in
formulation design [3]. The most important factor to ensure the desired therapeutic effect on
a patient is adequate bioavailability. Bioavailability is the fraction of API that incorporates
to the circulatory system, and it is controlled by two processes: solubility and permeability.
APIs are increasingly suffering from low solubility. It is estimated that 40% of currently
marketed drugs and up to 75% of pharmaceutical chemical entities under development are
poorly water-soluble [1]. Often, this means that in order to reach the blood concentration
required for pharmacological response, high dosages are administered assuming that only a
fraction will solubilise, resulting in waste and potential over-dosing risks.
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Numerous strategies to enhance drug solubility have been investigated and they can be
classified into three categories: physical modifications, chemical modifications, and the use of



















These approaches have been reviewed in detail by Savjani et al. and Williams et al.
[3, 4]. An amorphous solid dispersion (ASD) takes advantage of the amorphous physical
state of the drug and its dispersion in a water-soluble carrier, which acts as a stabilizer
preventing recrystallization. Compounds in the amorphous state lack the long-range order
of crystalline materials in the solid-state, and, consequently, exist at a higher energy than
the corresponding crystalline forms. Therefore, the energy penalty to dissociate molecules is
lower and this results in a higher solubility [9]. The formation of ASDs is one of the most
promising strategies for drug solubility enhancement and some of the main advantages it
poses over the approaches outlined in the diagram above are as follows:
• Solubilisation in a solvent results in a liquid dosage form, which is undesirable due to
challenges in administration, commercialisation and storage.
• Particle size reduction limit is about 2−5 µm, which is usually not enough to significantly
improve solubility.
• Chemical modifications are complex and compound-specific processes that transform
the drug into a new chemical entity and thus require additional regulatory approval.
1.2.1 Biopharmaceutical Classification System (BCS)
As was outlined in the previous section, the most important considerations to ensure that
the desired therapeutic effect of a drug is achieved are solubility and permeability. The BCS
(Biopharmaceutics Classification System) was developed by Amidon et al. [10], and is now
used by the US FDA as a framework to describe intestinal drug absorption. It is based on
the aqueous solubility (property to dissolve in or make a homogeneous mixture with a solvent
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- in this case the gastric juice) and intestinal permeability (ability to penetrate through a
solid - in this case the intestinal membranes) characteristics of drugs. Efforts to enhance
permeability have not been successful up to date [2].
The BCS definition of "good" solubility is when the highest strength dose is soluble in 250
ml of water at the full range of pH values that might be encountered in the gastrointestinal
tract [4]. According to the BCS (Table 1.1), drugs that belong to classes II and IV display low
bioavailability because they are poorly soluble in aqueous solutions. A wide variety of drugs
belong to classes II and IV, such as acetaminophen (analgesic), azithromycin (antibiotic),
cyclosporine (immunosuppressant), furosemide (diuretic), ibuprofen (anti-inflammatory),
lorazepam (anxiolytic) or phenytoin (anti-convulsant), among many others [11].
Table 1.1 Biopharmaceutical Classification System
High solubility Low solubility
High permeability Class I Class II
Low permeability Class III Class IV
The European Pharmacopoeia has standardised dissolution testing for pharmaceutical
solid dosage forms [12]. There are three conventional dissolution apparatus, from which a
certain volume of the dissolution medium is collected at intervals for analysis:
• Paddle apparatus: covered cylindrical vessel with a vertical stirrer along the axis of the
container that rotates smoothly.
• Basket apparatus: identical vessel as for the paddle apparatus, but the stirrer consists
of a vertical shaft attached to a cylindrical basket, where the dosage form is introduced;
the stirrer rotates smoothly.
• Flow-through apparatus: a pump forces the dissolution medium upwards through the
flow-through cell, with a filter to prevent the escape of undissolved particles.
1.2.2 Amorphous solid dispersions (ASDs)
Formulation of poorly-soluble compounds for oral delivery presents a serious hurdle in
pharmaceutical research and solid dispersions are deemed one of the most promising strategies
to improve their oral bioavailability. A solid dispersion is a homogeneous mixture of two or
more compounds - a drug and a carrier. Polymeric carriers have been the most successful for
solid dispersions because of their ability to stabilise drugs in dispersion [6].
Solid dispersions were first proposed in 1961 by Sekiguchi and Obi as a means to increase
drug solubility [13]. They prepared a drug/polymer eutectic mix (physical mixture, typically
of very fine crystals, that melts and freezes at a single temperature) through co-melting and
fast cooling. There are three different types of solid dispersions according to the molecular
arrangement of drug molecules within the carrier (Figure 1.1): dispersed small crystalline
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drug particles, amorphous drug particles in the polymer matrix and molecularly dispersed
amorphous drug in the polymer (ASDs) [4].
(a) (b) (c)
Fig. 1.1 Schematic of the three types of solid dispersions: a) dispersed crystalline drug
particles, b) amorphous drug particles and c) molecularly dispersed drug (ASD) (modified
from [4]).
A successful ASD is characterized by the presence of amorphous drug, which is dissolved
in the polymer, such that the dispersion is homogeneous on a molecular level (Figure 1.1 c).
The first to report the formulation of a pharmaceutical ASD were Chiou and Riegelman in
1969 [14]. Since then, there has been extensive research carried out on ASDs and this has
been reviewed by Serajuddin et al., Vasconcelos et al. and Williams et al. [4–6].
Up to several hundred-fold enhancement in dissolution has been reported for ASDs
relative to the crystalline form of the drug [8, 15]. Three key features play a role in the
increased drug solubility of ASDs: (i) maximised surface area available for dissolution, (ii)
reduced intermolecular forces in the solid state, and (iii) increased strength of solute-solvent
interactions in solution [4].
(i) Increased drug particle surface area
In the case of a molecular dispersion, the size of drug particles in the carrier is minimized,
theoretically, to the size of a single molecule. This provides the maximum available surface
area exposed to the solvent, which is a parameter that is directly proportional to dissolution
rate according to the well-known Noyes-Whitney model (further details are presented in
section 1.2.3). Moreover, the use of hydrophilic, highly water-soluble polymers as carriers
also promotes rapid solvent penetration (increased wetting), which enhances dissolution.
(ii) Reduced drug-drug intermolecular interaction
In ASDs, the drug exists in the amorphous form. Amorphous solids lack the tight packaging
and highly ordered lattice of crystalline solids. Intermolecular bond strength is strongly
dependent on molecular distance, which is increased in the disordered amorphous physical
state. Furthermore, it is common for the polymer in ASDs to establish ionic, hydrogen-bond
or Van der Waals interactions with the drug. This also reduces drug-drug interactions
since bonding sites get occupied with the polymer instead. The strength of intermolecular
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drug-drug interactions in an ASD can therefore be greatly reduced compared to that in
crystalline compounds, lowering solubilisation energy.
(iii) Increased solute-solvent interactions
Polymeric carriers can increase the aqueous solubility of the drug, so that an apparent super-
saturation is achieved in the dissolution medium. The fact that the polymer is molecularly
dispersed with the drug can slow crystal growth or altogether inhibit crystal nucleation by
interfering with drug lattice assembly. This results in a greater concentration of drug in
solution and increased drug-solvent interactions.
The main concern with ASDs is the generally poor predictability of the formulation due
to lack of basic understanding of its properties. According to the review by Craig et al. there
are several important areas of research [8]:
Solid state structure. The choice of polymeric carrier, as well as processing conditions,
determine whether the drug is present as a molecular, a crystalline particulate or an
amorphous particulate dispersion. Recently, calculations of the free energy of mixing and
the Flory-Huggins interaction parameter have been employed to anticipate miscibility
and solubility of a drug in a polymer (these models are explained in more detail in
section 1.5.1).
Mechanism by which dissolution enhancement occurs. It is believed that the
main contributing factors are as outlined above (maximised surface area, reduced inter-
molecular interactions and increased solvent interactions) but the specific mechanisms
are not yet fully understood.
Stability of the ASDs. Typically, the drug/polymer solid solution is in a supersatu-
rated state at storage conditions, which could trigger drug recrystallization. The glass
forming ability (GFA) is the ease with which a compound will remain in the amorphous
state without recrystallizing. This can provide an insight into the stability of a drug in
an ASD [16]. According to their GFA, compounds can be classified into:
- Non-glass formers: drugs that re-crystallize in the first cooling cycle after melting.
- Unstable glass formers: compounds that remain amorphous during the cooling
and re-crystallize in second heating cycle.
- Glass formers: compounds that remain amorphous upon cooling and reheating
Reproducibility of formulation properties. The final formulation is highly sen-
sitive to manufacturing conditions and process parameters. Subtle changes in these
could greatly influence the properties of the final formulation.
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1.2.3 Solubility and the Noyes-Whitney equation
It has been established that solubility, i.e. the amount of solute that can dissolve in a certain
volume of solvent, is an essential consideration in the design of solid dosage forms. The
kinetics of the solubility process are expressed in terms of the dissolution rate. The dissolution
rate is a measure of the pace at which a solute passes into solution and this is equally as
important: after oral administration drug dissolution rate should exceed the rate of transit





Fig. 1.2 Schematic of the Noyes-Whitney
model for drug dissolution rate
The most extensively used thin-film model
for drug dissolution up to date is known as the
Noyes-Whitney equation. Noyes and Whitney
published experimental evidence in 1897 show-
ing that the rate of solution of a solid substance
is a diffusion process, which is proportional to
the difference between the concentration of the
saturated solution and that of the bulk solution
[17]. Further contributions from Nernst and
Brunner shaped the Noyes-Whitney equation





× (cs − c) (1.1)
In equation 1.1, dcdt is the dissolution rate, A is surface area available for dissolution, D is
the diffusion coefficient of the solute, h is the thickness of the diffusion boundary layer (see
Figure 1.2), cs is the solute saturation concentration and c is the bulk concentration of drug
at time t. Considering this model, several of the approaches presented in section 1.2.2 to
increase drug solubility and dissolution rate can be interpreted [2]:
• Increasing surface area available for dissolution (A) by reducing particle size will directly
influence dissolution rate. Alternatively, enhancing wetting characteristics will decrease
diffusion boundary layer thickness (h).
• Polymeric carriers that can increase drug solubility to achieve stable supersaturation
will effectively increase cs, thus improving dissolution rate.
Thin-film systems are characterised by a diffusion boundary layer thickness (h) that
is small compared to the root-mean-square diffusion length (
√
4Dt). There are several
limitations to the Noyes-Whitney model stemming from the fact that it is a thin-film diffusion
system [19]: (i) static diffusion layers do not exist in stirred fluids, (ii) h cannot be measured
experimentally or obtained a priori, and (iii) in the absence of convection the diffusion
equations have no steady state solutions. More complex models for which the diffusion layer
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thickness could be determined (such as the rotating disc [20]) have been used to solve the
Noyes-Whitney model.
1.2.4 Amorphous solid dispersions preparation methods
Preparing an ASD involves dispersing a poorly soluble drug in a water-soluble polymeric
matrix. There are two main approaches to achieve ASDs: fusion and solvent evaporation
methods [3].
The fusion approach generally consists on melting a drug/polymer physical mixture
followed by rapid cooling. The heating, usually to the melting point of the drug to ensure
molecular level mixing [21], encourages the drug to disperse in an amorphous physical state
and the fast-rate cooling induces solidification before drug recrystallization can occur. This
approach is simple and cost-effective, but the components are required to be thermostable.
Hot-melt extrusion (HME) is a variant of the straightforward fusion method, in which mixing
and homogenization at high temperature is encouraged by rotating screws. HME is the most
widely used of the fusion manufacturing processes because the high viscosities of polymers
usually require active mixing for preparation of a single-phase formulation.
Other effective and simple high viscosity mixing methods for polymers include rotating
mixers and blade blenders. However, these usually require large quantities of material, which
is not desirable for drug development due to high material costs. These approaches also do
not allow for continuous manufacturing, as HME does, meaning that they are less efficient to
run in the long term and could suffer from batch to batch inconsistencies.
Solvent evaporation entails the dissolution of the drug and carrier in a common solvent
(typically ethanol or chloroform). The ASD is formed in dissolution and the polymer is then
relied on to stabilize the drug in its amorphous state once the solvent is removed. A review
on spray drying formulation of ASDs, from the effects of process parameters to scaling-up
consideration was published by Singh et al. [22]. The way in which the solvent is evaporated
(under vacuum, heating, rotary evaporator, spraying, nitrogen stream or slow evaporation at
low temperature) gives rise to different variants of the solvent evaporation approach. Spray-
drying is the most frequently employed alternative, and it involves spraying the drug/polymer
solution into a stream of heated airflow. A review on spray-drying technology, formulation
parameters and scaling up has been published by Patel et al. [23].
The primary benefit of spray-drying is that there is no risk of thermal degradation of the
ASD components (when dried at low temperatures) . However, disadvantages include the use
of large amounts of organic solvents, high processing cost, scalability issues, difficulties in
completely removing the solvent and the selection of a common volatile solvent (drugs of
interest are usually hydrophobic and polymers hydrophilic). It is essential that the solvent
be completely removed from the ASD formulation since residual traces could carry toxicity
hazards and also increases the likelihood of phase separation and crystallization. On the
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other hand, HME is an extremely cost-effective, continuous manufacturing process, easy to
scale up and requiring minimal downstream processing as the formulation can be shaped at
the outlet of the extruder while heated and malleable.
There are other less frequently used but highly innovative approaches to prepare phar-
maceutical ASDs. One such example is supercritical fluid impregnation, where supercritical
(fluid state) CO2 is introduced in a pressurized vessel containing the drug and carrier. The
CO2 swells the polymer matrix and promotes drug dissolution, penetration and mixing. Since
CO2 is a gas at room temperature, it is easily removed upon de-pressurisation. Although
ASDs were successfully prepared through supercritical fluid impregnation, HME achieved
stronger drug/polymer interactions and greater product homogeneity [24].
Comparative studies characterising different ASD manufacturing approaches have been
published. Mahmah et al. performed thermal, microscopic and dissolution testing and found
higher drug release rate in spray-dried formulations, but improved stability in HME products
[25]. Another comprehensive study by Benes et al. reported extensive experimental testing
and data interpretation was aided by computational analysis (principal component analysis
and partial least squares regression analysis) [26]. No fundamental differences in drug surface
area or dissolution profiles were observed for HME and spray-dried samples.
Regardless of the method employed, Verma et al. have proposed a systematic approach
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All the experimental and theoretical characterisation techniques mentioned above will be
introduced at later stages in this thesis.
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1.2.5 Investigations of amorphous solid dispersions
In the past decades, there has been extensive research conducted on ASDs, particularly on the
amorphisation of crystalline drugs, the kinetics of recrystallisation, the conditions for physical
stability and avoidance of phase separation, solid state micro-structural characterization
and solubility and dissolution behaviour of the formulations. A comprehensive review on
amorphisation, crystallisation, stabilisation, characterisation and solubilisation was published
by Baghel et al. [28]. The bulk of the literature can be divided in two fields: physical stability
of formulations and dissolution or drug release mechanisms.
Physical stability of ASDs
Phase stability is formally described as the susceptibility of a material to chemical and
external pressures that result in changes in the interatomic distances giving rise to the change
of relation between repulsive and attractive forces.
There are three indicators of physical stability that are frequently investigated: (i) the
glass transition temperature, (ii) likelihood of recrystallisation and (iii) the theoretical limits
of drug/polymer solubility and miscibility.
(i) Glass transition temperature
The glass transition temperature (Tg) marks the transition from a glassy (barely mobile) to
a rubbery (somewhat flexible) state. ASDs are in a high-energy thermodynamically unstable
state. Physical stability is more likely to be maintained, at least over short timescales, if the
storage temperature is below the ASD’s Tg [4].
The characteristic high viscosity of many polymers is associated with an elevated Tg.
High-Tg polymers raise the apparent Tg of a drug in a solid dispersion. The Tg can be
be determined experimentally using differential scanning calorimetry (DSC), or estimated
theoretically using the Gordon-Taylor equation [29] from the individual component’s weight
fractions (w) and glass transition temperatures (Tg):
Tg,mix =
wdrug · Tg,drug + K · wpolymer · Tg,polymer
wdrug + K · wpolymer
(1.2)
where parameter K can be approximated with the Simha-Boyer rule [30] from the densities
(ρ) of the drug and the polymer:
K = ρdrug · Tg,drug
ρpolymer · Tg,polymer
(1.3)
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(ii) Drug recrystallisation
The crystalline state is thermodynamically favoured over the amorphous, but an activation
energy (for molecules to mobilise and align), has to be overcome to initiate nucleation and
crystallisation. Experimentally, this energy is commonly estimated from the configurational
heat capacity (∆Cp). Heat capacity (Cp) is a basic thermal property, defined as the amount of
heat that needs to be supplied to a certain mass to produce a unit change in its temperature.
Heat capacity can be measured through DSC. The configurational heat capacity is the
difference in heat capacity between the crystalline and the amorphous states:
∆Cp = Ccrystallinep − Camorphousp (1.4)
It is generally assumed that dispersions in which no crystalline phase can be detected are
amorphous [2]. The most straight forward way to probe for crystallinity is by the presence of
a melting endotherm in DSC thermograms.
There are three main mechanisms through which polymeric ASDs hinder drug recrys-
tallisation: drug-polymer intermolecular associations, inhibition of nucleation and reduced
molecular mobility.
Drug-polymer intermolecular associations, such as ionic interactions, hydrogen bonding or
Van der Waals forces, decrease the likelihood of recrystallisation by holding the drug molecules
in place in the dispersion and limiting drug-drug molecular interactions. Traditionally, drug-
polymer interactions are probed through FTIR (Fourier-transform infrared spectroscopy), a
spectroscopic technique that operates in the infrared wavelength region. Positive deviations
from Gordon-Taylor behaviour (where experimental Tg values are greater than estimated
values) are also indicative of strong drug-polymer interactions [31–33].
Nucleation is the first step in the formation of a crystalline lattice. It entails the
spontaneous self-assembly of a few molecules into a structure upon which additional molecules
can attach to for a crystal to grow. The kinetics of nucleation are dependent on the activation
energy for molecular diffusion and appropriate alignment to join the incipient lattice. The
polymer chains in the ASD increase the activation energy for nucleation by: acting as a
diluent and providing physical separation between drug molecules, reducing drug diffusivity
and hindering their mobility, and accumulating at the nucleation interface to hinder or
prevent further drug molecules from attaching.
A certain extent of molecular mobility is required for nucleation and crystallisation. Non-
or unstable-glass formers (compounds with high crystallization tendencies) generally have
lower molecular weights and fewer rotational bonds, which increases the probability of the
drug exhibiting the appropriate orientation for crystallisation [34]. As mentioned above,
polymers’ high Tg decreases molecular mobility in ASDs, improving physical stability of
amorphous drugs. There is a trade-off to be considered between a high-Tg polymer, which
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reduces molecular mobility at storage temperatures, and a low-Tg polymer, which would
allow processing at lower temperatures.
(iii) Drug/polymer solubility and miscibility
Solubility and miscibility of drugs in polymers have been widely studied, both theoretically
and experimentally, in order to predict the behaviour and drug loading limits in ASDs.
This has been done by constructing temperature-composition phase diagrams (Figure 1.3)
consisting of three curves: solubility, miscibility and glass transition temperature [35–38].
The solubility curve defines the stable (A and B) and metastable (C and D) regions and
the miscibility curve indicates the limit between the metastable and unstable (E and F)
domains [39]. Regions B, D and F have enhanced stability over their A, C and E counterparts,
respectively, because molecular motion is hindered as the temperature is below the system’s
Tg.
Drug-polymer miscibility describes the tendency of a liquid (molten or solubilised) drug
to disperse in a polymer matrix; while solubility refers to the ability of a polymer to dissolve
a solid or crystalline drug [40]. There are several qualitative and quantitative approaches to
estimate drug/polymer solubility and miscibility.



















Fig. 1.3 Schematic of a traditional
drug/polymer phase diagram.
Qualitative methods:
• Differential scanning calorimetry is predic-
tive of drug-polymer miscibility when a sin-
gle Tg is observed. Although this technique
is considered the "gold standard", it has lim-
itations: (i) Tg’s of individual components
have to differ at least by 10◦C, and (ii) spa-
tial resolution is 30 nm [41].
• Solubility parameter: the cohesive energy
contribution of individual components can
be determined using the relationship from
Hansen (1967) [42]: δ2 = δ2d + δ2p + δ2h. This
takes into account the contribution from
dispersion (δd), hydrogen bonding (δh), and
polar (δp) forces. Low ∆δ = δpolymer −δdrug
is predictive of miscibility.
• Microimaging techniques, such as Raman mapping or hot stage microscopy has been
used to evaluate phase homogeneity of ASDs [43]. This method is limited by low spatial
resolution (µm scale).
Quantitative methods:
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• Flory-Huggins interaction parameter χ, describes the thermodynamic mixing of a drug-
polymer system [44, 45]. χ can be calculated from the difference in solubility parameters
between drug and polymer, or the melting point depression of the drug in the presence of
the polymer. Negative χ suggests miscibility.
• X-ray diffraction (XRD). The XRD pattern of a crystalline material exhibits sharp peaks,
while that of an amorphous compound shows a broad pattern. XRD combined with
computational methods such as Pair Distribution Function calculations (PDFs) can be
used to characterise nearest-neighbour interactions, from which drug-polymer miscibility
can be inferred [46].
• In solid-state NMR, a single 1H T 1 relaxation time for drug and polymer indicates
miscibility in the 100 nm scale, and a single 1H T 1ρ relaxation time for both components
estimates miscibility in the 5 nm scale [47, 48].
• High resolution imaging techniques such as atomic force microscopy (AFM) [43], scanning
electron microscopy (SEM) [49] or transmission electron microscopy (TEM) [50] can be
used to quantitate the growth rates of a drug crystal within polymers.
Dissolution of ASDs
Generally, the main objective for the formulation of ASDs is to improve solubility or disso-
lution rate of a drug. Therefore the dissolution behaviour of these preparations is studied,
often using the standardised dissolution testing apparatus mentioned in section 1.2.1 coupled
with UV/Vis spectrophotometers. Ultraviolet/visible spectroscopy is used for the determi-
nation of drug concentration in the dissolution medium. Combined with complementary
analytical techniques, (i) polymer dissolution as well as (ii) drug release mechanisms have




















Fig. 1.4 Schematic of polymer dissolution.
Polymer dissolution is a complex phenom-
ena. Several models have been proposed
as dissolution behaviour is strongly depen-
dent on the nature of the system (molecular
weight, interactions between chains, physical
state and solvent) [54–56]. Numerous tech-
niques have been employed to gain a better
understanding of polymer dissolution such
as FTIR, NMR spectroscopy and imaging,
optical and fluorescence microscopy, inter-
ferometry and gravimetry [57–61], among
others.
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Broadly, the dissolution of a polymer involves two transport processes: solvent diffusion
and chain disentanglement. In the case of ASDs the carriers of choice are amorphous polymers.
Their dissolution is characterised by the formation of a gel layer upon hydration and swelling
(Figure 1.4). As the solvent penetrates, it mobilises the polymer chains and these transition
from a dry glassy state to a rubbery material as chain disentanglement occurs. When the
solvent concentration in the polymer exceeds a certain value, the unwound chains begin to
truly dissolve. A comprehensive review of polymer dissolution can be found in [62].
(ii) Drug release mechanisms
Generally drug release rate is characterised through UV/Vis spectroscopy. This technique
suffers from limitations, such as certain analytes not being UV-absorbing or that the lack of
chemical sensitivity does not allow one to measure the dissolution rate of individual species
in a complex formulation. NMR has proven to be an appropriate alternative and it will be
discussed in more detail in section 1.4.1.
There are two main mechanisms of drug release from ASDs [63]: dissolution-controlled and
diffusion-controlled. Dissolution-controlled processes exhibit a surge of drug supersaturation
in the solution as the whole formulation solubilises rapidly. This may be followed by a
sharp decline in drug concentration due to crystallisation if the polymer fails to inhibit drug
nucleation. In diffusion-controlled dissolution the polymeric matrix is slow-dissolving and the
drug has to diffuse out into the medium. Supersaturation is built up gradually and sustained
as there is a continuous exchange of dissolved drug between the polymer matrix and bulk
solution.
1.3 Hot-melt extrusion
Hot-melt extrusion (HME) was introduced in the 1930’s for the plastic, rubber and food
industries to mould heated viscous materials into any desired shape [21]. It was investigated
for the first time as a manufacturing tool in the pharmaceutical industry by El-Egakey et
al. in 1971 [64]. In this context, HME is typically performed using a twin-screw extruder,
wherein a physical mixture of a drug and polymer are heated, at temperatures up to the
melting point of the drug, and intensively mixed to yield a homogeneous product (Figure
1.5).
The assembly, as shown in Figure 1.5, is made up of a motor that drives the rotating
screws, an extrusion barrel, and an end-plate die that shapes the product. The key input
process parameters are screw speed, drug loading and temperature; and these will determine
key characteristics of the process such as residence time or homogeneity of the formulation.
Twin-screw extruders are generally preferred over single-screw because they reduce residence
time (preventing thermal degradation) and exhibit greater mixing capabilities.
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HME is a simple, robust, versatile, efficient, scalable and continuous process. Additionally,
it has the ability to enhance the solubility of poorly soluble drugs. Particularly, compared to
solvent evaporation approaches, HME is solvent-free and requires less downstream processing,
as products can be easily moulded into marketable formulations (avoiding pulverisation and
pressing into tablets). Solvent evaporation is less apt for scaling-up as the recovery costs of
the evaporated organic solvents would be very high, and the removal of residual amounts
of solvent is challenging. The main concerns with HME is that it would not be suitable for
thermolabile compounds and that the viscoelastic properties of polymers need to fall within
processable limits to be used as carriers. Detailed reviews on HME theory, technology and
applications have been published by Maniruzzaman et al. [65] and Patil et al. [21].
Fig. 1.5 Schematic of the HME process (adapted from [21])
Despite the growth in the application of HME to drug development, there are still substan-
tial gaps in our understanding regarding drug solubility in polymers, product homogeneity,
drug-polymer interactions and long-term stability of the formulation, among others. This is
further hindered by the complexities involved in modelling (and thus predicting the outcome
of) HME and the amount of computational power required for accurate system representations.
Furthermore, there are numerous process parameters to be taken into account, such as screw
speed, architecture, dimension and rotation; drug loading and particle size; and extruder
degree of fill and residence time, to name a few. An encouraging fact, however, is that the
number of pharmaceutical products formulated by HME has been rising in recent years (a
table with the 11 commercially available formulations in 2014 was published by Li et al. [32]).
The body of literature investigating pharmaceutical extrusion has also been growing and
there are several companies that specialise in HME as a drug manufacturing technology, such
as PharmaForm (BioDuro, San Diego, USA) and SOLIQS (Abbott, Maidenhead, UK).
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1.3.1 Investigation of HME formulations
Most studies conducted up to the present day have been carried out on the extrusion products.
Many analytical techniques have been applied for this purpose, such as: DSC, XRD, SEM,
TGA (thermogravimetric analysis), FTIR, HPLC (high-performance liquid chromatography),
RS (Raman spectroscopy), NMR and AFM. The literature review presented in this section has
focused on three areas (dissolution enhancement, solid-state characterisation and prediction
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It is generally the case that the maximum dissolution rate enhancement is achieved when
complete drug amorphisation is obtained. However, Pina et al. showed that, at least for
a particular drug/polymer system, the dissolution behaviour of the polymer had a greater
influence on the drug release rate than the absence or presence of crystalline drug particles
in the formulation [66]. As Craig, reported in his review, there are two mechanisms for
drug release: carrier-controlled and drug-controlled. Carrier-controlled drug release is only
dependent on polymer behaviour, as the drug readily solubilises in the hydrated polymer
layer; whereas in drug-controlled dissolution, the drug is released into the solvent as it was in
the formulation [8]. It was reported by Ashour et al. that in drug-controlled dissolution, the
apparent drug solubility is strongly dependent on the polymer of choice and the drug loading
[15].
Solid-state characterisation has been the focus of many publications. XRD is the most
widely used technique to probe for drug amorphisation (characterised by a broad signal) or
detect the presence of residual crystals (narrow peaks) [43, 67]. Phase separation (homogeneity
of drug distribution) has been generally investigated through DSC [68], but its limit of
detection is 30 nm at most, so other approaches such as solid-state NMR, XRD and microscopy
have been employed to achieve greater resolution [43, 46].
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Extensive analysis of drug-polymer systems has been carried out to gain an understanding
on the miscibility and solubility behaviour and thus predict phase stability of the formulation.
Experimental as well as theoretical approaches have been used to estimate drug solubility
in the polymer. Theoretical solubility parameters (introduced in section 1.2.5) were used
by Maniruzzaman et al. in HME formulations to confirm drug-polymer miscibility [49]. On
the other hand, Qi et al. employed SEM, DSC and NMR to predict phase separation on
extrudates [69]. Sarode et al. studied phase separation and drug crystallization at different
temperatures and humidity levels during storage, which could lead to chemical degradation,
particularly in formulations with low T g [70].
1.3.2 Analysis of extrusion process parameters
There is also a body of literature investigating the extrusion process itself, particularly with
respect to making the optimal choice of processing parameters such as temperature, drug
loading or screw rotation speed.
Li et al. modelled drug dissolution behaviour by calculating the free energy of mixing
(∆Gmix) as this provides an insight into the spontaneity of phase mixing (more on this
model can be found in section 1.5.1) [71]. With this information, a temperature-composition
phase diagram, like the one shown in Figure 1.3, was constructed to provide miscibility
information for coordinates of interest. The phase diagram was corroborated experimentally
by extruding at different drug loadings and temperatures and performing XRD and RS on
the formulations. Li et al. also concluded that the shortage of thermodynamic forces for
conditions corresponding to the metastable phase diagram region (between the solubility
and miscibility curves) could be compensated for by increasing extrusion screw speed (which
raises system entropy).
Alternatively, Van Renterghem et al. used viscosity measurements to estimate drug
solubility in the polymer [72]. This was based on the plasticising effect (lowering of viscosity)
that polymers generally experience when a miscible drug is dissolved in them. The decrease
in viscosity is due to an increase in free volume as drug molecules separate polymer chains.
On the other hand, when crystalline particles remain undissolved, they act as filler and
increase the viscosity of the system.
In-line analysis of HME
In-line monitoring of the HME process is extremely challenging because the harsh environment
within an extruder (high temperature, viscous medium and strong mechanical parts moving)
makes it difficult to interface to analytical instruments. Among the investigations on extrusion
process parameters, there are a few publications that have conducted in-line analysis of HME.
For example where analytical techniques (Raman spectroscopy, near-infrared spectroscopy
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and Terahertz-Raman) are coupled to the extrusion barrel to collect data during the HME
process.
Raman spectroscopy was used by Saerens et al. and Van Renterghem et al. to investigate
the influence of screw speed, drug loading and barrel temperature on crystalline drug
dissolution and residence time distribution [73, 74]. Saerens et al. (2013) observed that for
higher drug loadings (40 wt %) the physical state of the final product was achieved further
down the barrel at lower temperatures and also at slower screw speeds. Van Renterghem et al.
corroborated the aforementioned results, and also noticed that for processing temperatures
below the melting point of the drug, increasing screw speed achieves lower residual crystalline
drug fraction.
More recently, Bordos et al. made use of Terahertz-Raman (THzR) to determine drug
solubility in polymer melts during HME [75]. Real-time measurements showed a decrease in
the spectral components associated with the crystalline drug. This allowed, for the first time,
for the construction of temperature-composition phase diagrams from experimental data.
1.4 Use of NMR and MRI techniques in the characterisation
of pharmaceutical ASD formulations
Nuclear magnetic resonance (NMR) is well established as a powerful characterisation technique
in pharmaceutical research, as its non-destructive, quantitative and chemically selective.
Despite being expensive and time- and resource-intensive, NMR will remain prominent for
structural and dynamic characterisation due to its versatility and capability [76]. The role of
NMR in the investigation of ASDs can be broadly divided in five categories: high resolution
spectroscopy, 2D correlation experiments, relaxometry, diffusometry and imaging.
1.4.1 Investigations of dissolution performance
The performance of many solid pharmaceutical dosage forms depends on their hydration
and dissolution capabilities [77]. NMR has benefits over traditional dissolution testing
(UV/Vis spectroscopy) due to much greater analyte selectivity and the ability to detect
non-UV-absorbing species (e.g. sugars). Magnetic resonance imaging (MRI) can be used non-
invasively to observe drug dissolution, polymer swelling and water penetration, concentration
and diffusion.
Miller-Chou et al. reviewed polymer solubility behaviour [62]. They identified three
spectroscopic NMR modalities that provide an insight into the dissolution dynamics of
polymers:
- 1H spectrum line width: narrowing of 1H resonance signals is indicative of increased
polymer mobility.
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- Integrated 1H signal: the area of polymer resonances as a function of time can be linked
to the amount of polymer in dissolution.
- T1 constant: the value of T1 decreases when molecular motion becomes faster.
Additionally, MRI has been used to visualise polymer swelling and dissolution [78, 79]. Fyfe et
al. determined polymer mobility and polymer distribution in swelling hydrogels [80]. Likewise,
Narasimhan et al. studied molecular motion during polymer dissolution in water [81]. They
showed that for a certain polymer, increasing molecular weight would result in a decrease
in solvent penetration rate. Ashraf et al. and Hyde et al. visualised water penetration into
polymer tablets using MRI. Ashraf et al. quantified the rate of penetration of the hydration
front in slow-release capsule matrices [82]. For a specific system, they determined that the
hydration rate was not a limiting step in the drug release process. Despite the spectral
overlap between solvent and polymer, Hyde et al. achieved quantitative measurements of the
concentration profiles for the solvent and polymer with T1-weighted one-dimensional MRI
[83]. This technique was able to resolve the two species due to their distinctive T1 behaviours.
The main draw-back of MRI is that, to achieve high resolution, experiments are long.
Chen et al. devised an ultra-fast MRI experiment (RARE - rapid acquisition with relaxation
enhancement) to visualise polymer dissolution in water [84]. The achievable spatial resolution
was high (469 µm) while experimental time was minimised (less than 3 minutes).
More recently, Coombes et al. and Tres et al. have integrated flow-through UV/Vis
cells with NMR to simultaneously measure dissolution rates of different species in complex
formulations [85, 52]. Coombes et al. determined the release profiles of three drug substances
and lactose from a single tablet through in-line acquisition of 1H spectra [85]. This was
possible due to water suppression techniques. Similarly, Tres et al. measured the dissolution
rates of both the polymer and API in an ASD from the 1H spectra of the dissolution medium.
Interestingly, they observed that, at low drug loading, the dissolution performance was
governed by the high solubility of the polymer, whereas for the high drug loading formulations
it was dominated by the properties of the drug. Tres et al. also showed that, while the
dissolution profile of the polymer reached a plateau, the drug concentration in solution
declined after reaching a maximum, as super-saturation was not maintained so the drug
recrystallised and precipitated [52].
1.4.2 Mass transport and diffusivity studies in polymers
A key parameter underpinning tablet hydration, dissolution rate and release profile character-
istics is the diffusion coefficient, D [m2/s]. The term diffusion coefficient alludes to two mass
transport phenomena: the self-diffusion of molecules in a homogeneously mixed medium
(Dself ) and the transport diffusion of molecules across a concentration gradient (Dtrans). A
more comprehensive review of diffusion in liquid systems can be found in [86]. Through
pulsed-field gradient (PFG) NMR techniques, it is possible to measure the self-diffusion
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coefficient of solvents, excipients and drugs in pharmaceutical formulations. Mathias et al.
compared the mass transport characteristics of a hydrophilic and a hydrophobic drug, of
similar size, in a hydrogel using 1H PFG-NMR [87]. The hydrophilic drug had a larger D
and the diffusion of the hydrophobic drug was more restricted, as it was held by the swollen
polymer layer for longer.
MRI pulse sequences can be preceded by a PFG programme to obtain a diffusion-weighted
MRI. The result is a map of diffusion coefficients. Similarly, T1- and T2-maps can be
acquired. These techniques have been widely used to study the spatial distribution of
diffusion coefficients, as well as T1 and T2 values to gain a deeper understanding on solvent
penetration, polymer swelling dynamics, and drug release kinetics.
Diffusion-weighted MRI (D-MRI) has been extensively used to study polymer hydration
through solvent mobility [88]. Using water concentration and D-MRI 1D profiles, Narasimhan
et al. observed that the diffusivity of water gradually decreased from the solvent interface
towards the core [81]. Also, D values within the dissolving polymer increased as dissolution
time progressed while those at the polymer-solvent interface remained constant. This
evidenced the disentanglement phenomenon: polymer chains become more flexible and
polymer-polymer interactions decrease as solvent penetrates. Weisenberger et al. Rajabi-
Siahboomi et al. and Kojima et al. obtained similar results by combining D-MRI with T1-
and T2-MRI [89–91]. Weisenberger et al. noted that not only does D decreases towards the
core, but also T1 and T2 values, despite solvent concentration being constant throughout
the hydrated region [89]. This indicated that solvent motions decreased towards the centre,
presumably because polymer chains were effectively fixed to the dry region. Furthermore,
Kojima et al. noted that the D and T2 values of water in polymer were much lower than
those of bulk water, indicating that the hydrating water is in a highly restricted environment,
likely interacting with the polymer [91].
D- and relaxation-weighted images have also revealed further insights on drug/polymer
tablet dissolution behaviour [92–94]. Madhu et al. identified four regions in a dissolving tablet
system: unhydrated tablet core, hydrated tablet core, gel layer and bulk solvent [92]. The D
and T2 profiles acquired by Kojima et al. revealed a positive correlation between drug release
rate and water T2 in the gel layer [93]. This suggests that water mobility measurements
could be adopted as an indicator of drug release dynamics. Baumgartner et al. studied
polymeric tablets for controlled drug release [94]. In these systems, it was the swollen gel
layer that restricted drug mass transport into the solvent. MRI revealed hydrated layer
thickness and T1- and T2-map determination allowed to quantify polymer concentration and
free and polymer-bound water fractions.
Mass transport in polymers can be categorised in terms of the rate of solvent diffusion
relative to the rate of relaxation and mobilisation of the polymer chains [95]:
• Case I: diffusion rate controls liquid ingress (Fickian diffusion)
• Case II: polymer chain relaxation is rate-controlling
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• Anomalous diffusion: both rates are of similar magnitude
Several studies have used MRI to analyse diffusion in polymers and assess which mass
transport mechanism best described the systems under consideration. Tritt-Goc et al.
investigated the effect of solvent pH on transport behaviour in a polymer through MRI
and T2-maps [96]. Time-dependence of the diffusion front evolution and water penetration
and distribution analysis revealed case II diffusion for pH 2 and case I diffusion for pH 6.
Obradovic et al. combined the use of terahertz (THz) time-domain reflectance spectroscopy
with MRI to measure solvent penetration in polymers [97]. Plots of hydration front position
versus evolution time indicated case I behaviour.
1.4.3 Characterisation of the solid state structure of ASDs
There are three major solid-state NMR (ssNMR) approaches that have been employed for
the characterisation of ASD formulations [98]:
(i) High resolution MAS spectroscopy, e.g. 13C CP-MAS (cross polarization magic angle
spinning): for the identification and quantification of different solid forms of API. Resonance
linewidths are affected by changes in structural properties. Amorphous compounds exhibit
broader linewidths due to the increased number of molecular orientations present in
unordered solids. High resolution MAS spectroscopy can also determine the presence
of impurities and degradation products from the emergence of additional peaks in the
spectrum as well as intermolecular associations from chemical shift changes.
(ii) 2D correlation spectroscopy, e.g. 1H-13C HETCOR (heteronuclear correlation): for the
determination of the structural properties of APIs such as molecular conformations,
polymorphism and intramolecular interactions. It can also uncover physical and chemical
interactions between drug and polymer. Cross-peaks in correlation spectroscopy reveal
spatial proximity or chemical connectivity between the probed nuclei.
(iii) Relaxation times, e.g. T1 and T1ρ: for insight into phase separation, physical stability
and average estimates of the dimensions of drug and polymer domains. 1H T1 and T1ρ
are affected by spin diffusion and tend to average. The degree of averaging serves as an
indicator of the heterogeneity of the sample at the nanometre level. Identical values of 1H
T1 (and/or T1ρ) are indicative of an intimately mixed ASD.
The use of high resolution MAS spectroscopy and 2D correlation experiments in the
investigation of drug/polymer interactions will be discussed in more detail in section 1.4.4.
High resolution spectroscopy for the elucidation of crystalline or amorphous drug physical
structure has been widely integrated as part of the routine characterisation of ASDs. Broader
drug resonances were observed in ASD samples than in physical mixtures in which the
drug was crystalline [51, 47]. Apperley et al. (2005) used real-time 1H and 13C band-shape
measurements to follow temperature-dependent drug recrystallisation [99].
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There are numerous examples of 1H T1 and T1ρ measurements to assess phase separation
and miscibility in the literature [100, 51, 47, 101]. Aso et al. observed that the 1H T1ρ of
one of the drug/polymer systems under study (nifedipine–PVP) was described by a mono-
exponential curve, which suggested miscibility [100]. The other system (nifedipine–PHPA)
was described by a bi-exponential equation, indicating that the drug and polymer were
immiscible. Song et al. detected no drug/polymer phase separation (single 1H T1 and T1ρ for
both species) in the felodipine/copovidone ASDs even after storage for two months at 40◦C
and 75% relative humidity [51]. Yuan et al. obtained the same 1H T1 for polymer (PVP)
and drug (nifedipine) in all the ASDs studied except for the 95% drug loading, and a single
1H T1ρ was identified for all except the 95% and 90% drug loaded ASDs [47]. They used
the formula for the length-scale of spin diffusion to estimate the drug domain sizes in the
formulations: samples with a unique T1 were miscible giving domain sizes between 20-50 nm
and those with the same T1ρ were determined to have domain sizes smaller than 2-5 nm.
Most recently, Yin et al. used ssNMR 1H T1 and T1ρ to assess in-situ thermal mixing of
a drug in a polymer [101]. The temperature in the magnet was stepped up from 115◦C to
140◦C while 1H T1 measurements were performed. As temperature increased, the T1 of the
drug and the polymer became closer, indicating higher degree of molecular miscibility.
1.4.4 Analysis of drug/polymer interactions in ASDs
It is well established in the literature that drug-polymer interactions can increase the stability
of a drug in an ASDs with respect to thermal degradation, drug recrystallization on storage
and maintaining supersaturation during dissolution [32, 102]. Strong drug-polymer bonds
favour the chemical potential depression and enhance the solubility and miscibility of the
drug and polymer. The main types of interactions, in decreasing order of bond energy, are
ionic, hydrogen bond, dipole-dipole and Van der Waals.
Traditional approaches to probe for intermolecular associations include FTIR and Raman
spectroscopy. These are revealed as a red shift of the spectral band (movement to lower wave
number) and/or band broadening. However, as mentioned in section 1.4.3, intermolecular
bonds in solid-state ASD formulations can also be investigated by NMR either through high
resolution MAS spectroscopy or 2D correlation experiments.
The chemical shift of API and polymer resonances can be affected by changes in structural
properties (local magnetic fields or shielding components) induced by the establishing of
interactions between them [98]. Usually, solid-state 13C high resolution spectra are required
to detect these changes, which can be smaller than 1 ppm, but solution-state 1H NMR
resonance line widths can also provide indirect information on drug-polymer interactions.
Peak width is proportional to T2, so that shorter T2 results in peak broadening. Faster T2
relaxation can be attributed to decreased rotational mobility; consequently peak broadening
could be attributed to strong interactions.
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There are numerous examples in the literature of one-dimensional high-resolution (solid-
state and solution-state) NMR spectra from which chemical shift differences are used to
investigate drug-polymer interactions in ASDs, particularly hydrogen bonds were hypothesised
[103, 104, 51, 47, 105, 102, 106, 101]. Generally, chemical shift differences range from 1 to
5 ppm and these occurred toward higher resonant frequencies due to deshielding of the
nuclei (1H, 13C and 15N are the most commonly studied). Yuan et al. deconvoluted the
isotopically labelled carboxylic acid carbon of the drug (the most likely moiety to bind to the
polymer) into four peaks at different chemical shifts [105]. These were a result of different
drug interaction patterns: drug-drug dimers, drug-drug chains, drug-polymer associations
and free drug (Figure 1.6a). Interestingly, drug-drug interactions were gradually disrupted
with increasing polymer content, until at 50 wt% they were almost undetectable (Figure
1.6a-d). Recently, Yin et al. observed evidence of drug-polymer hydrogen bonding in 13C
and 15N spectra at temperatures lower than melting [101].
Fig. 1.6 13C spectra of carboxylic acid in in-
domethacin/copovidone ASDs at (a) 90 wt%,
(b) 80 wt%, (c) 70 wt% and (d) 60 wt% drug
loading (modified from [105]).
A 2D correlation experiment is visu-
alised as an intensity plot in which each
signal is a function of two frequencies. The
position of the peak indicates the presence
of magnetic moment coupling (e.g. scalar
or J-coupling) between the correspond-
ing nuclei. Certain experiments probe
for through-space interactions (NOESY,
HETCOR) [107] and other sequences ex-
plore through-bond interactions (COSY)
[108].
Solid- and solution-state 2D NMR
correlation experiments have been em-
ployed to gain a deeper understanding
on drug-polymer interactions, structural
characteristics and bond strengths [109–
112, 43, 106]. Pham et al. (2010) per-
formed 2D solid-state analysis on ASDs.
Results from heteronuclear correlation
(1H-13C) and double quantum coherence (1H-1H) experiments showed that at longer contact
times, there was increasing evidence of dipolar coupling. They concluded that a large per-
centage of molecules must have been in intimate contact to produce the observed results,
proving molecular-level interactions between drug and polymer in ASDs [111]. Fule et al.
and Liu et al. conducted solution-state 2D correlation experiments (COSY and NOESY) on
drug/polymer mixtures in solution; evidence of 1H-1H coupling was observed between drug
and polymer [43, 106].
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Drug release and dissolution studies
(integrable with standard testing)
Drug, polymer and solvent dynamics
(through temporal image capture)
1.5 Modelling the formation and stability of ASDs
Mathematical and computational models are being increasingly implemented in drug de-
velopment and manufacturing as an efficient approach to understand systems and predict
process output. Moreover, regulatory bodies encourage the implementation of techniques
that allow quality by design (QbD) of pharmaceutical manufacturing processes [21]. QbD
implies gaining knowledge on the processes instead of following a trial-and-error approach
until a satisfactory end product is obtained. In the context of ASDs, mathematical and
computational models generally aim to estimate drug solubility and miscibility in polymers
to avoid phase separation and ensure stability. Similarly, in the context of HME, several
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mathematical and computational models have been proposed, frequently to predict optimal
processing conditions (e.g. temperature, residence time or drug loading). Some focus on the
mass transport of drug/polymer in the extruder to predict residence time distributions and
others investigate single particle dissolution and interactions to determine the drug particle
dissolution time. These models are simplifications of the actual HME process, due to the
mechanical complexities and the large number of variables and parameters to consider, but
they still require high computational power.
1.5.1 Models for ASD formulation stability
Physical instability in ASDs is likely when there is heterogeneous mixing, where drug-polymer
miscibility is poor and where drug loading exceeds the drug/polymer miscibility limit [4].
Miscibility denotes the dissolution of a liquid solute in a liquid solvent and it depends on
cohesive (drug-drug and polymer-polymer) and adhesive (drug-polymer) interactions. For
drug/polymer miscibility to be favoured, the free energy of mixing (∆Gmix) should be
negative:
∆Gmix = ∆Hmix − T∆Smix (1.5)
Traditionally, DSC is employed to probe for miscibility, where a single Tg is considered
satisfactory evidence of drug-polymer miscibility. However, this measurement is not necessarily
representative of miscibility at storage (lower temperature) conditions. A mathematical
expression for a temperature-dependent miscibility function can be obtained by combining
equation 1.5 with the Flory-Huggins theory of mixing or solubility parameters (introduced
in section 1.2.5). A more in-depth discussion will be presented in chapter 8. Examples of
this application can be found in Marsac et al., Maniruzzaman et al. and Calahan et al.
[113, 104, 48], among others.
1.5.2 Computational models of HME
Mathematical and computational modelling of the HME process has been conducted in the
past decades to determine optimal operating parameters and to aid in the development of
sensors and controllers. The complexity in formulating an accurate model for HME lies in
the number of process parameters and operational variables such as screw rotation speed,
barrel temperature, drug loading, filling ratio, residence time and screw elements. Based on




1. Residence time distribution functions How long material stays in the barrel
2. Systems of ordinary differential eqs.
Mass and energy balances
Variables are function of time
3. Systems of partial differential eqs.
Mass and energy balances
Variables are function of time and space
4. Population balance modelling
and discrete element modelling
Individual particle rate processes
Particle interactions (collisions)
5. Black-box (no a priori knowledge) Inferred from experimental data
Eitzlmayr et al. mathematically characterised the correlation between the axial pressure
gradient in the extrusion barrel with the material throughput in one-dimension for a completely
filled screw section [115]. This model was further developed by Eitzlmayr et al.to account
for heat and mass transfer [116]. A system of ordinary differential equations were solved to
yield a 1D profile of the filling ratio, pressure, and temperature, and predict residence time
distributions. Although the full complexity of HME was not captured in this simplified 1D
model, as further experimental and computational work would have been necessary to verify
empirical fitting parameters, the model was successful at predicting mixing performance and
optimising screw architecture.
Derksen et al. built a simplified HME model: spherical drug particles suspended in a
viscous matrix subjected to laminar shear flow [117]. They solved the convection-diffusion
equations to obtain an estimation of the time to dissolution as a function of shear rate, drug
loading, diffusion coefficient and solubility. Schittny et al. also explored the links between
the formation of ASDs and HME process parameters, but built a more complex model by
taking into account extruder and screw geometry [118]. They combined calculations of time
to dissolution of solid drug particles in a molten polymer with a model of mean residence
time of material in the extruder. With a few exceptions, experimental data supported the
validity of the model. These models are considered in more detail in chapter 8.
1.6 Aims and scope of thesis
The primary aim of this thesis is to assess and develop NMR based diffusion techniques to
quantify the self diffusion coefficient of drug molecules in polymer melts at temperatures
relevant to the hot-melt extrusion process. For this end, a model system of paracetamol and
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copovidone will be used. The significance of measuring the mass transport parameter will be
explored by using it in drug particle dissolution models to yield system behaviour predictions.
The aim is that more advanced versions of these models will eventually be used in industrial
settings to anticipate the characteristics of extruded product formulations and accelerate the
innovation process.
Additionally, a variety of techniques from the NMR-toolbox will be employed to further
characterise amorphous solid dispersions. This will include an analysis of the micro-structure
and phase separation behaviour of formulations and an innovative study of drug-polymer
intermolecular interactions. Both of these play a crucial role in the investigations of physical
stability and suitability of extruded products.
Finally, the techniques developed for the paracetamol/copovidone model ASD system,
will be applied to a variety of other systems. These will include a more industrially relevant
API (nifedipine), a comparison of three commonly used pharmaceutical polymers (PVP, PVA
and copovidone), and HME samples from a design of experiments run in which key process




2.1 Nuclear magnetic resonance (NMR)
Nuclear magnetic resonance (NMR) was first studied and described in hydrogen molecular
beams by the Nobel Laureate Isidor Rabi (1934) [119], and in liquids and solids by physicists
Felix Bloch [120] and Edward Mills Purcell [121] in 1946. The NMR phenomenon is based on
the absorption and emission of radio frequency (r.f.) electromagnetic radiation from specific
atomic nuclei when placed in an external magnetic field. This work led to the development of
NMR spectroscopy and the diverse toolbox that is used nowadays to characterise molecular
structures, behaviours and dynamics. In this chapter, the fundamental basics of NMR,
including several pulse sequences relevant for this thesis are introduced, however the complete
and detailed theory of NMR can be found in standard texts, such as the ones by Malcom
Levitt and James Keeler [122, 123].
2.1.1 Principles of NMR
The nuclear spin is an intrinsic quantum mechanical property that is characterised by a spin
quantum number (I). I represents the number of unpaired nucleons (protons and neutrons)
and it can be zero or an integral multiple of 12 . Only nuclei with odd number of protons
and/or neutrons will be NMR active. The hydrogen atom (1H) is of particular interest
because it has a spin number of 12 and is naturally abundant. Other common elements such
as carbon (12C) or oxygen (16O) have a spin number of zero, so they are NMR inactive.
In the absence of an external magnetic field, a nucleus displays (2I + 1) degenerate states
(meaning that they are all at the same energy level). However, when exposed to an external
magnetic field (B0), the degenerate states unfold to occupy (2I + 1) energy levels. This is
known as Zeeman splitting and, in the case of the 1H nucleus, a high (β) and a low (α) energy
state can be associated with I = −12 and I =
1
2 , respectively (Figure 2.1a). This can be
considered as the magnetic moments of the nuclei aligning with (α-state) or against (β-state)
B0. The transition between the α and β states is possible through the absorption/emission
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of electromagnetic energy packages:
∆E = h̄ · γ · B0 (2.1)
where h̄ is Planck’s constant (1.055·10−34 J·s), γ is a nuclei-specific constant known as the
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Fig. 2.1 Schematic of (a) an energy diagram depicting the Zeeman splitting effect for the 1H
nucleus and (b) a spin system (some in the α and others in the β state) precessing at ω0 in
the presence of an external magnetic field B0, where Mz denotes the total magnetisation
vector.
When a large ensemble of spins is considered, the presence of an external magnetic field
influences them to align in its direction; however, random thermal motion opposes this









where B0 is the external magnetic field magnitude, k is Boltzmann’s constant (1.38 · 10−23
J/K) and T is the temperature in Kelvin units. Due to the difference in Nα and Nβ , the sum
of the magnetic moments of all the spins in the system, or the bulk magnetisation (M), will
be parallel to B0. This is known as the Bloch vector model [120], which characterises the
magnetisation vector of the entire spin system in terms of the external magnetic field as:
dM
dt
= γ · M × B0 (2.3)
Equation 2.3, describes that the magnetic field exerts a torque that causes M to rotate
(or precess) about the axis of B0 (Figure 2.1b). The precession angular frequency (ω0), also
known as the Larmor frequency, is derived from equation 2.1 as:
ω0 = γ · B0 (2.4)
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This is also the frequency of the electromagnetic radiation emitted when a transition from
the β to the α state occurs.
Spin excitation and free induction decay (FID)
At equilibrium, in a magnetic field applied in the z-direction the total magnetisation along
B0 is Mz = M0. In the transverse (x-y) plane Mxy = 0 because the distribution of the x-
and y-components of the equilibrium magnetisation is random (i.e. there is no coherence).
Mz, however, cannot be detected directly, so the system has to be perturbed (i.e. excited) to
relocate M0 to the transverse plane. The excitation required is supplied through a temporary
B1 magnetic field in the form of an r.f. pulse perpendicular to B0.
For clearer visualisation, the system is considered in the rotating frame at the Larmor
frequency about B0 (i.e. the x- and y-axes are rotating about the z-axis, forming the x’-y’
plane), Figure 2.2a. If the B1 r.f. pulse is supplied in the same rotating frame (resonance
condition), M0 will effectively be tilted towards the transverse plane at a ‘tip’ angle (θ)
dependent on r.f. pulse magnitude (B1) and length (tp):
θ = γ · B1 · tp (2.5)
The most common pulses are: (i) for excitation (θ = 90◦), which tilts the entirety of M0
to the transverse plane, yielding maximum signal; and (ii) for inversion (θ = 180◦), which
inverts M0 to the negative z-axis. Henceforth, the rotating frame (x’-y’) will be considered in






















Fig. 2.2 Schematic of (a) Mz = M0 relocated to
the x’-y’ plane; (b) relaxation of the magneti-
sation to equilibrium; and (c) free induction
decay (FID) signal detected in NMR experi-
ments and its frequency-domain counterpart.
Once the magnetization has been ro-
tated to the transverse plane (Mxy =
M0), the precession of Mxy is detected
by an r.f. coil surrounding the sample.
The measured signal (S) decreases in in-
tensity as Mxy spontaneously returns to
its equilibrium state at Mz (Figure 2.2b).
This is a process of ‘relaxation’ and will
be explored in the following section. The
signal acquired after an excitation pulse
is known as a free induction decay (FID,
Figure 2.2c).
The FID is a time-domain sinusoidal
function that can be expressed as:
S(t) ∝ M0 · exp(i · ω0 · t) (2.6)
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if relaxation effects are ignored.
Interpretation of the FID acquired from a sample is highly complex, as it is generally
comprised of a superposition of several periodic signals corresponding to distinct nuclear
environments, as well as noise. Local magnetic environments (e.g. moving electrons) act to
shield/deshield nuclei from B0, resulting in different effective magnetic fields experienced by
the spins. The time-domain signal is converted to a frequency-domain signal, S(ω), via a
Fourier Transform (FT ) for explicit interpretation (Figure 2.2c):
S(t) FT−−→ S(ω) =
∫ ∞
−∞
S(t) · exp(i · 2π · ω · t)dt (2.7)
Frequency units, however, do not provide unambiguous classification of NMR signals
because precession frequencies depend on external field strength. For that reason, the
unequivocal chemical shift (δ) variable is used, with units of ppm:
δ = ω0 − ωref
ωref
· 106 (2.8)
where ωref is the Larmor frequency of a reference compound. For solution-state 1H and
13C NMR, tetramethylsilane (TMS) is accepted as the internal standard for calibrating the
chemical shift scale. Chemical groups have characteristic chemical shifts that can be used to
identify compounds, and this is the foundation of NMR spectroscopy.
Relaxation processes
Relaxation is the mechanism by which magnetization returns to equilibrium. This is a
spontaneous process driven by random thermal motion and exchanges with the environment
(lattice). In this section, the T1 and T2 relaxation constants are described based on the Bloch
equation (extended form of equation 2.3, which did not account for relaxation effects).
Spin-lattice, longitudinal or T1 relaxation is the recovery of magnetisation along the z-axis



























Fig. 2.3 (a) Schematic of the inversion recovery sequence to measure T1 relaxation, showing
the evolution of magnetisation throughout the pulse sequence. (b) Typical inversion recovery
plot for a range of delays (τ).
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The most common approach to measure T1 is through the inversion-recovery pulse
sequence [124] (Figure 2.3a). Mz is inverted with a 180◦ pulse, followed by a variable delay
(τ) during which the magnetisation begins to recover. Then a 90◦ pulse is applied, allowing
the signal to be recorded. The T1 constant provides a guideline for selecting appropriate




= −Mz − M0
T1
→ Mz(t) = M0
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Spin-spin, transverse or T2 relaxation characterises the loss of phase coherence in the
plane perpendicular to B0. There are two factors that contribute to transverse magnetisation
decay: (i) an irreversible component caused by molecular interactions (T2) and (ii) a reversible
component produced by inhomogeneities in B0 (T2,B0). The combined effect of these two






















































Fig. 2.4 (a) Schematic of the spin-echo sequence to measure T2 relaxation, showing the
evolution of magnetisation throughout the experiment. Schematic of (b) the CPMG sequence,
depicting the difference between T2 and T ∗2 relaxations; and (c) a typical CPMG plot for a
range of (180◦) refocusing pulses.
T2 relaxation can be measured through the Carr-Purcell-Meiboom-Gill (CPMG) sequence
[125], which is based on the spin-echo experiment. The spin-echo sequence (Figure 2.4a)
compensates for the reversible spin dephasing effects caused by field inhomogeneities, which
are constant throughout the experiment, to reveal the ‘pure’ T2 processes, which are random.
After a 90◦ pulse, the magnetisation dephases due to molecular and inhomogeneous field
effects, at a rate defined by T ∗2 . A 180◦ pulse is then applied to refocus the phases of the
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dephasing spins, causing them to rephase, until the only loss of coherence is that due to the
irreversible T2 effects.
In the CPMG sequence a spin-echo is followed by a train of equally spaced 180◦ pulses
(Figure 2.4b). By repeating this sequence with varying numbers of refocusing pulses, the T2












2.1.2 Diffusometry: Pulsed-field gradient (PFG) NMR
Diffusion is the passive movement of particles suspended in a medium. If it is driven by a
chemical gradient generated by differences in concentration of species, it is known as transport
diffusion (Dtrans). Diffusion can also be used to describe the Brownian (random) motion
of molecules suspended in a fluid. This is the case for self-diffusion Dself , which can be
measured with PFG NMR techniques as will be described in this section.
Magnetic field gradients
As mentioned before (and shown in equation 2.4), the Larmor frequency is dependent on the
magnetic field strength (B0). Applying a linear magnetic gradient (g), in any given direction
(r), results in a spatial dependence of spin Larmor frequency (ω(r)):
ω(r) = γ(B0 + g · r) (2.12)
Once the gradient is removed, the spins return to their original precession frequency, but
with a relative phase shift, ϕ, which is a function of the gradient applied and the time over
which it was applied (δ):
ϕ(r) = γ · δ · g · r (2.13)
δ is typically in the order of a few milliseconds, and for this reason the technique is called
pulsed field gradient (PFG) NMR.
In the case that the spins remain in their initial positions, application of a second gradient,
identical to the first but of opposite polarity (−g), results in all of the spins being rephased.
Neglecting relaxation effects, the initial magnetisation Mxy is recovered. In the case that
the spins evolve (diffuse) for a time (∆), the second magnetic gradient experienced by the
individual spins will not be of the same magnitude but inverse polarity to the first one, which
will result in incomplete recovery of the spin phases. The net phase shift after the second
gradient will be a function of the spins’ initial (ri) and final (rf ) positions:
ϕ(r) = γ · δ · g · (ri − rf ) (2.14)
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In a system undergoing Brownian diffusion, the spins will have moved randomly, so the
Mxy magnetisation will remain in the same orientation, but have a lower magnitude than
before the gradients were applied. The relationship between the diffusion coefficient (D) and
the intensity of the signal measured (S(g)) is known as the Stejskal-Tanner equation [126]:
S(g) = S(0) · exp
[





where S(0) is the signal intensity in the absence of gradients, g is the gradient strength and δ
its duration, and ∆ is the observation time between the two gradients. The term δ3 accounts
for diffusion during the application of the gradients. It should be noted that relaxation occurs
during the measurement and that is why, in practice, the NMR signal is acquired for different



























Fig. 2.5 Schematic of (a) the pulsed-gradient spin-echo (PGSE), (b) the pulsed-gradient
stimulated-echo (PGSTE), and (c) the alternating pulsed-gradient stimulated-echo (APGSTE);
where ∆ and δ are the pulse interval and duration respectively and T is the storage period.
PGSE
The pulsed-gradient spin-echo (PGSE) sequence [126] is one of the most basic NMR techniques
for measuring diffusion coefficients and it is based on the spin-echo experiment presented
in the previous section (Figure 2.4a). As shown in Figure 2.5a, in the PGSE sequence the
magnetic field gradients are applied with the same polarity and magnitude. The second
gradient comes after a refocusing 180◦ pulse, which has the same effect as applying a gradient
of opposite polarity. The sequence is repeated after a recycle time (TR) with increasing
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gradient strengths and the intensity of the measured signal is fitted to the Stejskal-Tanner
equation (equation 2.15) to obtain a diffusion coefficient (D).
The main issue with the PGSE sequence is that signal attenuation will occur due to T2
relaxation (as in the spin-echo sequence) during ∆. In systems with short T2 values or slow
diffusing particles that require long observation times, there will be no spin coherence by the
time of acquisition
PGSTE
The pulsed-gradient stimulated-echo (PGSTE) sequence [127] is an alternative to the PGSE.
As shown in Figure 2.5b, the PGSTE experiment is comprised of three sequential 90◦ pulses.
The first one rotates magnetisation to the transverse plane, the second one rotates it to
the negative z-axis. In this state, the spins no longer dephase according to T2, but undergo
only T1 relaxation (of particular interest for systems in which T1»T2). Consequently, longer
observation times (∆) can be used, which is necessary for slow-diffusing particles, such
as those suspended in viscous media. During this ‘storage’ period (T ) a spoiler gradient
(homospoil) is applied to dephase any magnetisation that remains in the transverse plane
due to pulse imperfections, which gives rise to unwanted spin-echoes.
APGSTE
A further improvement is the use of bipolar gradients in the alternating pulsed-gradient
stimulated-echo (APGSTE) sequence [128]. As shown in Figure 2.5c, the APGSTE is based
on the PGSTE experiment, but includes two refocusing pulses between the magnetic gradients
of opposite polarity.
The APGSTE improves NMR diffusion measurements in heterogeneous systems, par-
ticularly when components have different magnetic susceptibilities. This usually generates
local background gradients, which may cause excessive signal attenuation and a systematic
error in the diffusion measurements. The 180◦ pulse recovers the dephasing effects of the
local background gradients, under the assumption that the diffusing molecules experience a
constant internal gradient during the experiment.
It should be noted that a modified Stejskal-Tanner equation is required to calculate the
diffusion coefficient from APGSTE data:
S(g) = S(0) · exp
[
−D · (γ · δ · g)2 ·
(





where τ is the time between each of the gradient pulses in a pair of opposing gradients. If τ ,
which is dependent on the length of the 180◦ pulse, were insignificant, then equation 2.16
would tend to the traditional Stejskal-Tanner equation (equation 2.15).
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2.1.3 NMR profiles: 1D imaging
An NMR profile is a one-dimensional image, or intensity plot that spatially maps the
concentration of a certain nucleus along the desired axis (Figure 2.6a). 1D spatial resolution
is achieved through a magnetic field gradient, in a similar way as it is used to quantify spin
mobility (diffusion). An imaging gradient along the z-direction causes spins to precess at
different frequencies (equation 2.12). The signal (dS(t)) obtained from a slice in the sample
(dV ) when a gradient G is applied in direction r (neglecting relaxation effects and considering
it in the rotating frame) is proportional to:
dS(G, t) ∝ ρ(r) · exp(i · γ · G · r · t)dV (2.17)
S(G, t) ∝
∫ ∫ ∫
ρ(r) · exp(i · γ · G · r · t)dr (2.18)
where ρ(r) is the spin density in the considered voxel. By defining a reciprocal term (or
k-space) [129]:
k = γ · G · t2π (2.19)




ρ(r) · exp(i · 2π · k · r)dr (2.20)
ρ(r) ∝
∫ ∫ ∫
S(k) · exp(−i · 2π · k · r)dk (2.21)
This implies that an acquired time-domain signal (S(k)) can be Fourier transformed to yield
a spin density (ρ(r)) map or image.
The pulse sequence for such an experiment is shown in Figure 2.6b: the initial excitation
pulse is followed by a gradient that phase-encodes the positions of the spins along the chosen
direction. The spins acquire relative phase differences when the gradient is removed. The 180◦
pulse then refocuses the magnetisation in the transverse plane and a second gradient (applied
in the same direction as the first, but for twice as long) rephases the signal. With respect to
k-space definition, the first gradient sweeps from the center of k-space to the positive edge,
the 180◦ pulse moves the spins to the negative edge and the second gradient (twice as long
as the first) reads one whole line of k-space (S(k)) while signal is acquired (Figure 2.6c).
Resolution in additional Cartesian coordinates to obtain 2D and 3D signal intensity images
















(a) (b) (c) Ky
Kx
Fig. 2.6 (a) Diagram illustrating the 1D profile from a cylindrical sample when a gradient is
applied, (b) schematic of the pulse sequence to acquire 1D profiles (along the z-axis), and (c)
a Cartesian representation of k-space color-coded to match the pulses shown in (b). Each of
the intersections in (c) represents a different k-space coordinate.
2.1.4 Solid-state NMR for miscibility studies
Solid-state NMR (ssNMR) is an independent field within the magnetic resonance toolbox.
In the context of this thesis, and for the sake of brevity, this section will focus on the basic
principles of ssNMR and its uses in the context of miscibility and phase separation studies
[76, 98, 130].
The local magnetic field experienced by a nucleus (and thus its resonant frequency) is
dependent on the external field (B0) and a shielding factor, determined by the distribution
of surrounding electrons and the orientation of the molecular fragment the nucleus belongs
to with respect to B0. Unlike in liquids, molecular tumbling is absent in solids; consequently,
for a powder sample in which all orientations are statistically possible, a certain nucleus in a
molecule will precess at a range of frequencies, which results in severe broadening (lack of
resolution) of resonances. This is known as chemical shift anisotropy (CSA). In liquids, the
continuous molecular tumbling averages out the orientation-dependent contributions to its
frequency spectrum.
The line-broadening phenomenon in solids is further exacerbated by all the orientation-
dependent nuclear spin couplings. A coupling interaction between two nuclei occurs when a




Dipolar interaction Due to magnetic field associated with the nuclear spin
J-coupling/
scalar coupling
Magnetic interaction arising through bond electrons




Originates from uneven electric charge distribution
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Andrew et al. (1958) and Lowe (1959) were the first to describe that spinning a solid
sample at high speeds (∼kHz) at a specific angle with respect to B0 (θm=54.74◦) averages out
the orientation-dependence of spin interactions outlined above [131, 132]. This is known as
magic angle spinning (MAS) and if the rotating frequency was infinitely high, all anisotropy
would be averaged. In practice, the highest MAS frequency routinely achievable is ∼70
kHz, which averages J-couplings and quadrupolar interactions. However, it usually results
in a limited improvement for strong dipolar couplings, particularly in nuclei with high
gyromagnetic ratio, as is the proton. Another characteristic of MAS spectra is the appearance






































Fig. 2.7 Schematic of (a) cross-polarization (CP), (b) saturation recovery for 1H T1 via 13C
detection, and (d) 1H T1ρ via 13C detection pulse sequences for solid-state NMR. (c) Diagram
illustrating the magnetisation vector during the application of a spin-lock pulse.
High resolution proton studies are hampered by the excessive line broadening effects due to
the strong nature of the 1H–1H dipolar couplings, which even at high MAS rates and with the
use of decoupling techniques are only partially reduced. For this reason, it is more common to
acquire spectra from less abundant nuclei, such as 13C. In this case, heteronuclear decoupling
to remove 1H–13C dipolar coupling (such as SPINAL-64 [134, 135]) is highly effective, but
the 13C nucleus is so rare (1% natural abundance) that the sensitivity of the measurement is
very low. Therefore, cross-polarization (CP) is applied before heteronuclear decoupling. CP
is a pulse sequence (Figure 2.7a) that exploits the dipolar coupling between an abundant and
a rare (or low-γ) nucleus. It not only increases sensitivity through magnetisation transfer
of coupled spins, but it also reduces experiment time (TR) due to the shorter T1 relaxation
of abundant (a) spins compared to that of dilute (d) nuclei (usually up to three orders of
magnitude). For magnetisation transfer to be efficient, both nuclei need to be irradiated
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fulfilling the Hartmann-Hahn condition [136]:
γa · B1a = γd · B1d (2.22)
This condition ensures the 1H and 13C spin systems are in thermal contact, which enables the
flow of energy. As shown in Figure 2.7a, the CP contact pulse is ramped. This was proposed
by Metz et al. as it improved the performance of the conventional CP sequence, particularly
for 1H–13C CP [137].
Relaxation measurements in ssNMR carry information on nuclear dynamics and nanometric-
level structural conformation. In solution-state NMR T1 and T2 are usually of the same
magnitude, but in solid-state T2 is generally three to seven orders of magnitude shorter than
T1. There is another relaxation constant that is relevant in solids: the spin-lattice relaxation
time in the rotating frame, or T1ρ. It is defined as the decay of signal when magnetisation is
held aligned to an axis in the transverse plane by a spin-lock pulse, BSL, (refer to Figure
2.7c). T1 is sensitive to rapid molecular motions in the MHz scale and T1ρ to slower molecular
motions in the kHz regimen. Statistically identical values of 1H T1 and T1ρ is an indication
of an intimately mixed system in the 10-100 nm and 1-10 nm scale, respectively.
For abundant nuclei such as 1H, T1 and T1ρ are strongly affected by spin diffusion, which
is defined as the spontaneous transfer of magnetization between neighbouring spins. The
characteristic length scale (L) of spin diffusion is:
L =
√
6 · DSP · t (2.23)
where DSP is the spin diffusion coefficient of the system and depends on the distance between
neighbouring protons and t is the time constant associated with the diffusion process.
If the sample is an intimate mixture of two or more compounds, spin diffusion effects result
in the measured relaxometry constants being closer together to one another (due to averaging)
than the intrinsic ones. The degree of averaging is associated with the heterogeneity of the
sample at the nanometric scale. Since 1H spectral resolution is low in ssNMR, T1 and T1ρ
are measured via 13C MAS-CP with dipolar decoupling (pulse sequences shown in Figure
2.7b and d).
Saturation recovery [138] is used in ssNMR instead of the inversion recovery sequence
introduced in the previous section because there is no need for TR to be 5×T1, which
significantly reduces experimental time, especially in crystalline solids that have long spin-
lattice relaxation constants. In this pulse sequence, a train of 90◦ saturation pulses transfer
all magnetisation to the transverse plane and dephase the spins so that there is no coherence
and thus the initial Mxy = 0. The system is allowed to evolved for an increasing delay, τ ,
during which magnetisation begins to relax in the longitudinal direction. When a second
90◦ pulse is applied, the component of the total magnetisation that had relaxed towards the
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z-axis is tipped to the transverse plane and recorded (Figure 2.7b). For the shorter delays,
little signal is acquired, whereas for the longer ones almost the total magnetisation is recorded








Similarly, the decay of magnetisation along the spin-lock field (applied for a variable length









2.1.5 2D NMR for molecular interactions
This section briefly describes the basic principles of two-dimensional NMR and introduces
the pulse sequences used for the results presented in chapter 5. In two-dimensional NMR
spectroscopy (2D NMR) signal intensity is plotted as a function of two frequencies, usually
as a contour plot. The presence of cross-peaks between two resonances indicates a correlation
between homonuclear or heteronuclear spin pairs originating from scalar or dipolar coupling.
The intensity of the signal observed reflects the extent of nuclear proximities, which will be














Fig. 2.8 Interpretation of peaks
in a hypothetical 2D COSY spec-
trum consisting of two protons
that are coupled together
Correlation spectroscopy (COSY) was the first 2D NMR
experiment proposed [108]. COSY is a homonuclear
experiment that produces two types of signals (Figure
2.8): diagonal-peaks (at the same frequency coordinates),
which are centred at every resonance in the correspond-
ing 1D spectra; and cross-peaks, which indicate that
the nuclei pairs are coupled through scalar interactions
(through-bond).
The pulse sequence for a COSY experiment is shown
in Figure 2.9a. The first pulse creates transverse mag-
netisation along the y’ axis that is labelled by chemical
shift and coupling. This magnetisation is allowed to
evolve during d0 (variable delay). After the second 90◦
pulse, the magnetisation along y’ is tipped to the z-axis and is undetectable, only the compo-
nent in the x’ direction evolves and is detected. During td (detection time), the transverse
magnetisation contains components from the nuclei under observation as well as the frequency
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of the coupling. This sequence is repeated for increasing values of d0 and the FID is recorded
as a function of td to create the 2D plot.
In COSY spectra, all resonances give rise to diagonal-peaks and some may generate
cross-peaks as well. The appearance of a cross-peak between two frequencies (ωa and ωb)
implies that part of a signal that was present during d0 with a frequency of ωa was transferred
through a scalar interaction to another signal that precessed at ωb during td (Figure 2.8).
The rest of the signal precessing at ωa in d0 that remains unaffected during td leads to
the diagonal-peak. The COSY pulse sequence has two possible spin coherence transfer
pathways [123]. Traditionally, phase cycling is used to select one of the coherence pathways
and avoid them interfering with each other; however, it results in very lengthy experiment
times. An alternative for coherence pathway selection is applying pulsed field gradients,
















Fig. 2.9 Schematic of (a) COSY, and (b) SE-COSY 2D NMR pulse sequences, where d0 is
the variable delay, td the detection time and dSE the spin-echo delay. (c) Example 1H–1H
COSY spectrum of ethylbenzene (the chemical structure with protons labelled a-c, adapted
from http://chem.ch.huji.ac.il/nmr/techniques/2d/2d.html).
The conventional COSY experiment can be modified to include a spin-echo pulse sequence
(Figure 2.9b). Increasing the spin-echo delay (dSE) results in a stronger T2-weighting effect
of the COSY spectrum. In this way, the signals from the protons that have the shortest T2
constants are removed from the 2D contour plot.
Figure 2.9c shows the 2D 1H–1H COSY spectrum of a model compound, ethylbenzene
(EB). The structure of EB has three resolvable proton environments: methyl (a), methylene
(b) and aromatics (c). Outside the diagonal peaks, the cross-correlations detected correspond
to the methylene-methyl protons (a-b) and the aromatic-aromatic ones (c-c). These signals
indicate through-bond coupling.
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Fig. 2.10 (a) Schematic of a NOESY pulse
sequence where where d0 is the variable de-
lay, tm is the mixing time and td the detec-
tion time. (b) Example 1H–1H NOESY spec-
trum of ethylbenzene, the protons in the chem-
ical structure are labelled a-c (adapted from
http://chem.ch.huji.ac.i).
NOESY stands for nuclear Overhauser en-
hanced spectroscopy. The nuclear Over-
hauser effect (NOE) is the transfer of mag-
netisation between populations of spins
via cross-relaxation. NOESY is a 2D ex-
periment that detects dipolar interactions
between neighbouring protons undergoing
spin-lattice relaxation to probe average
distance between coupled nuclei.
The basis of NOESY is closely related
to COSY and the result is a 2D plot with
a diagonal-peak centred at each resonance
and cross-peaks indicating through-space
interactions (refer to explanation for Fig-
ure 2.8). The pulse sequence for a NOESY
experiment is shown in Figure 2.10a. The
excited magnetisation is labelled with the
chemical shift during the variable delay
d0. The second 90◦ pulse rotates mag-
netisation into the negative z-axis. This
magnetisation causes an NOE on spatially
close nuclei during tm: the Mz of a nucleus
A will oscillate at ωA in d0, and the NOE
magnetisation at the chemical shift of a
nearby nucleus B will also oscillate at ωA.
The interaction is detected with the third
90◦ pulse.
Figure 2.10b shows the 2D 1H–1H NOESY spectrum of EB. The same cross-correlations
as in the COSY experiment were detected (a-b and c-c). Two additional through-space
correlations are visible from the NOESY plot: the methyl and the methylene protons coupled
with the aromatic ones (a-c and b-c, respectively).
13C–1H HETCOR
13C–1H heteronuclear correlation (HETCOR) experiments highlight carbon nuclei with
directly attached or nearby protons (depending on cross-polarization time). The pulse
sequence used for this work is the 13C–1H CP-MAS HETCOR with FSLG (frequency-
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Fig. 2.11 (a) Schematic of a 13C–1H HETCOR
with FSLG and TPPM decoupling pulse se-
quence where θm is the magic angle, d0 is the
variable delay, tc is the contact time and td
the detection time. (b) Example 13C–1H HET-
COR spectrum of ethylbenzene, the protons
and carbons in the chemical structure are la-
belled a-c and 1-6 respectively (adapted from
http://chem.ch.huji.ac.i).
After a pulse of (90◦ + θm), where θm
is the magic angle, the 1H magnetisation
is aligned at the magic angle during d0
and forced to precess about it using 2π
pulses to average 1H–1H dipolar coupling
(FSLG proton homonuclear decoupling).
After d0, any magnetisation perpendicu-
lar to θm is transferred to the transverse
plane through a θm pulse. Heteronuclear
CP is then applied to transfer 1H magneti-
sation to 13C, since the natural abundance
of 13C is less than 1%. For short contact
times, tc, the correlation map exhibits 1H–
13C pairs that are most strongly dipolar
coupled; whereas for increasingly longer
tc, additional correlation cross-peaks ap-
pear, resulting from longer range couplings
and 1H spin diffusion. The 13C signal is
recorded during td using TPPM to de-
couple the protons from the carbons to
improve 13C signal resolution.
Figure 2.11b shows the 2D 13C–1H
HETCOR spectrum of EB. In the hori-
zontal dimension, the same three proton
environments (a, b and c) identified in
Figures ?? and 2.10 are observable. In
the vertical 13C dimension there are six
resonances: 1 corresponds to the methyl
carbon, 2 to the methylene one, and 3-6 to the aromatic carbons. Through-space correlations
are detected between the methyl and methylene carbons to both their corresponding protons
(1-a, 1-b, 2-a and 2-b). Additionally, the aromatic carbons 3, 4 and 5 display nuclear
proximity to the aromatic protons (c). There is no observed coupling between carbon 6 to
any proton.
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1H–1H MQC (DQ/SQ)
In a one-spin system there are two possible states (α and β). The transition between one
to the other involves only one quantum, which is why it is known as a single-quantum
transition (Figure 2.12a). In a two-spin system in which the spins are coupled through some
interaction (such as dipolar) there are four possible states (Figure 2.12b). Several transitions
can occur involving none, one or two quanta (zero-, single-, or double-quantum transitions).
The evolution of quantum transitions is also known as coherence transfer pathways.
90ᴼ
t1H
90ᴼ90ᴼ 90ᴼ 90ᴼ90ᴼ90ᴼ 90ᴼ90ᴼ
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Fig. 2.12 (a), (b) Illustration of zero-, single- and double-quantum transitions in a one- and a
two-spin system, respectively. (c) Schematic of a 1H–1H MQC SQ/DQ experiment, where τR
is the period of the rotating rotor, d0 is the variable delay and td the detection time.
Multiple quantum coherence (MQC) 2D NMR experiments can correlate single quantum
(SQ) and double quantum (DQ) coherence in dipolar coupled spins. Althugh pulse sequence
architecture is usually complex, they follow a basic scheme of four stages: excitation, evolution,
reconversion and detection (Figure 2.12c). The first stage is designed to excite the desired
MQC pathway, as could be 1H DQ coherence. The MQC system is then allowed to evolve
for a variable delay d0 under the influence of local and external magnetic fields. However,
MQ coherences are not directly measurable so they have to be transferred to the SQ modes
for detection (reconversion stage). Finally, the magnetisation has to be tipped from the B0
axis to the transverse plane for signal acquisition. The delay between the reconversion and
detection stages serves to dephase spurious (interfering) transverse magnetisation.
1H–1H MQC DQ/SQ correlation can be acquired with the BABA pulse sequence (Figure
2.12c) [139, 140]. BABA stands for back-to-back, since the rotor synchronisation is achieved
by setting the r.f. pulses back-to-back. Rotor synchronisation is required to recover dipolar
coupling when spinning at very high frequencies, which is why the spacing between pulses in
the excitation and reconversion stages is dependent on rotor spinning frequency (through
τR). At such high MAS rates, high resolution spectral lines can be accomplished, but
dipole-dipole couplings are greatly averaged. The advantages of DQ/SQ experiments is
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that double-quantum coherence selects spin pairs and the spectrum from isolated spins is
suppressed. Furthermore, there is no interference for the typically high-intensity diagonal
components.
Fig. 2.13 Example 1H–1H MQC SQ/DQ BABA
example spectrum of alanine, the protons in the
chemical structure are labelled a-c (adapted
from [141]).
Figure 2.13 shows the 2D 1H–1H
BABA spectrum of alanine (ALA). The
structure of ALA has three resolvable pro-
ton environments: methyl (a), methine (b)
and amine (c). In DQ/SQ experiments
like this one, peaks in the diagonal indicate
self-correlation. The methyl and amine
groups in ALA display diagonal peaks (a-a
and c-c, respectively) because they involve
more than one proton. No self-correlation
is observed for methine, as there is only
one proton in this group. Interpretation of
cross-peaks is made in the following way:
two resonances are considered to be cou-
pled when a signal is detected at both of
their corresponding chemical shifts in the
SQ dimension and their position along the
DQ dimension is the sum of said chemical
shifts. In Figure 2.13 there are three sets
of cross-peaks observable. The first one is
between the methyl and methine protons
(a-b); their chemical shifts are 1.5 ppm
and 4 ppm respectively and the position of these signals in the DQ dimension is at 5.5 ppm
(1.5 + 4 = 5.5). The second one is between methyl and amine resonances at 1.5 ppm and 9
ppm in the SQ axis, positioned at 10.5 ppm in the DQ axis (a-c). Finally, a coupling between
methine and amine protons (b-c) is exhibited by the signals at 4 ppm and 9 ppm along the
SQ axis, at 13 ppm in the DQ dimension.
2.2 Differential scanning calorimetry (DSC)
Differential scanning calorimetry (DSC) is a widespread thermoanalytical technique to
measure the temperatures and heat flows associated with physical and chemical transitions in
materials as a function of temperature and time. It was developed by Watson and O’Neill in
1962 [142]. A schematic of the cross-section of a typical DSC instrument is shown in Figure
2.14a. A sample (contained in an aluminium pan) and a reference (an identical, but empty
pan) sit on carefully calibrated discs. DSC measures the difference in heat flow rate, in Watts
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(W), between the sample and the reference as they are heated, cooled or held isothermally.
Nitrogen purge is used to maintain an inert atmosphere.
There are two main types of DSC experiments. Standard DSC is a relatively fast technique
that allows quantitative analysis of transitions (e.g. glass transition, crystallisation, melting
or degradation, Figure 2.14b). Its main limitation is in the interpretation of results for
mixture systems, since the DSC thermograms display the average heat flow from overlapping
processes. Sensitivity can be improved by increasing sample size and heating rate, but this
results in lower resolution. In modulated DSC (mDSC) the sample and the reference are
exposed to a linear heating or cooling ramp, which has a superimposed sinusoidal temperature
modulation. Experiments are longer, but it allows to separate the total heat flow (obtained in
standard DSC) into reversing (heat capacity-related) and non-reversing (kinetic) components,
which enhances sensitivity, resolution and accuracy. The reversing heat flow component
provides the best data for glass transition and melting events.
Fig. 2.14 Schematic of (a) a DSC instrument, adapted from TA Instruments documentation
(http://www.tainstruments.com/pdf/literature/DSC_2910.pdf) and (b) DSC thermogram
showing some common thermal transitions.
The glass transition temperature (Tg) is one of the most important thermophysical
properties of amorphous materials. It can be compared with the melting point of a crystalline
compound since it indicates the transition from hard, brittle, glassy material to soft and
rubbery. It is not a discrete event, but a range of temperatures over which the molecular
mobility increases significantly. The convention is to report a single temperature, defined as
the midpoint of the temperature range bounded by the tangents to the two baselines of the
heat flow curve.
2.3 Thermogravimetric analysis (TGA)
Thermogravimetric analysis (TGA) is a technique in which the mass of a material is monitored
as a function of temperature and time as the sample is heated, cooled or held isothermally.
The sample is contained in a TGA pan (platinum basket that has been previously tared),
which is placed in a furnace while supported by a precision balance, Figure 2.15a. TGA
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measures the percentage change in sample mass during the experiment for quantitative
analysis of events such as solvent loss, oxidation, decomposition or sublimation, Figure 2.15b.
Nitrogen purge is used to maintain an inert atmosphere. TGA has several applications, such
as evaluating thermal stability or purity of a substance.










Fig. 2.16 Schematic of parallel
plate rotational rheometer for
the determination of the complex
viscosity, η∗, of a sample.
Rheology is the study of flow and deformation of mat-
ter in response to applied forces or stresses [143]. The
physical property that characterises the resistance to
deformation of a material is the viscosity, quantified in
Pa·s. It reflects the internal frictional force between ad-
jacent layers of liquid as they shear or move with respect
to one another. Rheological properties are measured
on a rheometer, such as the parallel plate rheometer
illustrated in Figure 2.16. The bottom plate applies
a strain on the sample through continuous rotation or
rotational oscillation. A transducer attached to the top
plate converts the torque or stress transmitted by the
material into an electrical signal for interpretation. The
mathematical definition of pure viscosity (or shear viscosity), η, is:
η = shear stress [Pa]
shear rate [s−1] (2.26)
In rotational rheology tests, the complex (or frequency-dependent) viscosity, η∗, is
determined from two additional parameters: G′ and G′′. The storage or elastic modulus (G′)
is a measure of the energy stored in a material in which a deformation is imposed. This
energy allows the material to recover its initial shape after the stress has been applied. The
loss or viscous modulus (G′′) is the energy dissipated upon deformation. This energy is
unrecoverable and results in permanent deformation. The ratio of loss to storage modulus is
known as the damping factor (tanδ) and indicates viscous-dominant behaviours for values
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The overall resistance to rotational deformation, whether viscous or elastic, is characterised
by the complex modulus (G∗):
G∗ = G′ + iG′′ (2.28)
From the complex modulus definition in equation 2.28, the complex viscosity can be calculated








diffusion studies of paracetamol
3.1 Introduction
There is a growing body of literature exploring pharmaceutical HME, however, there are
still substantial gaps in our understanding regarding the dynamics of drug dissolution and
dispersion in viscous polymers. Computational models have been built in order to predict
optimal processing conditions (e.g. temperature, residence time or drug loading), but they
are limited by the lack of supporting data for key mass transport parameters. A common
omission is the lack of experimental data on the API diffusion coefficient at conditions
relevant to HME [117], and currently molecular diffusivities are extracted from complex and
time-consuming molecular dynamic simulations [118].
Diffusion coefficient measurements are not straightforward and there is no standard or
universally applicable method. As outlined in section 1.4.2, PFG-NMR has been extensively
used to observe and measure self-diffusion coefficients in drug/polymer pharmaceutical systems
as it is non-invasive, non-destructive, quantitative and chemically selective. Diffusion-weighted
NMR imaging has been performed on pharmaceutical polymers of interest for controlled-
release applications to study the rate of hydration or solvent diffusion into polymeric gels
and tablets [89, 90, 88, 92, 81, 93, 84]. However, all of these examples are either non-
quantitative (mass transport was observed but a diffusion coefficient was not calculated) or
were quantitative in measuring the diffusion coefficient of a solvent in a polymer, but not of
an API. There are a few reports of API diffusion measurements in polymers, but these are
either mediated by a solvent (hydrogels) [87] or in polymers with very low glass transition
temperatures (23◦C) [144].
PFG-NMR studies on molten polymers above 100◦C have been conducted by Liu et al.
and Stepisnik et al. to characterise mobility regimes [145, 146]. No publications were found
that explored the application of PFG-NMR at temperatures higher than 150◦C other than
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to measure the diffusion of ions (7Li, 19F, 23Na, 27Al and 39K) in molten salts, where a
specifically designed laser heating apparatus was used to reach temperatures of up to 1200◦C
[147–150].
In all of the pharmaceutical studies referenced above the focus was on the mass transport
of water into polymer tablets or solvent-mediated drug release. Recently, Moseson et al.
visualized the solubilisation of drug particles in polymer melts (with no solvents present) [151].
Through elemental composition analysis (SEM with an energy dispersive X-ray detector) of
carbon, oxygen, chlorine and nitrogen at 130◦C, the system was visualised to be diffusion-
based. There was no direct measurement of the drug diffusion coefficient in the polymer melt
and it was speculated that this could be estimated through the Stokes-Einstein model.
Gupta et al. has published several studies on the importance of viscoelastic properties
of polymers for the understanding of HME [152]. Gupta et al. suggested that rheological
analysis provides more appropriate characterisation of polymer behaviour than the more
widely used DSC technique, due to mass effects. Rheological thermomechanical analysis
considers chain disentanglement and mobility phenomena that results in the characteristically
broad glass transition and melting events in polymers. These transitions are influenced
by the amount of material; and DSC experiments samples are of a few milligrams, while
rheology uses 0.5-1 g. In a subsequent publication, Gupta et al. argued that the most relevant
rheological property in the context of polymer HME is the complex viscosity [153]. This
is due to the decrease in complex viscosity exhibited by polymers at increasing shear rates
(this characteristic is known as shear thinning), which is representative of the high shear
environment in the extrusion barrel due to screw rotation and friction with the wall. They
also reported that the optimal system viscosity range for extrusion is 1,000-10,000 Pa·s.
Rheological characterization has been used in the context of HME to assess API solubility
in pharmaceutical polymers at high temperatures [154, 155]. It has also been recently employed
for thermal assessments of API/polymer solid dispersions prepared by different methods
(physical mixtures, cryo-milled and extrudates) and as a predictive tool for processability
and for the selection of optimal processing temperature [156, 157, 72]. In this study, I used
rheological analysis to further interpret observations from high-temperature diffusion NMR
experiments and to improve our understanding of paracetamol/copovidone systems.
To the best of my knowledge there is no quantitative data on API mass transport in
polymer melts in the literature and the work presented in this chapter reports the first
observations of API diffusion in pharmaceutical polymers at temperatures relevant to the
HME process, by means of high-temperature PFG-NMR. The relationship between diffusivity
and viscosity is also explored with the Stokes-Einstein and Arrhenius models.
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3.2 Materials and methods
3.2.1 Materials and sample preparation
API/polymer systems were studied using paracetamol (mean particle diameter ∼300 µm,
Mallinckrodt) and copovidone (Kollidon VA 64®, Mw 45,000-70,000 and 20-200 µm chain
length [158], BASF), supplied by AstraZeneca. Copovidone is a copolymer of 1-vinyl-2-
pyrrolidone (VP) and vinyl acetate (VA) in mass ratio 6:4.
Fig. 3.1 Haake Minilab II twin-screw ex-
truder (Thermo Fisher Scientific) config-
ured with co-rotating screws.
Hot-melt extrudate was prepared using a
Haake Minilab II twin-screw extruder (Thermo
Fisher Scientific, Waltham, MA) configured
with co-rotating screws in the Alford facility
in AstraZeneca, Macclesfield (Figure 3.1). Ex-
trusion was performed at 170◦C and a screw
speed of 40 rpm by manually feeding 10 g of a
30 wt% paracetamol/copovidone physical mix-
ture, prepared using a Turbula blender for 5
min at 23 rpm. Once cooled, extrudates were
collected and ground to powder with a mortar
and pestle.
Non-HME physical mixtures of paracetamol and copovidone at 20:80, 30:70, 40:60, 50:50
and 70:30 weight ratios were prepared by weighing and blending the two powders with a
mortar and pestle.
All samples for NMR studies were vacuum dried at room temperature for 10 min to
remove moisture and sealed with paraffin film prior to analysis.
3.2.2 NMR spectroscopy and diffusometry
All 1H NMR experiments were performed on a 7.07 T Bruker Biospin DMX 300 MHz
spectrometer (BrukerBiospin, Billerica, USA) operating at a 1H frequency of 300.23 MHz
through the ParaVision 4.0 software. A Bruker Biospin DIFF-30 probe was equipped with
an extended variable temperature range 1H/19F 5 mm internal diameter (i.d.) r.f. coil (the
90◦ pulse length was 8 µs). All NMR measurements were made on 100 mg of sample and
over a range of temperatures from room temperature to 180◦C.
Diffusion measurements were performed using a single z-axis shielded gradient system
capable of producing a maximum gradient of 12 T/m. These experiments were based
on the PGSTE sequence for paracetamol and the APGSTE pulse programme for parac-
etamol/copovidone mixtures (schematics of the pulse sequences are shown in Figure 2.5).
APGSTE was used for the heterogeneous systems because it minimises effects of background
gradients due to differences in magnetic susceptibility. The recycle delay (TR) was three
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times the measured longitudinal relaxation (T1) of the system at each temperature. For the
paracetamol/copovidone systems, the TR used were: 6 s at 150◦C, 5 s at 160◦C and 3 s at
170◦C. Diffusion coefficients (D) were calculated by fitting the normalised peak integrals
(from the spectra recorded at different gradient strengths) to the Stejskal-Tanner equation
(equation 2.15). The key experimental parameters are listed in Table 3.1. Curve fitting was
performed on MATLAB_R2017b.
Table 3.1 Values of experimental parameters for the PGSTE and APGSTE experiments:
pulsed field gradient strength range (g), duration (δ), interval (∆) and number of scans (ns),
and stabilization delay (SD).
g [G/cm] δ [ms] ∆ [ms] ns [−] SD [ms]
Paracetamol (PGSTE) 10-300 1 50 16 1
Parac/copov (APGSTE) 10-1,000 1.5-5 30 32 1.5
Prior to recording spectra at high temperatures, the temperature performance of the
PFG probe was calibrated at 10◦C intervals in the 100-180◦C range for an airflow of 670 L/h.
The results of the temperature calibration are presented in section 3.3.1.
3.2.3 Differential scanning calorimetry
Thermal analysis was conducted with a Q2000 (TA Instruments, New Castle, DE, USA)
differential scanning calorimeter. Approximately 3-7 mg of sample was sealed in a standard
aluminium pan and heated from 20◦C to 200◦C at a rate of 4◦C/min, with a modulation
amplitude of ±1◦C and period of 60 s, and cooled back to 20◦C at 10◦C/min. Two controlled
sequential heat-cool cycles were performed on all samples under a nitrogen stream of 50
mL/min. Melting and crystallisation temperatures were determined as the inflection points
of the corresponding peaks in the normalised heat flow thermogram. The data was processed
and plotted using TRIOS software (TA Instruments).
3.2.4 Parallel-plate rotational rheology
An ARES G2 rheometer (TA Instruments, New Castle, DE, USA) with parallel plate geometry
(diameter 25 mm) was used for rheological evaluation. Zero gap calibration was performed at
the test temperature. Powder samples were loaded on the heated bottom plate until a uniform
disc of approximately 1 mm height was formed. A 3 min delay was allowed for thermal
equilibration before tests. Dynamic strain sweeps (ω = 10 rad/s, strain = 0.01% − 100%)
were conducted at 150◦C and 170◦C and from these, a strain of 10% was selected for
subsequent tests to ensure operation within the linear viscoelastic region (LVR). The LVR
is the range of frequencies and strains for which the structural integrity of the sample is
maintained. Frequency sweeps at 150◦C and 170◦C were conducted at angular frequencies
from 0.1 to 100 rad/s. For temperature ramps the samples were heated from 140◦C to 180◦C,
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at rate of 2◦C/min, 10% strain and 10 rad/s. The gap distance was kept constant using the
expansion coefficient tool (2.3 µm/◦C for the apparatus used), which accounts for the thermal
expansion of the metallic parallel plates at increasing temperatures. All tests were conducted
under nitrogen to avoid sample oxidation. Storage modulus (G′), loss modulus (G′′), complex
viscosity (η∗) and damping factor (tanδ) plots were generated using the TRIOS software (TA
Instruments).
3.3 Results and discussion
3.3.1 High temperature calibration of the PFG probe
For high temperature experiments, a heating system that introduces hot air into the magnet
at 670 L/h was incorporated to the PFG probe. A thermocouple to measure the temperature
inside the magnet was located 5 cm below the r.f. coil so as not to disrupt the magnetic
field and cause artefacts. In order to calibrate the temperature in the middle of the r.f.
coil (optimal sample position), a sealed glass-bulb (Wilmad) with ethylene glycol (EG) was
used (Figure 3.2a). The chemical shift of the hydroxyl (OH–) proton in EG is temperature
dependent and shifts to lower frequencies at increasing temperatures [159]. This is a result
of the higher thermal energy disrupting the hydrogen bonds in which the OH– groups are
involved, which leads to greater shielding. The relationship between temperature (T ) and
chemical shift difference (∆δ) between the hydroxyl and the methyl groups of EG is defined
by [160]:
T [◦C] = 191.9 − 100.3 × ∆δ (3.1)
The 1H spectrum of EG was recorded every 10◦C in the range 100˘180◦C (Figure 3.2b)
with a simple pulse-and-acquire experiment (refer to Figure 2.2c for the schematic of this
pulse sequence). A linear calibration curve between the sample (Tsample) and thermocouple
(Tthermocouple) temperature was produced (Figure 3.2c) and the relationship between the two
was found to be:
Tsample[◦C] = 0.78 × Tthermocouple[◦C] + 7.8 (3.2)
Axial temperature gradients along the ∼20 mm span of the r.f. coil were studied by
centring the EG bulb at 4 mm, 10 mm and 16 mm (Figure 3.2d) and acquiring a 1H spectrum
at 120◦C, 150◦C and 175◦C. The standard deviation of the measurements was of the same
order as the differences in temperature in the three axial positions at all temperatures studied,
so it was concluded that if there was an axial temperature gradient, it was negligible over
the 20 mm active region of the r.f. coil (data not shown).
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Fig. 3.2 (a) 1D profile of the EG bulb positioned in the middle of the r.f. coil with an overlaid
schematic of the glass bulb (inset: chemical structure of EG); (b) 1H spectra of EG at a range
of temperatures between 80-210◦C, where the temperature-dependent resonance corresponds
to the OH– proton; and (c) calibration curve to characterise the relationship between the
temperatures of the thermocouple and the sample. (d) 1D profiles of the EG bulb positioned
at three axial positions centred at 4, 10 and 16 mm.
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3.3.2 High temperature characterisation of materials
1H NMR spectroscopy
The 1H NMR spectra of copovidone and paracetamol are shown in Figure 3.3. The proton
resonances of molten paracetamol, by holding it above its melting point were assigned by
comparison with the literature [161, 162] (chemical structure and nuclei labelling in Figure
3.3a). Assignments of the copovidone spectrum (chemical structure and proton labels in
Figure 3.3b) when dissolved in deuterated acetone (Figure 3.3d), were based on previously
reported chemical shifts of similar molecules [163–165]. The spectrum of molten copovidone
at 170◦C (Figure 3.3c) shows a single broad resonance. The large peak width is a consequence
of the short T2 of copovidone (Table A.1), which in turn is due to its high viscosity and
hindered molecular tumbling. Molten paracetamol resonances are generally well resolved,
with the exception of the OH– and NH– protons (1 and 6 in Figure 3.3a), which overlap at
170◦C. Since the chemical shifts of OH– and NH– protons are temperature dependent, both
resonances were resolvable as the temperature was lowered to 130◦C (Figure 3.3c inset).
Fig. 3.3 Chemical structures of (a) paracetamol and (b) copovidone (Kollidon VA 64) with
protons labelled (1-7 for paracetamol and a-g for copovidone). (c) Overlaid 1H spectra
of molten paracetamol and copovidone at 170◦C. (d) Stacked 1H spectra of a 30 wt%
paracetamol/copovidone physical mix, paracetamol and copovidone dissolved in deuterated
acetone (resonance assignments refer to the molecular structures).
To further characterise the temperature dependence of the OH/NH protons in paracetamol
and in the 30 wt% physical mixture, the 1H spectra was acquired at a range of temperatures
in the 120-170◦C range. The position of the hydroxyl peak (or OH/NH when they overlapped
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in the spectrum) was plotted as a function of temperature (Figure 3.4). For comparison, the
chemical shifts of EG’s hydroxyl proton (Figure 3.2b) are shown in the same graph. The data
points fitted well to a linear function [166], the slope of which is known as the temperature
coefficient (λ [ppm/◦C]). The temperature coefficients of the three compared samples are
similar: λP AR = −0.0064, λmix = −0.0079 and λEG = −0.0101 ppm/◦C. It should be noted
that the chemical shift of the OH– and NH– peaks in the 1H spectrum of paracetamol when
dissolved in deuterated acetone (Figure 3.3d) is significantly different than in the molten
state, when held above its melting point (Figure 3.3c). This is an effect both of temperature
and hydrogen bonding activity with the solvent.
Fig. 3.4 Chemical shift temperature dependence of the OH/NH protons in paracetamol, a 30
wt% paracetamol/copovidone physical mix and ethylene glycol.
DSC
To better understand the high temperature behaviour of paracetamol, a DSC experiment
where the sample was subjected to two consecutive heat-cool cycles from room temperature
to 200◦C was performed. For comparison, a similar heating cycle was carried out in the NMR
magnet and the 1H spectra of paracetamol was acquired at several temperatures.
In the first heating ramp, DSC shows no events other than the melting of polymorph I at
170◦C (Figure 3.5a, blue trace). In agreement, no NMR signal was observed for paracetamol
as it was heated from 20◦C to 160◦C. At 165◦C two peaks are present (one for the aliphatic
and another for the aromatic protons), but these are broad and weak due to the slow molecular
tumbling rate. At 170◦C (melting temperature) these become sharp and resolved intro four
distinct peaks (Figure 3.5b).
The four distinct NMR peaks remained sharp as the paracetamol was cooled down (Figure
3.5c) to 80◦C. This is indicative of the paracetamol remaining in a super-cooler state in which
a high molecular tumbling rate was maintained. Below 80◦C, thermal energy was too low for
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molecular tumbling and the sample yielded no signal. Similarly, the first DSC cooling stage
exhibits no thermal events (Figure 3.5a, green trace).
Upon reheating, the thermogram shows a large exothermic transition at 80◦C followed by a
smaller one at 132◦C (Figure 3.5a, red trace). These have been assigned to the crystallisation
to polymorph form III and a solid-solid transition to form II, respectively, in accordance
with the literature [167]. As the heating is continued, another melting event is observed, but
this time at 163◦C, since it corresponds to the melting point of paracetamol’s form II. These
observations are supported by the NMR data (Figure 3.5d), in which the signal disappears at
80◦C (due to crystallisation) and then reappears at 160◦C. It should be noted that the spectra
at 160◦C and 170◦C in Figure 3.5d are distorted because the NMR tube broke during the
experiment. This would have been caused by the thermal expansion as form III transitions
to form II [168]. No thermal events are present in either of the cooling processes because
paracetamol is a class II drug in regard to its glass-forming ability, meaning that it remains
amorphous as its melt is cooled down and it crystallises upon reheating [169].
Fig. 3.5 (a) High temperature characterisation of paracetamol using DSC consisting of two
consecutive heat-cool cycles. 1H NMR spectra of paracetamol corresponding to (b) the first
heating ramp, (c) the first cooling stage, and (d) the second heating ramp.
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3.3.3 Determination of the microscopic self-diffusion coefficient of parac-
etamol and paracetamol/copovidone blends
Figure 3.6a shows the PGSTE diffusion-weighted spectra for pure paracetamol at 170◦C,
and Figure 3.6b its corresponding Stejskal-Tanner plot. The gradient of the line of best fit
yields a molecular self-diffusivity of molten paracetamol of 1.9·10−10 (±0.2·10−10) m2/s. This
is three times slower than the value obtained by Ribeiro et al. (2012) for 0.001 − 0.05 M
paracetamol in aqueous solutions at room temperature, 0.66 − 0.62·10−9 m2/s [170]. The
diffusion coefficient obtained is similar to that of the measured diffusivity of small drugs in
hydrogels by Mathias et al. (2010), which where in the range of 3.3 − 6.8·10−10 m2/s [87].
The diffusion-weighted 1H spectra of an extrudate sample (Figure 3.7a) are chemically
similar to that of pure molten paracetamol except for the lower overall spectral resolution
(due to slower molecular tumbling of the paracetamol molecules in copovidone, as is evident
from the T2 relaxation values in Table A.1). Additional peaks that resonate between 3 − 5
ppm and at 1 ppm are attributed to the 1H resonances of copovidone. The peaks due to
the polymer have the appearance of those already shown in Figure 3.3d and suggest that,
for the copovidone/paracetamol system at 160◦C, copovidone is dissolving in paracetamol
(and vice versa). The fact that paracetamol’s NMR signal can be detected as low as 120◦C
(data shown in page 113, chapter 6) means that there has been a significant depression of its
melting point in the presence of copovidone, which is indicative of high miscibility between
paracetamol and copovidone [154].
Fig. 3.6 (a) Diffusion-weighted spectra for different pulsed-field gradient strengths and (b)
corresponding signal attenuation plot fitted to the Stejskal-Tanner equation for molten
paracetamol at 170◦C. The standard deviation from three independent measurements is
indicated in parenthesis. Error bars indicate the standard deviation at each data point.
The diffusivity of copovidone could not be measured because the transverse relaxation
time (T2) of the polymer was determined to be less than 2 ms in the 140˘170◦C range (see
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Table A.1), and the minimum achievable echo time for the PGSTE experiment was 2.94 ms.
The lack of mobility in high molecular weight polymers that leads to rapid T2 relaxation has
been previously known to prevent the use of some pulse sequences [145]. Even though the
diffusivity of pure copovidone could not be determined, its signal is detected in APGSTE
experiments when mixed with paracetamol. This behaviour can be explained by paracetamol
molecules diffusing between and separating (i.e. plasticising) the polymer chains (further
evidence for this is found in the viscosity measurements presented in the following section).
Copovidone then becomes more mobile resulting in an increase in its T2 constant making
the polymer 1H signal observable in the diffusion-weighted spectra of physical mixtures and
extrusion samples containing paracetamol and copovidone.
Figure 3.7b shows that paracetamol’s aromatic and aliphatic resonances seem to not be
attenuating at the same rate, which is counter-intuitive since the whole molecule should be
diffusing at the same speed. Data from the aliphatic peak in Figure 3.7b (green symbol)
exhibits an initial decay that tails off well above noise level due to the very slow diffusion
associated with the polymer. The aromatic peak, on the other hand, attenuates linearly
to noise level with a gradient that can be attributed to the "true" diffusion of paracetamol
(Figure 3.7b, purple symbol). The initial linear decays of aliphatic and aromatic resonances
are different because the aliphatic curve is comprised of a weighted average of contributions
from both the polymer and paracetamol. This is due to the spectral overlap of copovidone
groups d, e and f (Figure 3.3b) with the aliphatic peak of paracetamol (7 in Figure 3.3a)
in the 2 ppm region. Due to this overlap, diffusion data was calculated from the signal of
paracetamol’s aromatic resonances only.
Fig. 3.7 (a) Diffusion-weighted spectra for different pulsed-field gradient strengths and (b)
corresponding signal attenuation plot fitted to the Stejskal-Tanner equation for 30 wt%
paracetamol/copovidone extrudate at 160◦C. The fits correspond to the paracetamol-only
aromatic region (purple) and aliphatic paracetamol/copovidone protons (green). Integration
regions to provide plot (b) were calculated form the purple and green boxes in (a).
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Table 3.2 summarises paracetamol’s diffusion coefficients in physical mixtures and extru-
date samples of different drug loadings at several temperatures. Paracetamol’s self-diffusivity
(at 170◦C) is included for comparison. Samples were prepared in triplicate to determine
sample-to-sample variation in the diffusivity measurement, but this was found to be of the
same order as the standard deviation errors quoted in Table 3.2. The fact that the diffusion
of paracetamol is over twenty times slower at 170◦C in 30 % polymer mixtures than when in
a pure molten state suggests that the diffusion of paracetamol is controlled by copovidone
(viscosity effects and molecular interactions will be discussed in the following section).
Figure 3.8a shows that there is a small but statistically significant increase in diffusion
coefficient over the 20◦C range studied (150 − 170◦C) for all samples, with a greater difference
being observed in the samples with higher drug loadings (40 − 70%). There is a positive
correlation between diffusivity and temperature. Figure 3.8b depicts diffusion data against
drug loading, and it exhibits a positive correlation of diffusivity with paracetamol content,
which can be explained by the increased plasticisation of copovidone. However, there is a
significantly greater increase in the diffusion coefficient between 30% and 40% paracetamol
content than between any of the other drug loadings. This could be an indication that the
solubility limit of paracetamol in copovidone is close to 30-40 wt% and thus there are dispersed
drug-rich domains that contribute with faster diffusivity values. Bordos et al. identified the
solid solution capacity of paracetamol in copovidone as 40 wt% and the solubility at 150◦C
as 45-60 wt% [75]. The solubility was determined as the extrusion temperature for which no
crystalline paracetamol was detected, but this does not rule out the presence of amorphous
drug-rich domains.
Fig. 3.8 Visual representation of part of the data in Table 3.2. (a) Diffusion coefficients
of paracetamol in physical mixtures with copovidone vs temperature (error bars represent
the standard deviation from three measurements) and (b) diffusion coefficients in physical
mixtures with copovidone vs drug loading.
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The difference in diffusion coefficient in the 30% paracetamol/copovidone mix and the
30% extrudate is very small statistically (Table 3.2) due to the associated variation (standard
deviation from three repeat measurements). It is apparent, however, that the physically
mixed sample exhibits consistently faster diffusivity. This can be explained by the presence of
small paracetamol-rich domains in the physical mixture. No active mixing is applied on this
sample, unlike the extrudate, relying only on passive mass transport (diffusion) to achieve
homogenisation. Due to the very slow diffusion coefficients, it would be reasonable to assume
that drug-rich domains will exist during measurements, particularly if this drug loading was
close to the solubility limit. According to Einstein’s discrete formula to predict the average
distance travelled, root-mean-square displacement (rmsd), by a randomly diffusing particle
in a one-dimensional system is [171]:
rmsd =
√
2 · D · t (3.3)
According to equation 3.3, the average molten paracetamol molecule at 170◦C (D =
6·10−12 m2/s) will travel 0.2 mm in 1 hour. The fact that the viscosity of the 30% extruded
sample is almost an order of magnitude smaller than that of the 30% physical mix, as will
be discussed in the next section, supports this hypothesis. The presence of small drug-rich
domains, arising due to insufficient mixing in the physical mixtures would suggest that the
diffusion coefficients measured are slightly over-estimating the diffusivity of paracetamol in
paracetamol/copovidone ASDs.
Table 3.2 Diffusion coefficients of paracetamol with copovidone in extrudates and physical
mixtures with different drug loadings at 150-170◦C. The self diffusion coefficient of paracetamol
measured at 170◦C is also included for comparison.
D × 10−12m2/s
Paracetamol content 150 ◦C 160 ◦C 170 ◦C
20% physical mix 1.56 (±0.35)a 2.69 (±0.70) 5.47 (±0.54)
30% extrudate 2.18 (±0.64) 4.23 (±1.6) 6.09 (±1.0)
30% physical mix 3.85 (±0.59) 5.04 (±0.71) 7.40 (±0.73)
40% physical mix 7.16 (±0.68) 15.4 (±1.1) 27.1 (±0.21)
50% physical mix 8.96 (±0.31) 20.4 (±0.14) 40.7 (±2.4)
70% physical mix 9.17 (±0.32) 27.4 (±2.6) 78.0 (±2.5)
Paracetamol – – 190.0 (±20.0)
a The numbers in parenthesis indicate the standard deviation of three repeat measurements.
3.3.4 Rheological characterisation
Figure 3.9a shows the complex viscosities of pure copovidone, a paracetamol/copovidone
physical mixture and an extrudate at 150◦C for a range of angular frequencies (0.1 − 100
rad/s). The dashed vertical line at 4.2 rad/s has been included to indicate the angular
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frequency that corresponds to 40 rpm (rotational speed of the twin screws used in this study’s
small-scale extruder), although it should be noted that shear rate cannot be directly related
to angular frequency. In any extrusion barrel system, there will be a distribution of shear
rates dependent on screw diameter, screw speed and gap between moving surfaces [172]. For
the HME system used in this work (10 mm screw diameter at its widest point, 40 rpm screw
speed and 0.5 mm gap between rotating screws and extrusion barrel) the upper limit of
shear rate expected is approximately 40 s−1. In large-scale extruders, however, shear rates
reach values of hundreds and even low thousands (in the high shear regions, as are the tips
of the mixing elements) [173]. This could mean that the diffusion values measured under
static conditions would not be relevant at high shear rates, but it would depend on the shear
thinning characteristics of the sample.
Fig. 3.9 (a) Complex viscosities from a frequency sweep at 150◦C (vertical dashed line at 4.2
rad/s) and (b) complex viscosity (solid) and damping factor (dotted) from a temperature ramp
of copovidone (black), and paracetamol/copovidone physical mixture (red) and extrudate
(blue). In (a) the dotted black trace corresponds to the frequency sweep of copovidone at
170◦C. In the temperature ramp, extrudate data was only obtained at 140◦C, 150◦C and
170◦C as indicated by the blue × symbols.
The comparative shear thinning study of different pharmaceutical polymers by Gupta
et al. concluded that copovidone’s viscosity has a significantly lower angular frequency
dependence than the other polymers studied [153]. The complex viscosities of the two
paracetamol/copovidone systems shown in Figure 3.9a exhibit an even weaker dependence
on angular frequency than copovidone. This suggests that the difference between the zero-
shear-rate viscosity and the viscosity at 4.2 rad/s is small and thus the diffusion coefficients
measured in the previous section are representative of HME in the Minilab extruder under
the conditions used. A frequency sweep was also performed for the three samples at 170◦C
and the same conclusions were drawn (copovidone’s frequency sweep at 170◦C is shown in
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Figure 3.9a, black dotted trace). The shear rate dependence of diffusivity via viscosity is
explored at the end of this section through the Stokes-Einstein equation.
Figure 3.9a also shows that the physical mixture has a much lower viscosity than copovi-
done, which supports the argument that the incorporation of paracetamol results in a
significant plasticising effect in this polymer. This is not surprising, since API molecules
are known to increase the mobility of polymer chains by creating space between them and
reducing intermolecular chain interactions [49]. The plasticising effect of drugs on polymers
is favourable for HME because it enables processing at lower temperatures [174]. Compared
to the physical mixture, the extrudate exhibits a viscosity four times lower (at 150◦C). This
difference can be explained by chain separation being more efficient in the extrudate as the
paracetamol molecules are more homogeneously dispersed [156]. This is to be expected since,
as will be discussed in the next chapter, extrudate systems achieve amorphous dispersions on
the nanometre scale, whereas molten physical mixtures do not. Furthermore, due to potential
for incomplete dissolution of paracetamol into the polymer over the time-scale of the rheology
test, any undissolved paracetamol particles could be acting as a filler, which could contribute
to an increase in apparent viscosity of the physical mixture [175].
The depression of paracetamol’s melting point in copovidone presents the opportunity to
extrude physical mixtures and form ASDs at temperatures lower than pure paracetamol’s
melting point. In practical terms, processability limitations can be assessed by the viscosity
of the system. The processable viscosity range in the HME process was estimated by Gupta
et al. as 1,000 Pa·s to 10,000 Pa·s [152]. The upper limit of this range was established as the
viscosity at which 80% of the maximum torque was reached. This varies with equipment: the
maximum torque in the melt extruder from Gupta et al. was 12 N·m and the Haake Minilab
extruder used in this study could only reach 5.5 N·m. The lower limit of the processable range,
however, was selected under the rationale that below 1,000 Pa·s, the benefits of extrusion
would not be maximised because the material would be free flowing and it would not provide
a good mixing medium, which could result in the API degrading as it settled at the bottom
of the barrel.
Figure 3.9b shows the complex viscosity (solid lines) and damping factor (dotted lines)
temperature ramps for copovidone and the paracetamol/copovidone physical mixture. The
rheometer settings allowed compensation for the thermal expansion of the parallel plates
(which was known to be 2.3 µm/◦C for the apparatus used) in order to keep the distance
between the plates constant. However, the viscosity of the extrudate system dropped so
low that, if a variable-temperature experiment was performed, the sample leaked from
the rheometer plates even at a constant plate gap. Consequently, only three individual
measurements (at 140◦C, 150◦C and 170◦C) were taken for comparison with the other
samples. With reference to Figure 3.9b, the viscosity of the 30% paracetamol/copovidone
physical mixture is below 1,000 Pa·s for temperatures over 144◦C, which suggests that
lowering the processing temperature of this system under 170◦C is not only possible (with
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respect to rheological behaviour and processability), but would be necessary to operate at the
optimal conditions. This would especially be the case for larger scale extruders where shear
rates and residence times are greater than for the small-scale extruder used in this study.
The maximum in the damping factor (Figure 3.9b) has been used as an indication that
the API in pharmaceutical polymer mixtures is no longer in a crystalline state. The study
by Yang et al. in which a 50 wt% physical mixture of nifedipine/copovidone exhibited the
transition maximum 13◦C below the melting point of crystalline nifedipine, proposed that this
thermal event could be correlated with crystalline nifedipine dissolution [157]. The damping
factor for the system under consideration peaks around 170◦C (dashed vertical line), which
coincides with the melting point of crystalline paracetamol. The rheology temperature ramp
experiment, however, is not representative of the HME process, so perhaps processing at
lower temperatures could still yield extrudates with no crystalline paracetamol.
As mentioned previously, to prove the link between viscosity and diffusivity, the Stokes-
Einstein (SE) relationship was explored. The SE equation [171] correlates the diffusion
coefficient of infinitely dilute spherical particles undergoing Brownian motion with the
viscosity of the fluid they are suspended in:
DSE =
k · T
6 · π · r · η (3.4)
where DSE is the SE diffusion coefficient, k is Boltzmann’s constant (k=1.38·10−23 J/K), r
is the diffusing-particle’s radius, T is the temperature in Kelvin and η is the bulk viscosity. If
the data collected in the previous sections for the 30% extrudate system at 170◦C (T =443 K):
D=2.2·10−12 m2/s and η=35 Pa·s, was used in equation 3.4, the predicted molecular radius
(r) would be 1.5 pm. This value is two orders of magnitude smaller than the molecular radius
of benzene [176], raising the question of the validity of the SE equation for this system.
There are several reasons why the SE equation is not applicable to the 30% paraceta-
mol/copovidone extruded system. Firstly, the SE model is only predictive of systems in which
the particles undergoing diffusion are significantly larger than the solvent molecules [177]. Liu
et al. reported that for nano-particles in polymer melts, in which the diffusing-particle radius
(r) is smaller than the polymer’s gyration radius (rg), the SE becomes invalid [178] (Figure
3.10a). The gyration radius of a polymer chain is a characteristic length scale, which is
defined as the average distance from the monomers to the centre of mass of the polymer chain.
The radius of a paracetamol molecule is approximately 0.3 nm [179] and the gyration radius
of PVP-based polymers usually lies between 1 − 80 nm, according to several studies [180–183].
The fact that the gr of the polymer (acting as the solvent) is larger than the molecular radius
of paracetamol (solute) means that the local viscosity (nano-viscosity) experienced by the
solute molecules is smaller than the measured macro-viscosity of the bulk medium. This
results in an underestimation of the diffusion coefficient by the SE equation.
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Secondly, the SE model assumes infinite dilution and non-interacting solute-solvent
systems. At significant diffusing-particle volume fractions and for interacting drug/polymer
systems, particle-particle and particle-polymer interactions hinder mobility and result in
further underestimation of the diffusion coefficient by the SE equation. For a highly dilute
system and considering rpar=0.3 nm, ηcopov,150◦C=8,735 Pa·s and ηcopov,170◦C=1,290 Pa·s,
the SE model predicts the diffusion coefficient of paracetamol to be Dpar,150◦C=1.2·10−16
m2/s and Dpar,170◦C=8.4·10−16 m2/s. These are four orders of magnitude smaller than the
direct measurements presented in this chapter, and result from the gross underestimation
due to the two factors explained above.
The relative solute/solvent size argument would be the fundamental reason why the SE
equation is not valid for small (drug) molecules in polymer melts. Moreover, practical drug
loads necessary to develop a viable ASD product will be well above infinite dilution with
respect to the drug concentration, and interactions between drug and polymer are not a given
but are typical in ASDs. Therefore, the SE equation is not a good predictor of the diffusion
coefficient of drug molecules in drug/polymer melts and there is a need to measure this mass
transport parameter experimentally in order to understand and model system dynamics.
Fig. 3.10 Schematic of (a) paracetamol radius and copovidone gyration radius and of (b)
the Arrhenius diffusion mechanism. (c) Diffusion data (presented in Table 3.2) fitted to
the Arrhenius model (equation 3.5) for paracetamol/copovidone physical mixtures and an
extrudate (error bars are the standard deviation of three measurements); the coloured traces
represent the experimental data and the black lines the fit to the Arrhenius model.
Alternatively, the Arrhenius equation [184] has been used to describe the diffusion
hopping mechanism (Figure 3.10b) [185, 186]. This equation correlates a rate constant (as the
diffusivity) with temperature and an activation energy required to move to a neighbouring
location of free volume:
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where EA is the activation energy of the diffusion process and D0 is an amplitude parameter
that represents the diffusivity as T → ∞. All systems considered in this study fitted equation
3.5 very well (Figure 3.10c), with R-squared values greater than 0.956 (Table 3.3), although
it should be noted that there were only three data points available to fit the model.
The Arrhenius law has been used before to mathematically characterise the high tem-
perature diffusion of ions in molten salts [148, 150]. The Arrhenius equation has also been
employed to model the diffusion of drug release from polymeric matrices during dissolution
and predict diffusion coefficients [187]. Lucero-Acuña et al. modelled controlled drug release
parameters such as temperature-dependency of drug release, time to achieve 50% of release
and effective diffusion coefficient constant using mathematical expressions of the Arrhenius
equation form. In that case, the interpretation of EA was of the energy needed to overcome
drug-drug and drug-polymer interactions and allow molecular diffusion. The activation energy
obtained by Lucero-Acuña for the diffusion of nano-particles in a polymer, mediated by a
liquid buffer, was 41.5 kJ/mol, which is of a similar magnitude as the values obtained in this
study (Table 3.3). In this context, a higher activation energy would be indicative of stronger
drug-polymer interactions and so of a greater barrier to diffusion. It would be expected
that the 30% paracetamol/copovidone extrudate sample would exhibit a higher EA than the
physical mixture, because the formation of drug-polymer interactions has been encouraged
by the molecular dispersion achieved via HME. This is in fact the case, as an activation
energy for diffusion of 73 kJ/mol was calculated for the 30% extrudate, whereas that of its
corresponding physical mixture was 53 kJ/mol.
Table 3.3 The equation used in Matlab to fit the diffusion data from Table 3.2 to the Arrhenius
model (equation 3.5) was: y = a · exp(b · x). The table below presents the results from the
fits, where a and b are the fitting coefficients and R2 is the adjusted R-squared value of the
fit. EA is the calculated activation energy for diffusion; EA = −1000 · b · R, by comparison of
the fitting model with the Arrhenius equation (x = 1000/T ).
Paracetamol content a b R2 EA [kJ/mol]
20% physical mix 1.05·1013 -12.54 0.991 104
30% extrudate 2.51·109 -8.78 0.956 73
30% physical mix 1.34·107 -6.39 0.978 53
40% physical mix 9.79·1012 -11.79 0.992 98
50% physical mix 1.19·1015 -13.74 0.998 114
70% physical mix 3.71·1021 -20.08 1.000 167
3.4 Conclusion
The work included in this chapter reports the first direct, non-invasive measurements of API
diffusion in polymer melts. These were carried out at temperatures relevant to extrusion
processes (150 − 170◦C) of a paracetamol/copovidone system, providing a new way to gain
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fundamental information about HME (and other high temperature processes where mass
transport is critical). In a 30% paracetamol/copovidone extruded sample, the diffusion
coefficient at 170◦C is 6.1(±1.0)·10−12 m2/s, which is over twenty-five times slower than the
self-diffusion coefficient of paracetamol in the molten state (1.9(±0.2)·10−10 m2/s). This
indicates that the diffusion of paracetamol is greatly influenced by copovidone.
The diffusion coefficients were measured at several paracetamol loadings (20-70 wt%)
and temperatures (150 − 170◦C) and their values ranged from 1.56·10−12 m2/s for 20 wt%
paracetamol at 150◦C to 78.0·10−12 m2/s for 70 wt% at 170◦C. A sudden increase in the
diffusion coefficient was observed between 30% and 40% drug loaded samples at the three
considered temperatures. This was associated with the presence of small drug-rich domains
(exhibiting faster diffusion coefficients) as the solubility limit of paracetamol and copovidone
was approached (∼ 40 wt%). The presence of paracetamol-rich regions in the higher drug
loading physical mixtures would suggest that the diffusion coefficients measured are slightly
overestimating the diffusivity in paracetamol/copovidone ASDs, but these measurements are
still relevant for API/polymer mixing during extrusion.
Following rheological characterisation, the mass transport behaviour of the 30% paraceta-
mol/copovidone system was compared to the Stokes-Einstein equation. However, it was found
that it was not applicable as the size of a paracetamol molecule is smaller than the character-
istic length scale (gyration radius) of copovidone resulting in a nano-viscosity experienced by
the drug molecules that does not correspond to the measured macro-viscosity. Additionally,
the large particle volume fraction and the probable drug-polymer interactions act to interfere
with Brownian diffusion. Both of these factors result in an overestimation of the diffusion
coefficient by the Stokes-Einstein model. Since this model is not a good predictor of the
diffusion coefficient of drug molecules in drug/polymer systems, there is a need to measure
this mass transport parameter experimentally. Alternatively, the data was successfully fitted
to the Arrhenius equation, in which the activation energy can be interpreted as the energy
needed to overcome drug-drug and drug-polymer interactions to allow molecular diffusion.

Chapter 4




A key area of concern regarding ASDs is their post-processing stability, particularly that
the API remains in an amorphous state (no recrystallisation) and that no API/polymer
phase separation occurs (miscible mixture). These features are indicative of a molecular-
level dispersion and provide maximum stabilisation of the amorphous API. 13C solid-state
NMR (through CP-MAS techniques) conveys information on the physical state of the API:
narrow line-widths are characteristic of crystalline materials, while broad line-widths are
indicative of an amorphous state (due to the increased number of molecular orientations in
unordered, amorphous solids) [111, 76, 156]. CP-MAS spectra also provide information on
chemical interactions, which are known to play a crucial role in maintaining the physical
stability of ASDs [106]. They manifest as a change in the chemical shift of the resonances
involved in the interaction. Typical interactions in API/polymer systems are hydrogen bonds
(H-bonds), which cause a deviation to higher chemical shifts due to delocalisation of electrons
[188, 103, 111, 101].
DSC has been traditionally used to assess API/polymer miscibility in solid dispersions
through observation of the number of glass transition temperature (Tg) events [69, 189, 156, 26].
A single Tg with an intermediate value between that of the polymer and the API is regarded as
indicative of the formation of an ASD. The limit of detection of this technique is approximately
30 nm, but a more important limitation is that other thermal events may overlap with the Tg,
concealing this transition [100, 111]. Experimental evaluation of the Tg of an API/polymer
system can also provide information on molecular interactions. A positive deviation of the
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measured Tg from the theoretical prediction by Gordon-Taylor’s equation (further details
presented in section 4.3.4) indicates strong API-polymer interactions [190, 68, 155, 27, 106].
As an alternative to DSC, there is ample evidence in the literature of 1H CP-MAS T1
(spin-lattice relaxation constant in the laboratory frame of reference) and T1ρ (spin-lattice
relaxation constant in the rotating frame) measurements being used to obtain micro-structural
information in pharmaceutical ASDs [100, 47, 48, 191]. If the API and the polymer are
homogeneously mixed, the rates of relaxation will average out through spin diffusion mech-
anisms (spontaneous magnetisation exchange between neighbouring spins). Magnetisation
transfer through this mechanism can span long distances (hundreds of nanometres) because
protons are abundant and strongly coupled in the solid state. Consequently, the measured
relaxation times for both species will equal the weighted average of the values of the individual
components. The characteristic length scale (L) of spin diffusion, or diffusing path length is:
L =
√
6 · DSP · t (4.1)
where DSP is the spin diffusion coefficient of the polymer and depends on the distance
between neighbouring protons, and t is the relaxation time. DSP is generally approximated to
10−16 m2/s for organic polymers [192]. If drug domain sizes (∆x) are larger than L, different
relaxation time constants will be measured for drug and polymer resonances. Therefore,
if relaxation time constants are the same for both species, domain sizes are smaller than
the diffusive path length associated with that time value (e.g. ∆x<
√
6 · DSP · T1). In order
to obtain chemical resolution and be able to differentiate between resonances of the two
species, 1H relaxation was measured indirectly through 13C observation (for improved spectral
resolution), following the method of Yuan et al. (2014) [47].
Dempah et al. conducted 1H CP-MAS T1 and T1ρ measurements on samples with markedly
different particle sizes and concluded that smaller particles exhibited shorter relaxation times,
to the extent that mixtures containing two particle sizes of the same compound could be
deconvoluted based on their 1H relaxation behaviour and their relative populations estimated
[191]. More examples on the use of 1H T1 and T1ρ relaxometry on ASDs can be found in
chapter 1 (section 1.4.3). The work presented in this chapter includes 1H CP-MAS T1 and T1ρ
via 13C measurements as an insight into physical state, phase separation and API/polymer
interactions in ASD formulations.
4.2 Materials and methods
4.2.1 Materials and sample preparation
The materials and preparation methods followed were the same as those outlined in chapter
3 (section 3.2.1). The samples used for the work presented in this chapter are as follows:
- Physical mixtures: 30 wt% paracetamol/copovidone
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- Extrudates: 20 wt%, 30 wt% and 40 wt% paracetamol/copovidone
4.2.2 Solid-state NMR spectroscopy and relaxometry
Solid-state NMR characterisation was performed in a Bruker Avance spectrometer (Bruker-
Biospin, Billerica, USA) operating at a frequency of 400.23 MHz and 100.64 MHz for the 1H
and 13C nucleus, respectively, using a 4 mm DB-MAS probe. Spectroscopy experiments were
based on the magic angle spinning (MAS) ramped-cross polarization (CP) pulse sequences
[137] under a spinning frequency of 9 kHz. Contact and decoupling pulses were optimised
with adamantane and glycine (refer to section 4.3.1).
Samples were packed in 4 mm diameter Zirconia rotors and sealed with Kel-F caps. 13C
CP-MAS spectra were obtained with 2 ms contact time, 120 W proton decoupling power and
the SPINAL-64 decoupling programme. The length of the 90◦ pulse was 2.5 µs for 1H and
1.7 µs for 13C. A 1H saturation recovery sequence via 13C detection was implemented with
32 pulses in the saturation train and the following list of delays: [1, 2, 3, 5, 7, 10, 15, 20, 30]
all in seconds. The 1H T1ρ sequence via 13C detection had a 120 W spin-locking field and
was repeated with the following spin-locking pulse lengths: [1, 2, 5, 7.5, 10, 15, 20, 25, 30, 40,
50, 60, 70, 80, 90, 100] in milliseconds. T1 and T1ρ values were calculated from fitting the
peak areas from the different delays and pulse spin-lock pulse lengths, respectively, to the
exponential functions introduced in section 2.1.4 (equations 2.24 and 2.25). The number of
scans acquired for CP-MAS 13C spectra were 256, while for relaxometry experiments 512
averages were performed. The recycle delays used for the different samples and experiments
are listed in Table 4.1. Curve fitting was performed on MATLAB_R2017b.
Table 4.1 Recycle delay experimental values for CP-MAS experiments, where PAR stands for
crystalline paracetamol, COP for copovidone, Extr for extrudate, PM for physical mixture
and mPM for molten physical mixture.
PAR COP Extr PM mPM Relaxometry
TR [s] 60 5 5 30 7.5 5
4.2.3 Modulated differential scanning calorimetry
Thermal analysis was conducted with a Q2000 (TA Instruments, New Castle, DE, USA)
differential scanning calorimeter. Approximately 3-7 mg of sample was sealed in a standard
aluminium pan and heated from 20◦C to 200◦C at a rate of 4◦C/min, with a modulation
amplitude of ±1◦C and period of 60 s, and cooled back to 20◦C at 10◦C/min. Two controlled
sequential heat-cool cycles were performed on all samples under a nitrogen stream of 50
mL/min. Glass transition temperatures were assigned to the stationary point of the normalised
reversing heat flow data. Similarly, melting temperatures were determined as the inflection
point of the endotherms. The thermogram data was processed and plotted using TRIOS
software (TA Instruments).
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4.3 Results and discussion
4.3.1 Calibration of the CP-MAS pulse sequence parameters
Prior to conducting CP-MAS solid-state experiments, key pulse sequence parameters (1H
and 13C 90◦ pulses, high-power decoupling power and cross-polarization contact pulse and
decoupling pulse lengths) were calibrated on reference samples.
Fig. 4.1 (a) 1H spectrum of adamantane; 13C spectra of adamantane (b) without and (c)
with high power decoupling cross polarisation (inset: chemical structure of adamantane). (d)
13C CP-MAS spectrum of glycine (inset: chemical structure of glycine).
Adamantane (ADM) is a crystalline compound with chemical formula C10H16 (chemical
structure is shown in Figure 4.1c, inset). ADM is used as a 1H and 13C 90◦ pulse calibration
standard because: (i) the proton signal is easily detectable as, even at low MAS spinning rates,
proton homonuclear dipolar interactions significantly average and (ii) 13C signal-to-noise ratio
(SNR) is high and few scan averages are required to obtain a high resolution spectrum [193].
The 1H and 13C spectra of ADM are shown in Figure 4.1a and b, respectively. These spectra
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were used to calibrate the 1H and 13C 90◦ pulses, which were 2.5 µs and 1.7 µs respectively,
for 150 W magnitude.
To improve 13C sensitivity, high power heteronuclear (proton-carbon) decoupling can be
implemented through a decoupling pulse. The optimal amplitude of this pulse was found
to be 120 W. ADM also serves as a chemical shift calibration standard, as peak 2 (refer to
Figure 4.1c) is known to be centred at 29.46 ppm [194]. The cross-polarisation sequence
further increases signal intensity (Figure 4.1c).
Glycine (GLY) is the simplest amino acid, and its structure is shown in Figure 4.1d inset.
GLY is used to calibrate the CP pulse (contact pulse during which polarisation is transferred
from the protons to the carbons) instead of ADM because it is more representative of solid
samples of interest [193]. The optimised contact pulse length and power is selected as the
parameter combination that maximises the intensity of peak 1 (refer to Figure 4.1d). These
were found to be 2 ms and 50 W, respectively.
4.3.2 13C CP-MAS spectra of paracetamol/copovidone physical mixtures
and extrudates
13C CP-MAS NMR spectra of pure copovidone and crystalline paracetamol were acquired
and are shown in Figure 4.2c. Assignment of paracetamol and copovidone 13C resonances
(with reference to the labelling in Figures 4.2a and b) have been made by comparison with
the literature [195, 157]. In agreement with DSC results from section 3.3.2, as-received
paracetamol’s crystalline spectrum corresponds to polymorph form I [168].
Fig. 4.2 Chemical structures of (a) paracetamol and (b) copovidone, with carbon atoms
labelled (1-8 for paracetamol and a-j for copovidone). (c) Overlaid 13C CP-MAS spectra of
solid-state paracetamol and copovidone.
13C NMR spectroscopy has been used to distinguish between crystalline and amorphous
API because amorphous materials exhibit characteristically broad peaks, in contrast with
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crystalline compounds, which produce sharp resonances [51, 47, 76]. The line-broadening is
caused by the lack of structural isotropy in amorphous compounds, as different molecular
orientations will result in different resonant frequencies and thus a loss of resolution. Figure
4.3a shows the 13C high resolution spectra of a 30 wt% paracetamol/copovidone physical
mixture. The paracetamol resonances (1-8 ) are noticeably sharper than the copovidone ones
(a-j), because paracetamol is in a crystalline physical state while copovidone is amorphous.
The 13C spectra of three extruded samples at 20%, 30% and 40% drug loading are displayed
in Figure 4.3b. In contrast to Figure 4.3a, all resonances appear broad indicating that both
paracetamol and copovidone are in an amorphous state.
Fig. 4.3 13C CP-MAS spectra of paracetamol/copovidone systems: (a) 30% physical mix, and
(b) 20%, 30% and 40% extrudates. Resonance assignments refer to the molecular structures
shown in Figure 4.2a and b.
Closer examination of Figure 4.3b reveals that the intensities of the resonances that
correspond to paracetamol increase with drug loading, as expected. However, the intensity
of the copovidone peaks also strengthens with paracetamol content. This could be due to
increased CP (proton to carbon magnetisation transfer) efficiency. The CP efficiency to a
dilute nucleus, as is 13C, is dependent on the proximity of the abundant nuclei (1H) [76].
Paracetamol/copovidone extrudates have been characterised as a homogeneous and intimate
dispersion of the drug particles. This was evidenced by a decrease in viscosity in extrudates
when compared to physical mixtures in chapter 3 (section 3.3.4) and will be further backed up
by the results from the CP-MAS relaxometry experiments presented in the following section.
As a result of the homogeneous dispersion, the small paracetamol molecules are in closer
contact with the copovidone chains than the polymer-polymer chain spacing. This means
that, while the system remains miscible and homogeneous, increasing drug loading increases
CP efficiency from the 1H in paracetamol to the 13C in copovidone and thus increases the
signal from copovidone resonances.
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Figure 4.4 is a comparison of the spectra of three different 30 wt% paracetamol/copovidone
systems: (1) extruded, (2) physically mixed and (3) a physical mixture that was heated
to 170◦C and held isothermally for 10 min and then let to cool down before acquisition at
room temperature. For the extruded sample, trace (1), all peaks are broad, indicating that
paracetamol was rendered amorphous via HME. In trace (2), as expected for a physical
mixture, the paracetamol resonances (Figure 4.4 purple box) are sharp and well resolved,
as in the spectrum of crystalline paracetamol shown in Figure 4.2c, purple line. In the 30%
molten mix, trace (3), paracetamol is present both in crystalline and amorphous states as
can be observed by the presence of overlapping broad and narrow resonances.
Fig. 4.4 13C CP-MAS spectra of 30 wt% drug loading paracetamol/copovidone extruded
sample (1), physical mixture (2) and a physical mixture that was molten at 170◦C (3). The
purple box surrounds the paracetamol-only region of the spectra. The red vertical dashed
lines mark the resonances that exhibit a change in chemical shift between the extrudate and
physical mixture systems.
Interestingly, in traces (1) and (3) of Figure 4.4, the copovidone peak at the highest
chemical shift is centred at 179 ppm (Figure 4.4, red dashed line), whereas for trace (2) that
resonance is at 177 pm (while the position of all other copovidone resonances is essentially
identical in the three traces). This peak is assigned to the carbonyl group of the vinyl-
pyrrolidone (VP) monomer (carbon e in Figure 4.2b), which is the most likely to interact with
other molecules (more so than the carbonyl of the vynil-acetate group) [106]. Likewise, if the
position of paracetamol peaks is compared in the three traces, there is only one resonance
that differs: the peak that corresponds to the carbon from the phenolic group (carbon 6 in
Figure 4.2a) shifts from 155 ppm in trace (2) to 157 ppm in trace (1), Figure 4.4, red dashed
line. In trace (3), both resonances (at 155 ppm and 157 ppm) are present. The chemical shift
of the carbonyl in the VP monomer of copovidone and the phenol in paracetamol occurs to
higher chemical shift values, that is downfield. This is consistent with HME having induced
hydrogen-bonding in the paracetamol/copovidone systems because this type of interaction
will decrease the electron density around the carbons closest to the acceptor and donor atoms,
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resulting in deshielding [188]. Such features have also been reported by Watanabe et al. in
ASD formulations of PVP polymer with indomethacin [103]. It is also well established in the
literature that drug-polymer H-bonding can increase the stability of ASDs with respect to
drug recrystallisation on storage and maintaining supersaturation during dissolution [32, 102].
4.3.3 1H T1 and T1ρ measurements for phase separation studies
Additional information regarding phase separation of samples was obtained through CP-MAS
1H relaxometry by measurement of T1 and T1ρ parameters via 13C observation. The four
13C peaks used for paracetamol 1H T1 and T1ρ calculations were the ones resolvable in the
105-165 ppm region, as there is no copovidone signal in that frequency range (Figure 4.2b).
Four copovidone-specific resonances, centred at 34 ppm, 45 ppm, 70 ppm and 178 ppm were
selected for calculating copovidone’s relaxation constants. The saturation recovery T1 plots
for the 30 wt% physical mixture and extrudate are shown in Figure 4.5a and b.
Fig. 4.5 T 1 saturation recovery plots for four resolved copovidone and paracetamol resonances
in (a) a 30% physical mixture and (b) a 30% extrudate.
For each species (paracetamol and copovidone), a 1H T1 and T1ρ value was calculated as
the average from the four individual peaks. The absolute difference between copovidone’s
and paracetamol’s T1 and T1ρ constants are shown for five different paracetamol/copovidone
systems are shown in Figure 4.6a. Error bars represent the standard deviation of the relaxation
values for each species. The dashed line at zero represents the position at which the T1 or
T1ρ is identical for paracetamol and copovidone (because the difference between the two is
zero). The difference in T1 and T1ρ was so large in the physical mixture sample between
paracetamol and copovidone resonances that the data was scaled down by a factor of 10
and 200, respectively, for representation purposes. The reason for comparing the absolute
differences in relaxation instead of the relaxation constants’ values is that these are highly
sensitive to moisture content [47].
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Figure 4.6a shows that there is no statistical difference between T1 or T1ρ of paracetamol
and copovidone in any of the extrudate systems at any of the drug loadings considered
(20-40 wt%). This indicates that there is no phase separation and, using equation 4.1,
that the paracetamol domain size in these systems is smaller than the diffusive path length
corresponding to the smallest time constant (T1ρ): ∆x<3.8 nm. In the 30% physical mix
case, both relaxation constants are considerably different for paracetamol and copovidone.
As expected, the results reveal phase separation with paracetamol domain sizes larger than
130 nm. These results can also be observed in Figure 4.5a and b, where paracetamol exhibits
a much longer T1 than copovidone in the physical mixtures, but their values are identical in
the extrudate sample.
Fig. 4.6 (a) 1H T 1 and T 1ρ difference between average paracetamol and copovidone relaxation
values obtained via 13C resolved resonances for 20%, 30% and 40% extrudates, a 30% physical
mixture and a 30% molten physical mixture. (b) Deconvolution of 1H T 1 data for the 30%
molten mix system.
In agreement with the observations made from Figure 4.4 trace (3), the results for the
molten mix system lie in between the extrudate and the physical mixture samples. While
no significant difference was detected for paracetamol and copovidone in T1, the opposite
was true for T1ρ. According to equation 4.1, paracetamol domain sizes in this system are
estimated as larger than 5 nm, but smaller than 58 nm. By integrating over the paracetamol
peaks in the 105-165 ppm region and fitting a two-component exponential, it is possible to
deconvolute the relaxation into two rates [191]. For T1 two relaxation rates were obtained:
3.5 s corresponding to molecularly dispersed paracetamol, and 101.4 s from the crystalline
paracetamol [195] (Figure 4.6b). This means that a physical mixture that has been heated
to 170◦C does not have the same microscopic structure as one that has been through the
HME process. It is also further evidence that a multi-phase system with paracetamol-rich
domains was formed upon heating, which backs up the hypothesis presented in section 3.3.4
regarding incomplete intimate mixing in molten physical mixtures.
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4.3.4 Glass transition temperature assessment by mDSC
The normalised reversing heat flow thermograms of copovidone, paracetamol, a paraceta-
mol/copovidone physical mixture and extrudate can be found in Figure 4.7a (a section of
the thermogram for paracetamol is shown as an inset). The measured Tg of copovidone
(Tg,copov=108.5◦C) is consistent with literature values [196], as is the Tg of paracetamol
(Tg,par=23.7◦C) [197].
In Figure 4.7a, the 30% drug loaded physical mixture exhibits a Tg (105.0◦C) that
corresponds to the copovidone in the system. The melting peak at 168◦C has an early onset
that overlaps with the baseline at the end of the glass transition event. Despite the overlap
of events, the apparent start of the endotherm is at 120◦C (vertical dotted line), which agrees
with the melting point depression observations in NMR experiments (data shown in chapter
7). Marsac et al. revealed that strong API/poymer interactions result in large melting point
depression and are indicative of miscible systems [154]. Paracetamol and copovidone can
thus be considered to be miscible according to DSC characterisation.
Fig. 4.7 DSC thermograms of copovidone (black), paracetamol/copovidone physical mixture
(red) and extrudate (blue), and paracetamol (green) for the (a) first and (b) second heating
cycles. The dashed vertical line in (a) indicates the depression of the onset of the melting
point of crystalline paracetamol in the physical mixture.
The thermogram of the extrudate in Figure 4.7a displays no melting endothem (indicating
that there is no crystalline paracetamol present in the sample) and a single glass transition
(56.5◦C) at a temperature that lies between the Tg’s of copovidone and paracetamol. This is
indicative of the successful formation of an ASD during the extrusion process, in agreement
with the CP-MAS results presented in the previous section. However 56.5◦C is not a
representative value of the system’s Tg because it was not vacuum dried prior to analysis;
any water present would plasticise the sample, decreasing its apparent Tg [4, 32]. Water loss
during the first heating cycle resulted in an increase in Tg of the extrudate and decrease
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in Tg for the physical mixture, in the second heating ramp (Figure 4.7b), to 77.9◦C and
72.3◦C, respectively. The same is true for copovidone, which is why its Tg is taken from
the second heating cycle, once water was removed from the sample (this was not the case
for pure paracetamol, which contained no moisture as revealed by DSC and TGA). The
disparity in Tg between the two 30% paracetamol/copovidone systems was not considered to
be significant as it is likely a result of differences in composition. DSC sample sizes are very
small, which can lead to inaccurate drug loading of the individual samples.
The Gordon-Taylor equation predicts glass transition temperatures of amorphous mixtures
from the glass transition temperatures of the individual components [29]:
Tg,mix =
w1 · Tg,1 + K · w2 · Tg,2
w1 + K · w2
(4.2)
where Tg,1 and Tg,2 are the glass transition temperatures of the two components in the
mixture and w1 and w2 are their weight fractions. K is a constant parameter that can be
estimated from the Simha-Boyer rule [30]:
K = d1 · Tg,1
d2 · Tg,2
(4.3)
where d1 and d2 are the densities of the components. The density of amorphous paracetamol,
was calculated from the specific volume curve for liquid paracetamol provided by Espeau et al.:
V [cm3/g] = 0.671+0.000539×T [K] [198]. Extrapolating for room temperature (T = 293 K):
V [cm3/g] = 0.829. Applying equations 4.2 and 4.3 to the 30% paracetamol/copovidone
system and using the parameters from Table 4.2, the predicted glass transition temperature
of the 30% paracetamol/copovidone system is 52.8◦C.
Table 4.2 Parameters for the Gordon-Taylor and Simha-Boyer equations for Tg prediction.
w [−] Tg [◦C] d [g/cm3]
Paracetamol 0.3 23.7a 1.21b
Copovidone 0.7 108.5a 1.18c
a Experimental value from DSC. b Value calculated from [198]. c Value from [199].
The predicted Tg of the system (52.8◦C) is well below the experimentally obtained
ones (77.9◦C and 72.3◦C for the extrudate and physical mixture, respectively). A strong
positive deviation from the Gordon-Taylor prediction indicates that paracetamol-copovidone
interactions are strong (stronger than paracetamol-paracetamol or copovidone-copovidone
interactions) [106]. Strong drug-polymer interactions are favourable, among other factors,
because they stabilise the ASD formulation in the presence of moisture. As mentioned above,
moisture physically affects the stability by lowering the Tg of the mixture, which increases
molecular mobility and the potential for phase separation; it also chemically decreases stability
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by lowering the solubility of API in the polymer, increasing the supersaturation degree and
leading to crystallisation [32]. The fact that this data suggests drug-polymer interactions
reinforces the conclusion that the Stokes-Einstein equation is not applicable to the system
under study (chapter 3, section 3.3.4).
It should be noted that in the second heating cycle the physical mixture displays the same
behaviour as the extrudate in that the thermogram lacks a melting endotherm and exhibits
a single glass transition, which suggests the formation of an ASD. This result disagrees
with the CP-MAS NMR data presented in the previous sections 4.3.2 and 4.3.3, in which a
paracetamol/copovidone physical mixture that has been heated to 170◦C shows some degree
of phase separation. Consequently, its micro-structural features are different from those of an
extruded sample. However, the very small sample size in DSC pans (few milligrams) increases
the likelihood of mixing and decreases the chances of nucleation and recrystallisation.
4.4 Conclusion
CP-MAS 13C high resolution spectral line width observations were used to show that parac-
etamol is in an amorphous state (rather than crystalline) in all the hot-melt extruded samples
(20-40 wt% drug loading). Differences between the chemical shift of the carbonyl VP (copovi-
done) resonance and the phenol paracetamol peak in the 30 wt% physical mixture and
extruded systems provide an insight into drug/polymer molecular interactions promoted by
the intimate mixing of paracetamol and copovidone via the HME process. This observation
was backed up by DSC: the Tg predicted by Gordon-Taylor’s equation of the paraceta-
mol/copovidone system is well below the experimental Tg, which is indicative of strong
paracetamol/copovidone interactions. The evidence of molecular interactions supports the
statement made in chapter 3 regarding the validity of the Stokes-Einstein diffusion prediction
to the paracetamol/copovidone system. Specifically for the sample under investigation, H-
bonding between copovidone’s VP carbonyl and paracetamol’s phenolic moiety was identified.
This intermolecular association could be responsible for stabilising paracetamol/copovidone
ASDs. Paracetamol/copovidone interactions will be studied in more detail in chapter 5.
1H relaxometry data via 13C acquisition revealed no phase separation or recystallisation
in the 20%, 30% and 40% extrudate systems. There was, however, some degree of phase
separation in the 30 wt% physical mixture that was heated to 170◦C, in which the T1 constants
of paracetamol and copovidone were identical (within the associated error), but the T1ρ
values were different. In this sample, drug-rich domains were estimated to be 4.8 nm to 57.7
nm in size and crystalline in nature (as evidenced from the very long T1 constant obtained
from the deconvoluted bi-exponential fit). This result is further evidence that a multi-phase
system with paracetamol-rich domains was formed upon heating during measurement of the
self-diffusion coefficients in the paracetamol/copovidone physical mixture systems, as was
hypothesized in chapter 3.
Chapter 5
Application of 2D NMR techniques
for molecular interaction studies
5.1 Introduction
The role of drug-polymer interactions in the performance of ASD formulations has recently
become a topic of interest. Intermolecular associations between the API and the excipient
have been revealed to influence two key mechanisms in ASDs: crystallisation and dissolution.
The nucleation and crystallisation kinetics of an API in a supersaturated ASD formulation
is hindered or inhibited by the presence of drug-polymer interactions [76]. The extent of
inhibition has been correlated with the strength of the molecular association [33]. Mistry
et al. observed a relationship between the strength of the interaction and the extent of
crystallisation inhibition; and this is hypothesized to be linked to the decrease in molecular
mobility [102]. Drug-polymer interactions also play a role in enhancing drug solubility. The
improved dissolution profile is achieved in two ways: intermolecular associations maintain
the physical stability in supersaturated ASDs and they have been observed to increase
the solubility of the drug in water (both by preventing crystal growth and increasing the
saturation concentration) [32, 53]. Furthermore, drug/polymer interactions are favourable
for the HME process because they lead to depression of the drug’s melting point (enabling
extrusion at lower temperatures) and because they lead to lower chemical potentials of the
systems, enhancing solubility and miscibility of the drug in the polymer [32].
Several techniques have been used in the elucidation of drug/polymer molecular interac-
tions in ASDs. Fourier-transform infrared, Raman and NMR spectroscopy are among the
most widely employed [4, 102]. Some studies have applied alternative methods such as X-ray
photoelectron spectroscopy and molecular dynamic simulations [200]. In spectroscopy-based
techniques, such as high resolution NMR, drug/polymer associations can be inferred from
shifts in the frequency/wave number of those atoms involved in the interaction (as discussed
in chapter 4). Additionally, the NMR toolbox has several 2D experiments aimed at under-
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standing the associations (scalar or dipolar) between atoms both intra- and inter-molecularly,
hetero- and homo-nuclear as well as through-space and through-bond. Some frequently used
2D correlation experiments include COSY, HETCOR, MQC and NOESY (see chapter 2,
section 2.1.5, for detailed explanations of the relevant techniques) [76].
Tatton et al. observed intermolecular drug/polymer through-space coupling via solid-
state heteronuclear (14N-1H) MQC in ASDs [112]. These were identified as hydrogen bonds
(H-bonds) between the drug’s hydroxyl group and the polymer’s carbonyl. Pham et al.
used solid-state 1H-13C HETCOR to identify drug/polymer interactions and 1H-1H MQC
for additional structural information [111]. HETCOR spectra at increasing contact times
displayed more intense drug/polymer cross-peaks, as proton spin diffusion covers larger length
scales. This is proof that a large percentage of API molecules are in intimate contact with
polymer chains (molecular-level interactions).
2D correlation NMR experiments have also been performed in solution-state drug-polymer
systems. Fule et al. used the 1H-1H COSY sequence on a pharmaceutical system dissolved
in DMSO [43]. Couplings were observed at several points in the correlation spectra that
indicated strong molecular interactions between the drug and the polymer. Liu et al. assessed
the impact on intermolecular association by substituting the hydrogen-bonding proton in the
API by a fluorine when the system was dissolved in deuterated chloroform [106]. Apart from
the characteristic chemical shift, NOESY experiments revealed H-bonding between the drug
and the polymer’s carbonyl group.
Hydrogen bonding is the most common type of drug/polymer interaction identified in
ASDs. In H-bonds a hydrogen atom is in association with two (electronegative) atoms,
typically O or N. 2D NMR techniques such as HETCOR, NOESY and MQC indirectly probe
for H-bonds by detecting through-space nuclear proximity. By selecting shorter mixing or
contact times, smaller length scale (stronger) interactions become evident. The nuclei on both
sides of the H-bond are magnetically coupled via a scalar interaction, which is what allows
their observation in COSY (through-bond) experiments [188]. This coupling occurs through
the re-distribution of electron densities around the bridging proton, which also manifests
itself in the chemical shift changes discussed in the previous chapter.
This chapter reports findings from traditional solid-state 13C-1H HETCOR, which provide
insights into API-polymer molecular interactions in ASD formulations. Additional solid-state
1H-1H NOESY and 1H-1H MQC experiments were performed at high-field (850 MHz) and
fast MAS (60 kHz). This set-up offers the opportunity to obtain resolved solid-state 1H
spectra, as otherwise no resolution is obtained from static solid samples. Furthermore,
this chapter presents results from molten-state 1H-1H COSY, which, when compared to
solid-state techniques, has greater proton spectral resolution and provides further insights
into API-polymer associations. To the best of my knowledge, there are no accounts in the
literature of 2D NMR COSY being performed in the molten state, without a solvent present
and at high temperatures relevant to the HME processes.
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5.2.1 Materials and sample preparation
The same materials and sample preparation methods were followed as those outlined in
chapter 3 (section 3.2.1). The samples used for the work presented in this chapter are as
follows:
- Paracetamol and copovidone
- Extrudate: 30 wt% paracetamol/copovidone
5.2.2 2D high-field solid-state NMR
High-field solid-state NMR characterisation was performed in a Bruker Avance spectrometer
(BrukerBiospin, Billerica, USA) operating at a frequency of 850.23 MHz and 213.79 MHz
for the 1H and 13C nucleus, respectively, at the UK 850 MHz solid-state Facility (University
of Warwick, Coventry, UK). 1H-1H experiments were conducted at 60 kHz MAS in 1.3 mm
rotors for improved proton resolution, while 13C-1H HETCOR was performed at 15 kHz in 4
mm rotors. The signal-to-noise ratio (SNR) of 13C spectra at 60 kHz was very low. This was
a combined effect from the low natural abundance of 13C and the small sample volume in
the 1.3 mm rotors used for spinning at 60 kHz and the decreased CP efficiency at high MAS
rates [130, 201].
13C-1H HETCOR
13C-1H HETCOR was performed on a 4 mm DB-MAS dual-resonance probe at a MAS rate
of 15 kHz. The pulse sequence used was based on the ramped CP-MAS with FSLG and
TPPM decoupling HETCOR (schematic of the pulse sequence is shown in Figure 2.11a).
Samples were packed in 4 mm diameter Zirconia rotors with Kel-F caps. The CP contact
time was varied between 1-4 ms for an 80 Watt power pulse. The length of the 90◦ pulse was
2.5 µs for 1H and 3.5 µs for 13C, the magic angle pulse length was 1.52 µs (refer to Figure
2.11a) and the recycle delay was 2 s. Contact and decoupling pulses were optimised with
glycine and alanine (refer to Figures 5.1 and 5.2). The data was processed in TopSpin and
plotted using MATLAB_R2017b.
1H-1H NOESY
1H-1H NOESY experiments were performed on a 1.3 mm triple-resonance probe operating
in double-resonance mode at a MAS rate of 60 kHz, (schematic of the pulse sequence is
shown in Figure 2.10). Samples were packed in 1.3 mm diameter Zirconia rotors with Vespel
caps. The mixing time was varied between 0.3 and 100 ms for 80 Watt power level pulses.
The length of the 90◦ pulse was 2.5 µs and the recycle delay was 4 s for copovidone and
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the extrudate formulation and 120 s for crystalline paracetamol. The data was processed in
TopSpin and plotted using MATLAB_R2017b. Chemical shifts are referenced with respect
to TMS using β-AspAla as a secondary reference.
1H-1H MQC SQ/DQ BABA
1H-1H MQC SQ/DQ rotor-synchronised BABA MAS experiments were performed on a 1.3
mm triple-resonance probe at a MAS rate of 60 kHz, using two rotor periods of double
quantum excitation and two rotor periods of reconversion (schematic of the pulse sequence is
shown in Figure 2.12). Samples were packed in 1.3 mm diameter Zirconia rotors with Vespel
caps. The variable delay d0 was stepped-up in 1 ms increments. The length of the 90◦ pulse
was 2.5 µs and the recycle delay was 4 s for copovidone and the extrudate formulation and
120 s for crystalline paracetamol. The data was processed in TopSpin and plotted using
MATLAB_R2017b. Chemical shifts are referenced with respect to TMS using β-AspAla as
a secondary reference.
5.2.3 2D molten-state NMR: 1H-1H COSY
1H-1H liquid-state COSY was conducted on a 7.07 T Bruker Biospin DMX 300 MHz spectrom-
eter (BrukerBiospin, Billerica, USA) operating at a 1H frequency of 300.23 MHz through the
ParaVision 4.0 software. A Bruker Biospin DIFF-30 probe was equipped with an extended
variable temperature range 1H/19F 5 mm i.d. r.f. coil. Experiments were performed with 8
µs 90◦ pulse, on 100 mg of sample and either at room temperature or at 170◦C.
COSY experiments were performed using a pair of pulsed-field gradients of 0.6 T/m for
coherence transfer pathway selection (schematics of the pulse programs are shown in Figure
2.9a). The recycle time was 2 s (longer delays were evaluated, but SNR did not improve
significantly and experimental time increased sharply). A sweep width of 5 kHz was used
for the high-resolution spectra (dissolved copovidone and molten paracetamol) and 50 kHz
for the spectra with wider-linewidths (molten paracetamol/copovidone extrudate). 32 scans
were acquired for the traditional COSY experiments (Figure 2.9a), 64 scans for the SE-COSY
(Figure 2.9b) at dSE=1 ms and 80 scans at dSE=10 ms, resulting in an experimental time
of 5 hours, 10 hours and 12.5 hours, respectively. The data was processed in TopSpin and
plotted using MATLAB_R2017b. Prior to recording at high temperatures, the temperature
performance of the probe was calibrated as outlined in section 3.3.1.
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5.3.1 2D high-field solid-state NMR
Calibration
Prior to conducting the high-field CP-MAS solid-state experiments, key pulse sequence
parameters (1H and 13C 90◦ pulses, and cross-polarisation contact pulse power) were calibrated
on reference sample glycine (GLY) - its structure is shown in Figure 5.1 as an inset. The CP
pulse power was optimised for a pulse length of 2 µs (Figure 5.1) and it was determined as
80 W.
Fig. 5.1 13C CP optimisation spectra of GLY for different CP pulse power levels. The
individual spectra within the optimisation experiment are marked in grey and the optimum
spectrum is shown in red. The chemical structure of GLY is shown as an inset with carbon
atoms labelled.
Alanine (ALA) is a simple amino acid very similar to GLY, but with a methyl group
attached to the central carbon atom. The ionised form of ALA (chemical structure in Figure
5.2c) was used to select an appropriate HETCOR pulse sequence variant. As outlined in
the methods sections, the sample was spun in a 4 mm rotor at 15 kHz and the contact time
was 2 ms. Figure 5.2a shows the 2D HETCOR spectrum of ALA, with the 13C projection
along the top and the 1H projection at the right of the plot. Carbons are labelled 1-3 and
protons a-c with respect to the chemical structure in Figure 5.2c. The coloured horizontal
lines in Figure 5.2a show the position of the individual rows plotted in Figure 5.2b. These
correspond to the three peaks in the proton projection spectrum.
The 2D plot in Figure 5.2d was obtained from an identical HETCOR experiment to
Figure 5.2a, but a FSLG pulse sequence was added for 1H-1H decoupling (d-HETCOR). This
resulted in an improvement in proton linewidth resolution and for this reason the d-HETCOR
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Fig. 5.2 13C-1H CP-MAS (15 kHz) spectra of (a) HETCOR, (d) HETCOR with homonuclear
FSLG decoupling (d-HETCOR) of calibration sample alanine with the carbon and proton
spectra projections along the top and right axes, respectively. Carbon spectra extracted from
proton rows in (b) HETCOR and (d) d-HETCOR experiments (resonance assignments refer
to molecular structure (c)). (c) Chemical structure of alanine with protons (a-c) and carbons
(1-3 ) labelled. Number-letter pairs in (d) refer to the carbon-proton interactions identified.
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pulse program was employed with the paracetamol and copovidone samples. Figure 5.2e
shows the 13C spectra of three rows, each corresponding to one of the protons in ALA: the
yellow for proton a, the red for b and the blue spectrum for proton c. These spectra indicate
that the three protons are coupled with the three carbons, which is to be expected for a small
molecule such as ALA at 2 ms contact time. Carbon-proton coupling is also indicated in
the number-letter pairs in Figure 5.2d, next to each of the cross peaks. The way 2D NMR
experiment results are presented in Figure 5.2 will be used throughout this chapter.
13C-1H HETCOR
The 13C-1H CP-MAS d-HETCOR of pure copovidone and crystalline paracetamol were
acquired at 2 ms contact time and the results are shown in Figure 5.3. Assignment of
paracetamol and copovidone 13C and 1H resonances (with reference to the labelling in Figures
5.3d and e) have been made by comparison with the literature [195, 157, 162, 164, 165, 163].
Note that carbon atoms are labeled with numbers and proton atoms with letters. The
colour-bar in Figure 5.3b indicates the cross-peak signal intensity in 2D NMR plots, where
higher intensity (red) is associated with a stronger coupling. This color-bar applies to all of
the 2D plots presented in this chapter.
Figure 5.3a shows that every carbon in copovidone is coupled with both resolved proton
environments. This is not surprising as, even though there are at least six proton environments
discernible when dissolved in acetone (refer to chapter 3, Figure 3.3d), only two (and with
a high degree of overlap) are observable in this solid-state experiment (as is observed in
the proton spectrum projection), despite using the sequence with homonuclear decoupling.
Cross-peaks involving a protons appear stronger than those involving b protons, but this is
likely to be an effect from the stronger signal from the a protons rather than an indication of
stronger coupling.
In Figure 5.3f there are three resolved paracetamol proton resonances: c corresponds
to the methyl protons, d to the aromatic protons, and e to the OH– and NH– ones (the
corresponding rows are shown in yellow, orange and blue, respectively, in Figure 5.3g). In this
case, not all proton and carbon environments display cross-peaks. The signal arising at the
chemical shift coordinates of peaks 16-c reveal close interaction between the methyl carbon
and methyl protons; and that at 11-c is between the methyl protons and their neighbouring
carbonyl carbon. Aromatic protons (orange trace in Figure 5.3g), as they are located in
the middle of the molecule, display interactions with all carbons: methyl (16-d), carbonyl
(11-d) and aromatic (12,13,14,15-d). Finally, a faint cross-peak is observable between the
carbonyl carbon and, either the amine or hydroxyl protons (11-e), or even with both as will
be described later in this chapter. These results agree with the observations by Zhou et al.
[202].
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Fig. 5.3 13C-1H CP-MAS (15 kHz) d-HETCOR of (a) copovidone and (f) paracetamol with
the carbon and proton spectra projections along the top and right axes. Carbon spectra
extracted from the proton rows of (c) copovidone and (g) paracetamol d-HETCOR (resonance
assignments refer to molecular structures (d) and (e)). Chemical structure of (d) copovidone
with protons (a, b) and carbons (1-10 ) labelled; and (e) paracetamol with protons (c-e) and
carbons (11-16 ) labelled. (b) Colour bar used to plot all the 2D NMR spectra presented
in this chapter. Number-letter pairs in (a) and (f) refer to the carbon-proton interactions
identified.
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Fig. 5.4 13C-1H CP-MAS (15 kHz) d-HETCOR of a 30 wt% paracetamol/copovidone extrudate
for a contact time of (a) 1 ms, (c) 2 ms, and (e) 4 ms. The carbon and proton spectra
projections are shown along the top and right axes. 13C spectra extracted from the 1H rows
of the (b) 1 ms, (d) 2 ms, and (f) 4 ms contact time d-HETCOR experiments (resonance
assignments refer to molecular structures shown in Figure 5.3d and e). Number-letter pairs in
(a), (c) and (e) refer to the carbon-proton interactions identified in the extrudate sample that
were not observed in the paracetamol or copovidone d-HETCOR experiments from Figure
5.3a and f (where green characters correspond to copovidone and the purple to paracetamol).
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Figure 5.4 shows the 13C-1H HETCOR spectra of an amorphous dispersion prepared
by HME with 30 wt% paracetamol and 70 wt% copovidone acquired at different cross-
polarisation contact times (tc): 1 ms, 2 ms and 4 ms. A number of cross-peaks are observable,
but only those that were not detected for individual samples of paracetamol’s and copovidone’s
HETCOR spectra (Figure 5.3) have been labelled.
At tc=1 ms (Figure 5.4a and b), although faint, two sets of cross-peaks are highlighted.
One of these corresponds to paracetamol’s aromatic carbons with the 2 ppm 1H resonance that
pertains to both the methyl protons in paracetamol and copovidone (14,15-a/c). Although
this signal was not observed in pure paracetamol (Figure 5.3f), it is not possible to assign it
unequivocally to a drug-polymer interaction. The SNR of paracetamol’s HETCOR spectrum
was low and it could be that this cross-peak was hidden in the noise. The first unequivocal
paracetamol/copovidone coupling detected was between part of copovidone’s VP monomer
carbons and paracetamol’s aromatic protons (4,5-d). This agrees with the observations by
Wen et al. that paracetamol’s phenolic resonances formed Van der Waals coupling with PVP
aliphatic groups [203].
Fig. 5.5 Schematic of hydrogen bonding be-
tween paracetamol and the PVP monomer of
copovidone (modified from [204]).
At tc=2 ms and 4 ms (Figure 5.4c, d,
e and f), several additional cross-peaks are
detected. Those that correspond to unam-
biguous paracetamol/copovidone correla-
tions include 15-b, paracetamol’s aromatic
carbons with copovidone’s aliphatic pro-
tons. Additionally, copovidone’s carbons
3, 4, 5, 6, 7, 8, 9 and 10 display cross-
peaks with paracetamol’s aromatic protons,
which most likely arise from Van der Waals
forces (copovidone’s aliphatic with paracetamol’s aromatic group) as well as H-bonding
interactions (copovidone’s PVP carbonyl with paracetamol’s hydroxyl). Although, as pre-
viously mentioned, cross-peaks 12,13,14,15-a/c cannot be unequivocally determined to be
paracetamol-copovidone interactions, it would make sense if they were, as they correspond to
paracetamol’s aromatic carbons and copovidone’s aliphatic protons and there has been other
evidence of this interaction.
The number of cross-peaks detected as well as their intensity in Figures 5.4a, b and c
increase at longer tc. This occurs because CP is based on heteronuclear dipolar interactions
and is sensitive to nuclear distances and mobility of the molecule or functional group to
which the interacting nuclei belong [130]. As a consequence, longer contact times result in
more cross-polarisation being transferred (from 1H to 13C) via dipolar couplings, as it is
supplemented by spin diffusion effects [205]. However, the spin diffusion effect is limited to
0.3 − 0.5 nm, which means that a large proportion of paracetamol molecules have to be in
close contact with copovidone chains in order to produce the signals observed in Figure 5.4.
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These conclusions were also drawn by Pham et al. for a 30 wt% paracetamol/PVP ASD
system [111].
A summary of the results from the 13C-1H HETCOR experiments is found in Figure 5.6,
where the circles denote the correlations identified between paracetamol and copovidone.
Some of the cross-peaks in the red circle (12,13,14,15-a/c) cannot be unambiguously assigned
to paracetamol-copovidone interactions because of the spectral overlap of methyl peaks
from both species. The remaining highlighted signals provide evidence of drug-polymer
molecular-level interactions in the paracetamol/copovidone HME ASD formulation, most
likely through a mixture of Van der Waals and H-bond couplings [111, 106].
Fig. 5.6 Overlapped 13C-1H CP-MAS d-HETCOR of paracetamol (purple), copovidone (green)
and a 30% extrudate (black) (the carbon and proton spectra projections of the extrudate
are shown along the top and right axes, respectively). Number-letter pairs refer to the
carbon-proton interactions identified in the extrudate sample that were not observed in the
paracetamol or copovidone HETCOR spectra (resonance assignments refer to molecular
structures shown in Figure 5.3d and e).
1H-1H NOESY
The 2D ssNMR 1H-1H experiments presented in this and the following sections were conducted
at 60 kHz MAS. This resulted in improved proton spectral resolution, as can be observed
by comparing the 1H spectra at 60 kHz MAS of paracetamol, copovidone and a 30 wt%
extrudate in Figure 5.7a with the 15 kHz MAS 1H projections of the HETCOR experiments
in Figures 5.3 and 5.4.
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Figure 5.7 shows a comparison between the 1H spectra of paracetamol (purple), copovidone
(green) and a 30 wt% paracetamol/copovidone extrudate (black) obtained from solid-state
samples at high-field 60 kHz MAS (Figure 5.7a) and from liquid-state samples (molten for
paracetamol and extrudate and dissolved in deuterated acetone for copovidone, Figure 5.7b).
As expected, the resolution is much higher for the liquid samples, as molecular tumbling
averages out chemical shift anisotropy contributions. Other than that, the signals observed
in both sets of spectra are very similar, with a few exceptions. Firstly, the methyl peak of
crystalline (solid) paracetamol is centred around 1 ppm, while it appears at 2 ppm in the
solid and molten extrudate formulation, as well as in the molten paracetamol. This suggests
that the chemical shift of the methyl 1H resonance for crystalline paracetamol is 1 ppm,
whereas for amorphous paracetamol it is 2 ppm. Secondly, water peaks are visible in the
extrudate and copovidone samples in the solid state in the 3.5 − 4 ppm region because of
copovidone’s hygroscopicity. None is observed in the molten extrudate because it was at
a temperature above water’s boiling point. Finally, copovidone peaks between 3 − 5 ppm,
which are resolved in the extrudate and copovidone spectra in the liquid-state experiments,
appear as a broad shoulder to the left of the methyl peak in the solid-state acquisitions due
to the lower resolution.
Fig. 5.7 Stacked (a) solid-state (MAS 60 kHz) and (b) liquid-state 1H spectra of paracetamol,
copovidone and a 30 wt% extrudate. The * indicates the presence of water
The 1H-1H NOESY spectra of copovidone and paracetamol were acquired with a mixing
time (tm) of 20 ms and the results are shown in Figure 5.8. Assignment of proton resonances
was made with reference to the chemical structure labelling in Figure 5.8b and c. Figure 5.8a
shows that due to the lack of resolution for copovidone, no meaningful information can be
extracted from its 1H-1H NOESY spectrum other than that there is evidence of coupling
between the a and b protons. However, a positive observation is that the water peak present
in its 1H spectrum (Figure 5.7a) does not appear in the NOESY plot.
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Fig. 5.8 1H-1H MAS (60 kHz) NOESY of (a) copovidone and (d) paracetamol with the proton
spectrum projection along the top and right axes. Chemical structure of (b) copovidone and
(c) paracetamol with protons labelled (a, b for copovidone and 1-5 for paracetamol). (e) 1H
spectra rows extracted from the paracetamol 2D NOESY experiment. Letter-letter pairs in
(a) and number-number pairs in (d) refer to the proton-proton interactions identified.
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Fig. 5.9 1H-1H MAS (60 kHz) NOESY of a 30 wt% paracetamol/copovidone extrudate for
mixing times of (a) 0.3 ms, (b) 20 ms, and (c) 100 ms (resonance assignments refer to the
molecular structures shown in Figure 5.8b and c). The proton spectrum projection for each
experiment is shown along the top and right axes. (d) 1H spectra rows extracted from the
extrudate NOESY 2D spectra at 20 ms mixing time (b). Number-letter pairs in (b) and
(d) refer to the proton-proton interactions identified in the extrudate sample that were not
observed in the paracetamol and copovidone NOESY experiments from Figure 5.8a and d.
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In Figure 5.8d there are five resolved paracetamol proton resonances: 1 corresponds to
the hydroxyl protons, 2 to the amine, 3 and 4 to the aromatic protons and 5 to the methyl
protons (the corresponding rows are shown in blue, orange, yellow, purple and green in Figure
5.8e) [202, 112]. Distinct cross-peaks are observed between most of the resolvable proton
environments. This is not surprising, as paracetamol crystal structures are tightly packed,
enabling through-space couplings, particularly at long mixing times.
Figure 5.9 shows the 1H-1H NOESY spectra of a 30 wt% paracetamol/copovidone ASD
prepared by HME acquired at different tm: 0.3 ms, 20 ms and 100 ms. Similarly as with the tc
in HETCOR, the number of cross-peaks detected and their intensity increase in the NOESY
spectra at longer tm. This happens because during tm, the NOE effect affects spatially close
nuclei, so for longer mixing times, the magnetisation reaches nuclei that are further away
[206].
At tm= 0.3 ms, the diagonal peaks are clearly visible, but the only cross-peaks detected
are those between 2 ppm and 4 ppm (likely a-b proton intramolecular coupling in copovidone)
and aromatic-aromatic proton intramolecular interactions in paracetamol (3-4 ).
At a mixing time of 20 ms several additional cross-peaks are observable, but only those
that were not detected in paracetamol’s and copovidone’s NOESY spectra (Figure 5.8) have
been labelled. Four proton environments were resolved: methyl group in paracetamol and
methyl and methylene groups in copovidone (a, 5 ), other aliphatic protons in copovidone
(b), paracetamol’s aromatic protons (3, 4 ) and paracetamol OH– and NH– (1, 2 ). The
corresponding rows are shown in blue, orange, yellow and purple in Figure 5.9d.
In the 4 ppm row (yellow), corresponding to copovidone’s aliphatic protons, there are clear
cross-peaks with the aromatic (3,4-b) and hydroxyl/amine (1,2-b) protons in paracetamol.
These could result from Van der Waals forces between the aromatic ring in paracetamol
molecules and copovidone’s aliphatics and/or H-bonding between copovidone’s carbonyl
and paracetamol’s hydroxyl protons. Further cross-peaks are observed along the 2 ppm row
(purple), with the OH–/NH– resonances (1,2-a/5 ). Although it is not possible to definitively
assign those as drug-polymer interactions, it is likely the case as the cross-peak was not
observed in the paracetamol NOESY spectrum (Figure 5.8d). This interaction would probably
be mediated through an H-bond between paracetamol and copovidone (refer to Figure 5.5 for
a schematic). There is another cross-peak involving the aromatic protons (3,4-a/5 ), but this
cannot be unambiguously assigned to paracetamol-copovidone interactions due to spectral
overlap. At 100 ms tm there was so much signal intensity that cross-peaks overlapped with
each other and it was difficult to see fainter signals.
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Fig. 5.10 Overlapping 1H-1H MAS NOESY
of paracetamol (purple), copovidone (green)
and a 30 wt% extrudate (black) (the proton
spectrum projection of the extrudate is shown
along the top and right axes). Number-letter
pairs refer to the proton-proton interactions
identified in the extrudate sample that were not
observed in the paracetamol and copovidone
2D NOESY spectra (resonance assignments
refer to molecular structures shown in Figure
5.8b and c).
NOESY experiments have been used
previously in the literature to explore in-
termolecular associations in pharmaceu-
tical formulations. Liu et al. performed
solution-state NOESY of a drug-polymer
ASD and confirmed the existence of in-
teraction between the drug (sorafenib)
and the polymer (PVP) [106]. Due to
the higher resolution achieved in liquid
samples, it was possible to determine
which specific protons were involved in
the coupling and, combined with com-
putational methods, it was determined
that drug-polymer interactions occurred
through H-bonds with the carbonyl group
of PVP. Mann et al. conducted MAS
1H-1H NOESY on highly viscous phar-
maceutical mixtures [207]. Specifically,
intermolecular H-bonding was identified
between ibuprofen and lidocaine.
A summary of the results from the 1H-
1H NOESY experiments presented in this
section is found in Figure 5.10, where the
coloured circles denote the identified cross-
peaks that suggest correlations between
paracetamol and copovidone. Although the cross-peaks in the red circle (1,2-a/5 ) cannot
be unambiguously assigned to paracetamol-copovidone interactions because of the spectral
overlap of methyl peaks from both species at 2 ppm, this signal was not present in either of the
pure component’s NOESY spectra, suggesting that it could in fact result from drug-polymer
interactions. The remaining highlighted signals (1,2,3,4-b) provide evidence of drug-polymer
molecular-level interactions in the paracetamol/copovidone HME ASD formulation, most
likely through a mixture of Van der Waals and H-bond couplings.
1H-1H MQC SQ/DQ BABA
In order to facilitate the interpretation of results from 1H-1H MQC experiments, it is useful
to refer to the H-bonding pattern of paracetamol in its polymorph I crystal lattice structure
shown in Figure 5.11.
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The 1H-1H MQC BABA experiment, although similarly to NOESY in that it detects
proton-proton through-space couplings, provides clearer observations as there is no interference
from high-intensity diagonal components to conceal weak cross-peaks within the noise level.
The MQC BABA spectra of copovidone and paracetamol are shown in Figure 5.12, where
assignment of proton resonances is made with reference to the chemical structures labelled
in Figure 5.12b and c. As for the NOESY experiment, due to the lack of proton spectral
resolution for copovidone, no meaningful information can be extracted from its 1H-1H MQC
BABA spectrum. There is some evidence suggesting coupling between the a and b protons
in copovidone: at 6 ppm in the DQ dimension (blue line in Figure 5.12a) there is signal both
at 2 ppm and 4 ppm in the SQ axis, but this could also be due to line broadening.
Fig. 5.11 Paracetamol polymorph I crystal
lattice structure (modified from [208]).
In Figure 5.12d the same five paracetamol
resonances resolvable in the NOESY experi-
ment are present in the MQC BABA spec-
trum. There are six cross-correlations (the cor-
responding row of each one of them is shown in
Figure 5.12e) and one self-correlation present.
The self-correlation corresponds to the only
group in paracetamol that has several protons
- the methyl (5-5 ), therefore this signal is po-
sitioned at the intersection of 1 ppm (SQ) and
2 ppm (DQ). The cross-correlations identified
involved the following atom numbers:
5-4 : corresponds to methyl and aromatic proton coupling at 1 and 6 ppm respectively.
These are far apart in the paracetamol molecule, but when the molecules are assembled
through H-bonds in the crystal lattice of polymorph I (refer to Figure 5.11), the protons
in these groups are in close proximity, resulting in through-space intermolecular coupling
being exhibited in the MQC BABA spectrum at 7 ppm in the DQ axis.
5-3 : similar to the above, this corresponds to methyl protons with aromatic protons (the
ones closer to the amine). As for 5-4, this corresponds to intermolecular coupling
because the H-bonds in the crystal lattice brings the protons involved in this interaction
into close proximity.
5-1 : this coupling involves the protons that are furthest apart in the paracetamol molecule -
the methyl and the hydroxyl protons, at 1 and 9 ppm respectively. Again, looking at
the arrangement of neighbouring molecules in the crystal structure (Figure 5.11), the
methyl and hydroxyl protons become close in space (intermolecular coupling), giving
rise to a cross-correlation at 10 ppm in the DQ dimension.
3-4 : aromatic-aromatic coupling, likely arising from intramolecular interactions.
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3-2 : this corresponds to the intramolecular coupling between the aromatic protons closer to
the amine and the amine protons themselves.
4-1 : in an analogous way as the previously mentioned correlation, this one corresponds to
the other aromatic protons (the ones closer to the hydroxyl group) and the hydroxyl
resonances (intramolecular coupling).
Fig. 5.12 1H-1H MAS (60 kHz) MQC SQ/DQ BABA of (a) copovidone and (d) paracetamol,
with the proton spectrum projection along the top and right axes. Chemical structure of
(b) copovidone and (c) paracetamol with protons labelled (a, b for copovidone and 1-5 for
paracetamol). (e) 1H SQ spectra rows extracted from the paracetamol 2D BABA experiment.
Number-number pairs in (d) refer to the proton-proton interactions identified.
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Figure 5.13a shows the 1H-1H MQC BABA spectrum of a 30 wt% paracetamol/copovidone
extrudate. Several rows of interest showing cross-peaks that were not observed in parac-
etamol’s or copovidone’s MQC BABA spectra (Figure 5.12) have been extracted for more
detailed examination in Figure 5.13b, and the chemical shift position in the DQ axis they
correspond to has been noted next to them.
Several correlations have been identified that could suggest drug-polymer interactions. In
the green row at 9 ppm in the DQ axis, there is evidence of two correlations. One of them is
a copovidone self-correlation between the b protons (b-b), located around 4.5 ppm in the SQ
dimension. The other one is between paracetamol’s aromatic protons (7 ppm) and a signal
at 2 ppm. This coupling could be either with paracetamol’s methyl (5 ) or with copovidone’s
a protons. There is evidence that paracetamol exists in an amorphous state in extrudates,
meaning that the crystalline lattice has been disrupted by the polymer chains. Therefore the
extent of paracetamol-paracetamol intermolecular interactions is expected to be significantly
lower than for Figure 5.12d. The nature of this cross-correlation is intramolecular, but it is
uncertain whether it corresponds to drug-polymer or drug-drug [111] .
Fig. 5.13 (a) 1H-1H MAS (60 kHz) MQC SQ/DQ BABA of a 30 wt% paracetamol/copovidone
extrudate, with the proton spectrum projection along the top and right axes (resonance
assignments refer to the molecular structures shown in Figure 5.12b and c). (b) 1H SQ
spectra rows extracted from the 2D BABA experiment in (a). Number-letter pairs in (a) refer
to the proton-proton interactions identified in the extrudate sample that were not observed
in the paracetamol and copovidone BABA experiments from Figure 5.12a and d.
Along the purple row (11 ppm in the DQ axis) there is evidence of another two couplings.
The first one (2-a/5 ) is between paracetamol’s amine (9 ppm) and a signal at 2 ppm,
which, following the same rationale as that in the previous paragraph, could be either from
paracetamol or from copovidone’s methyl protons and it is no possible to determine which.
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The second one (3,4-b) involves paracetamol’s aromatic protons (7 ppm) and copovidone’s
b resonances (4 ppm). This coupling unambiguously identifies a paracetamol-copovidone
interaction, which could be a result from Van der Waals forces as was described in the
previous section on the HETCOR experimental results [203].
On the yellow row (12 ppm in the DQ axis) there is evidence of two interactions, very
similar to those described in the previous paragraph. One of them (1-a/5 ) involves parac-
etamol’s hydroxyl (10 ppm) and protons at 2 ppm, either from paracetamol or copovidone,
engaging in intermolecular couplings. The second one (3,4-b) entails paracetamol’s aromatic
groups (8 ppm) and copovidone’s resonances at 4 ppm.
Finally, the grey row (14 ppm in the DQ axis) highlights the position of a cross-correlation
(1,2-b) between paracetamol’s OH– or NH– groups with copovidone’s b protons. This
unambiguous paracetamol-copovione coupling is likely to be the result of hydrogen bonding
between paracetamol’s hydroxyl and copovidone’s carbonyl groups (although H-bonding is
expected to occur at a greater extent with VP’s carbonyl than VA’s). H-bonding between
paracetamol and PVP ASDs has already been reported by Tatton et al. (through ssNMR
14N-1H heteronuclear MQC) [112] and Liu et al. published evidence of H-bonding between
other APIs with both PVP and copovidone (observed via solution-state 1H-1H NOESY)
[106].
Fig. 5.14 Overlapping 1H-1H MAS MQC SQ/DQ
BABA of paracetamol (purple), copovidone
(green) and a 30 wt% extrudate (black) (the
proton spectrum projection of the extrudate is
shown along the top and right axes). Resonance
assignments refer to molecular structures shown
in Figure 5.12b and c.
A summary of the results from the
1H-1H MQC BABA experiments pre-
sented in this section is found in Fig-
ure 5.14, where the coloured lines de-
note the rows in which the recorded sig-
nals suggest correlations between parac-
etamol and copovidone. As it was dis-
cussed, some of the cross-correlations
(1,2,3,4-a/5 ) cannot be unambiguously
assigned to paracetamol-copovidone in-
teractions because of the spectral over-
lap of methyl peaks from both species at
2 ppm. The remaining highlighted sig-
nals (1,2,3,4-b) provide evidence of drug-
polymer molecular-level interactions in
the paracetamol/copovidone HME ASD
formulation, most likely through a mix-
ture of Van der Waals and H-bond cou-
plings, which coincides with the findings
from the HETCOR and NOESY experi-
ments presented previously.
5.3 Results and discussion 103
5.3.2 2D liquid-state NMR: 1H-1H COSY
Fig. 5.15 Schematic of scalar
coupling in hydrogen bond-
ing (modified from [188]).
Due to the lack of resolution in the proton spectrum on
the 2D ssNMR plots shown in the previous section, it is not
possible to determine exactly which nuclei in the molecule are
involved in the paracetamol-copovidone couplings. Liquid-
state spectra display significant resolution improvement (as
was shown in Figure 5.7) due to the averaging of chemical
shift anisotropy contributions. Therefore this section explores
the use of liquid-state (achieved through solubilisation or
melting) 2D NMR techniques to gain better understanding on
paracetamol/copovidone mixtures at temperatures relevant
to HME. The experiment of choice was 1H-1H COSY, which
identifies through-bond molecular couplings. COSY detects nuclei that are involved in scalar
interactions. This means that the magnetic moment of one nuclei (D) disturbs the electron
cloud of the another nuclei (A), which in turn induces a magnetic field that interacts with
the magnetic moment of the second nuclei (Figure 5.15). This applies to covalent bonds,
but also to H-bonds and Van der Waals forces as they follow the same electron-mediated
interaction mechanism (Figure 5.15) [188, 209].
The 1H-1H COSY of copovidone dissolved in deuterated acetone (at room temperature)
and molten paracetamol (no solvent, at 170◦C) were acquired and the results are shown
in Figure 5.16. Assignment of proton resonances was made with reference to the chemical
structure labelling in Figure 5.16c and d. Figure 5.16a shows that there are five resolvable
proton environments in solution-state copovidone (whereas there were only two in ssNMR,
even at high-MAS rates), but there is still an overlap between protons d, e, f and g. Some
rows have been extracted in Figure 5.16b for closer examination of the signals acquired.
There are numerous cross-peaks detected, particularly involving those around the 2 ppm
region, but it should be noted that all copovidone-copovidone couplings are observed in the
chemical shift region from 1 to 5 ppm.
In Figure 5.16e there are four discernible proton environments in molten paracetamol
(the corresponding rows are shown in Figure 5.16f) and distinct couplings between several
of them have been labelled. One of these corresponds to aromatic-aromatic intramolecular
interaction (3-4 ). Another coupling detected is OH– or NH– with methyl protons (1/2-5 ).
Due to spectral overlap it is unclear which of the two resonances is displaying an interaction
with the methyl group. It could be intramolecular correlation between the NH– and methyl
or intermolecular coupling between the OH– and methyl (through the H-bond between
neighbouring OH– and C=O groups, as was illustrated in Figure 5.11).
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Fig. 5.16 1H-1H COSY of (a) copovidone dissolved in deuterated acetone and (e) molten
paracetamol (170◦C), with the proton spectrum projection along the top and right axes.
Chemical structure of (c) copovidone and (d) paracetamol with protons labelled (a-h for
copovidone and 1-5 for paracetamol). 1H spectra rows extracted from (b) copovidone and (f)
paracetamol 2D COSY experiments. Number-number pairs in (e) refer to the proton-proton
interactions identified.
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Fig. 5.17 Paracetamol polymorph I
crystal lattice structure (modified
from [210]).
Lastly, there is a cross-peak between the aro-
matic and the methyl protons (3,4-5 ). These nuclei
are too far in the paracetamol structure to dis-
play intramolecular coupling in COSY experiments.
However, there is evidence in the literature that
the layers of H-bonded paracetamol molecules are
secured to each other via Van der Waals forces [208].
A schematic of paracetamol’s (polymorph I) crystal
structure is shown Figure 5.17. Methyl groups are in close proximity to the aromatic rings of
neighbouring molecules, so it could be possible that the Van der Waals interactions between
paracetamol layers are responsible for the cross-peak observed in the COSY spectrum. As
COSY is a through-bond technique, it does not detect the through-space couplings observed
in NOESY and MQC BABA plots between neighbouring paracetamol molecules.
Fig. 5.18 (a) 1H-1H COSY of a molten 30 wt% paracetamol/copovidone extrudate (170◦C),
with the proton spectrum projection along the top and right axes (resonance assignments
refer to the molecular structures shown in Figure 5.16c and d). (b) 1H spectra rows extracted
from the 2D COSY experiment in (a). Number-letter pairs in (a) refer to the proton-proton
interactions identified in the extrudate sample that were not observed in the paracetamol
and copovidone COSY experiments from Figure 5.16a and e.
Figure 5.18a shows the 1H-1H COSY spectrum of a 30 wt% paracetamol/copovidone
extrudate. There are eight resolvable resonances: three from paracetamol (1/2, 3 and 4 ),
four from copovidone (a, b, c and h) and one peak at 2 ppm resulting from the overlap of
four copovidone (d, e, f and g) and one paracetamol (5 ) proton environments. Seven rows of
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interest have been extracted for closer examination and these are plotted in Figure 5.18b.
The six cross-peaks that were not observed in paracetamol’s or copovidone’s COSY spectra
(Figure 5.16) have been labelled. The cross-correlations identified involved the following
resonance pairs:
3,4-h: corresponds to copovidone’s PVP methylene and paracetamol’s aromatic protons
coupling. This agrees with the previous ssNMR (HETCOR, NOESY and MQC BABA)
observations and with literature sources that report drug-polymer Van der Waals
interactions between paracetamol’s aromatic ring and PVP aliphatic groups [203, 111].
1,2-c,d: this coupling involves the OH– or NH– protons in paracetamol and the closest protons
to copovidone’s PVP carbonyl. This corresponds with the evidence presented in the
previous section on paracetamol-copovidone H-bonding, which has also been identified
in the literature [112, 111], especifically between PVP’s carbonyl and paracetamol’s
OH– group.
3,4-a,b: similarly to 3,4-h, this correlation corresponds to copovidone’s methine groups in the
polymer backbone and paracetamol’s aromatics. Therefore the same interpretation
applies: Van der Waals interactions between the aromatic ring of paracetamol and the
aliphatic resonances of copovidone are being detected in the COSY experiment.
Fig. 5.19 Overlapping 1H-1H COSY of parac-
etamol (purple), copovidone (green) and a 30
wt% extrudate (black) (the proton spectrum
projection of the extrudate is shown along the
top and right axes). Number-letter pairs refer
to the proton-proton interactions identified in
the extrudate sample that were not observed in
the paracetamol and copovidone COSY spec-
tra. Resonance assignments refer to Figure
5.16c and d).
A summary of the results from the 1H-
1H COSY experiments presented is found
in Figure 5.16, where the coloured circles
denote the cross-peaks that suggest corre-
lations between paracetamol and copovi-
done. In accordance with previous inter-
pretation of results, 1,2-c,d (blue circle)
suggest H-bonding between paracetamol’s
hydroxyl and copovidone’s PVP carbonyl.
This does not mean that H-bonding is not
taking place with copovidone’s PVA car-
bonyl [211]. There is a cross-peak that
could correspond to 1,2-e, but since this
overlaps in the 2 ppm region with parac-
etamol’s methyl resonance, the interpreta-
tion is ambiguous. The other cross-peaks,
4-h and 3,4-a,b (red and orange circles),
are consistent with Van der Waals interac-
tions between the paracetamol aromatic
ring and copovidone’s aliphatic backbone
chain.
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Fig. 5.20 Relationship between T1 and
T2 values and molecular "tumbling"
rate, where f0 is the Larmor frequency
(modified from http://mri-q.com).
To further substantiate the idea that the cross-
peaks identified are paracetamol-copovidone inter-
actions were in fact so, spin-echo weighted COSY
(SE-COSY) experiments were conducted. The ra-
tionale behind this is that, generally, slower molec-
ular motions originating from large molecules,
solid lattices or bound species are associated with
a shorter T2 constant (Figure 5.20) [32]. During
the spin-echo delay, magnetisation dephases at
a rate proportional to the T2 value. Therefore
protons that are bound (through H-bonding or
Van der Waals forces) are expected to exhibit
shorter T2 and, at increasing spin-echo delays,
these signals would reduce in intensity or vanish
altogether.
Figure 5.21a-c shows the 1H-1H COSY and SE-COSY spectra of a 30 wt% paraceta-
mol/copovidone extrudate at different spin-echo delays: (a) no delay, (b) 1 ms and (c) 10 ms.
Figure 5.21a corresponds to Figure 5.18a, and so the same cross peaks are observed. When
a 1 ms spin-echo delay is introduced, the COSY spectrum remains the same except for the
3,4-a,b cross-peak (orange circle), which is not detected any more. This could be because the
Van der Waals interactions between aromatic paracetamol protons and copovidone’s aliphatic
backbone is the most rigid and has the shortest T2. It should be noted that the T2 value of
the OH/NH resonance in paracetamol is shorter than those of the aromatic protons (data
not shown), so the fact that cross-correlations involving protons 3 and 4 were the first to
disappear when spin-echo delay was lengthen is indicative that the reason for their decreased
T2 is associated with molecular interactions.
When the spin-echo delay is increased to 10 ms, all cross-peaks that had been associated
with paracetamol-copovidone couplings are no longer present (both the ones pertaining
to H-bonding, 1,2-c,d and the one identified as Van der Waals interactions, 4-h). The
resulting spectrum does not display any cross-peaks other than those observed for the pure
paracetamol and copovidone components (Figure 5.16), suggesting that all the cross-peaks
identified as drug-polymer interactions were probably in fact so. This is clearly depicted
in Figure 5.21, where the spectra of the SE-COSY experiments (at 0 ms, 1 ms and 10 ms
delay) are overlapped. These results are not in disagreement with the literature, that have
consistently shown that copovidone’s carbonyl form H-bonds with drugs, strongly favouring
the PVP monomer over the PVA one, and that specifically paracetamol engages both in
H-bonding and Van der Waals interactions with PVP-based polymers such as copovidone.
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Fig. 5.21 1H-1H COSY a 30 wt% paracetamol/copovidone extrudate for spin-echo times of (a)
0 ms, (b) 1 ms, and (c) 10 ms (resonance assignments refer to the molecular structures shown
in Figure 5.16c and d). The proton spectrum projection for each experiment is shown along
the top and right axes. (d) Overlapped 1H-1H COSY of a 30 wt% paracetamol/copovidone
extrudate for spin-echo times of 0 ms (blue), 1 ms (red), and 10 ms (green) (the proton
spectrum projection of the normal COSY experiment is shown along the top and right axes).
Number-letter pairs refer to the proton-proton interactions identified in the extrudate sample
that were not observed in the paracetamol and copovidone COSY experiments from Figure
5.16a and e, where green characters correspond to copovidone and the purple to paracetamol.
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5.4 Conclusion
A range of solid-state and liquid-state 2D NMR techniques were used in this chapter to
explore whether paracetamol-copovidone interactions were established as a result of the HME
process, and if so, what the nature of these molecular interactions were. This is relevant
because drug-polymer molecular associations are known to increase formulation stability and
prevent drug recrystallisation upon storage.
High-field 13C-1H HETCOR spectra were acquired at a range of contact times. The
unambiguous correlations observed involved paracetamol’s aromatic protons and copovidone’s
aliphatic carbons. Some of these aliphatic carbons belonged to the backbone of the polymer
chain, which, as suggested by the literature, was assigned to Van der Waals interactions, and
the rest corresponded to those carbons closest to the carbonyl groups, which could be a result
from H-bonding, as other experiments indicated. The increasing signal intensity and number
of cross-peaks at longer contact times suggested the presence of intermolecular through-space
interactions between a large proportion of paracetamol molecules and copovidone monomers.
1H-1H NOESY, and especially 1H-1H MQC BABA fast-MAS experiments, in agreement
with HETCOR results, displayed paracetamol aromatic ring coupling (via Van de Waals forces)
as well as paracetamol’s hydroxyl proton resonances (through H-bonds) with copovidone
aliphatic groups. However, all the solid-state experiments suffered from broad proton
resonance bandwidths, even at high-field and fast-MAS rates, which prevented assignment of
correlations to individual nuclei.
A key advantages of liquid-state spectroscopy is the increased resolution, which allows
more precise identification of the nuclei involved in the couplings. Overall, the results from
the 1H-1H molten COSY experiments agree with the conclusions drawn from ssNMR data.
Cross-peaks between several individual copovidone’s backbone protons and paracetamol’s
aromatic protons were observed. Also, a correlation was identified between paracetamol’s
hydroxyl and the two proton environments closest to copovidone’s PVP monomer carbonyl.
The introduction of a spin-echo delay in the COSY experiments resulted in the reduction
of the number of cross-peaks detected, which was correlated with the length of the delay,
indicating that the signals in question displayed a very short T2 value. A likely explanation
is that this occurred due to the establishment of paracetamol-copovidone interactions (in the




drug/polymer systems and the
effect of processing variables
6.1 Introduction
The previous chapters have focused on paracetamol/copovidone systems to illustrate the use
of high-temperature 1H NMR spectroscopy (for material characterisation) and diffusometry
(for drug/polymer mass transport analysis) and 13C CP-MAS spectroscopy and relaxometry
(as an insight into the microstructure of the formulation and drug-polymer interactions).
To demonstrate the versatility of this NMR toolbox, the techniques have been applied to
alternative drug/polymer systems. Traditional analytical DSC measurements were also
conducted to aid in the characterisation of the compounds and act as a benchmark.
The first systems studied included mixtures of paracetamol with PVA (poly vinyl acetate)
and PVP (poly vinyl pyrrolidone) polymers. These polymers are made up of the monomers
that comprise copovidone (also known as PVPVA). Despite the similarities between these
three polymers, they have contrasting properties with regards to their Tg, Tm and H-bonding
abilities. The second system studied involved another API - nifedipine, and copovidone.
Nifedipine is a small-molecule drug, but it is considerably larger than paracetamol, which
should result in slower self-diffusion coefficient. Additionally, it has no H-bonding hydroxyl
group.
Lastly, the experiments were conducted on several samples from a DoE (design of
experiments) run, in which extrudates were produced at different drug loadings, temperatures,
screw speeds and with two commercially available copovidone brands (Plasdone and Kollidon).
The aim was to identify if any of these variables had significant impact on either the mass
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transport coefficients of paracetamol in the melts (high-temperature diffusometry) or in the
microstructure of the formulations (solid state relaxometry).
6.2 Materials and methods
6.2.1 Materials and sample preparation
The two APIs used in the studies presented in this chapter were paracetamol and nifedipine,
provided by AstraZeneca. Paracetamol is a very common analgesic with a small molecular
weight of 151.2 g/mol (Tm=170◦C); whereas nifedipine is a calcium channel blocker to
treat high blood pressure and has a higher molecular weight of 346.3 g/mol (Tm=173◦C).
Additionally, three polymers have been used. These were PVP, a polymer composed of vinyl
pyrrolidone monomers, PVA, made up only of vinyl acetate monomers, and copovidone, a
copolymer of VP and VA monomers in 6:4 mass ratio.
The samples from the DoE were paracetamol/copovidone extrudates. They differed in
drug loading, processing temperature, screw speed and commercial brand of copovidone used
- Plasdone (Ashland) or Kollidon (Basf). The composition and processing details for each
sample can be found in Table 6.1.
Table 6.1 Composition and processing details of DoE extruded samples.
Sample Polymer Paracetamol [wt%] Temperature [◦C] Screw speed [rpm]
1A Plasdone 20 140 200
1B Plasdone 20 140 300
1D Plasdone 20 180 300
2A Plasdone 30 140 200
2B Plasdone 30 140 300
2D Plasdone 30 180 300
7A Kollidon 20 140 200
7B Kollidon 20 140 300
7D Kollidon 20 180 300
8A Kollidon 30 140 200
Extrudates and physical mixtures were prepared following the same methods that were
outlined in chapter 3 (section 3.2.1).
6.2.2 Solution-state NMR spectroscopy and diffusometry
The solution-state NMR spectroscopy and diffusometry experimental methods followed were
identical as those outlined in chapter 3 (section 3.2.2).
6.2.3 Modulated differential scanning calorimetry
The modulated differential scanning calorimetry experimental methods followed were identical
as those outlined in chapter 3 (section 3.2.3).
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6.2.4 Solid-state NMR spectroscopy and relaxometry
The solid-state NMR spectroscopy and relaxometry experimental methods followed were
identical as those outlined in chapter 4 (section 4.2.2).
6.3 Results and discussion
Section 6.3.1 will examine the behaviour of physical mixtures of paracetamol with three
different polymers. Section 6.3.2 will consider both nifedipine/copovidone physical mixtures
and extrudates and a discussion of the two will follow. Finally, section 6.3.3 will focus solely
on paracetamol/copovidone extrudates.
6.3.1 Alternative drug/polymer systems: paracetamol in PVA and PVP
physical mixtures
High-temperature characterisation via 1H NMR and DSC
The chemical structures of PVA, copovidone and PVP, with protons labelled a-g are shown in
Figure 6.1a-c. The variable-temperature 1H spectra were acquired for each polymer (Figure
6.1e-g), and these highlight some of the differences between them (note that there was no
solvent present in these samples, all polymer mobility was attained through thermal mobility).
Firstly, PVA’s spectrum displays two resolved peaks at as low as 130◦C, which indicates
a lack of rigidity in the polymer chains. For copovidone, the spectra at 100◦C and 120◦C
are likely from residual water tightly attached to the polymer chains via H-bonds, which
then evaporates. From 140◦C on, the single broad resonance increases in signal intensity, but
resolution is still low due to lack of mobility. Finally, PVP shows a general lack of resolution
and low signal intensity, which is a result of the broad resonance due to restricted mobility
and the long T1 constant (between 4.1 − 6.6 s for the range of temperatures examined),
leading to a certain degree of T1-weighting, respectively. Interestingly for PVP, the highest
signal intensity spectrum (Figure 6.1g, purple plot) is obtained at the lowest temperature
(130◦C), which suggests that this resonance is comprised of water protons to a large extent. It
is not surprising that PVP has a higher adsorbed water concentration, as it has the strongest
H-bonding ability [106]. Note that there is no T2-weighting in these spectra, because they were
obtained in pulse-and-acquire experiments. In agreement with the conclusions drawn from
the high-temperature NMR spectrosopy and relaxometry, the DSC thermogram (Figure 6.1d)
displays the markedly different glass transition temperatures (Tg) of the three polymers: PVA
transitions to a rubbery state at 40.2◦C, whereas copovidone remains glassy until 109.2◦C
and PVP has the highest Tg at 156.0◦C. There are no other events in the thermograms
because these polymers are amorphous in nature.
Figure 6.2a-c, shows the variable-temperature 1H spectra of 30 wt% physical mixtures of
paracetamol in PVA, copovidone and PVP. The trends observed are very similar to those
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Fig. 6.1 Chemical structures of (a) PVA, (b) copovidone and (c) PVP with protons labelled a-h;
(d) high temperature characterisation of PVA, copovidone and PVP using DSC thermogram -
only the second heating ramp of two consecutive heat-cool cycles is shown. 1H NMR spectra,
at high temperatures between 100-170◦C, of (e) PVA, (f) copovidone and (g) PVP (resonance
assignments refer to the molecular structures).
from the polymer-only experiments. In the paracetamol/PVA mixture, even the spectrum at
120◦C is clearly resolvable into several resonances: 2 ppm (paracetamol and PVA), 5 ppm
(PVA) and 6-9 ppm (paracetamol). This is a combined effect from the low Tg of PVA and
the plasticising ability of paracetamol (already pointed out in mixtures with copovidone in
chapter 3), which dissolves between the polymer chains creating space that enhances mobility.
The same two resonances (at 2 and 5 ppm) that were visible in the polymer-only spectra
are identified in Figure 6.2a. In the case of copovidone with paracetamol, line-widths are
very broad up to 160◦C, when several resonances become evident. Once 170◦C is reached,
peaks become sharper and several copovidone resonances (at 3 − 5 ppm) that had not been
visible in the polymer-only spectra, are discernible. At 170◦C paracetamol is fully molten, so
it would act as a solvent for copovidone, producing a spectrum similar to that obtained in
chapter 3 from copovidone in deuterated acetone. Finally, PVP is so stiff, that almost no
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signal is recorded at 130◦C and 140◦C. From 150 − 170◦C, paracetamol resonances become
recognisable, although the spectral resolution is very poor. This is a result of increased
polymer mobility through paracetamol plasticisation, although due to the very high Tg of
PVP, spectral line-widths remain broad. An interesting observation from these spectra is
that the paracetamol peaks are observed well below its Tm of 170◦C, indicating that the
presence of PVA, copovidone and PVP has lowered the melting temperature of paracetamol.
Figure 6.2d-f shows the DSC thermograms of the second heating cycle of 20, 30 and
40 wt% paracetamol physical mixtures in the three polymers of interest. Two trends that
become apparent are: (i) mixtures of paracetamol in PVP have significantly higher Tg than
mixtures in copovidone, which in turn display higher Tg than PVA systems; and (ii) for each
polymer, Tg consistently decreases with increasing paracetamol content. The first finding
agrees with the results from Figure 6.1d in that Tg,P V P > Tg,cop > Tg,P V A. The second
observation is consistent with paracetamol acting as a plasticising agent.
Fig. 6.2 1H spectra, at high temperatures between 120−170◦C, of 30 wt% paracetamol physical
mixture in (a) PVA, (b) copovidone and (c) PVP. (d) High temperature characterisation of
20, 30 and 40 wt% paracetamol physical mixtures in (d) PVA, (e) copovidone and (f) PVP
using DSC thermograms - only the second heating ramps of two consecutive heat-cool cycles
are shown.
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Furthermore, there are other interesting observations. Firstly, there are no other thermal
events in the thermograms shown, other than glass transitions, with the exception of a small
melting endotherm at 148◦C in Figure 6.2d, for the 40 wt% paracetamol/PVA system (dark
blue). The relevance of this is that, after a heating cycle, paracetamol has become amorphous
in the polymer mixtures. However, at the higher drug loading sample, and for the weak
H-bonding polymer, PVA has failed to stabilise all of the paracetamol in an amorphous state,
so a fraction of the drug recrystallises and melts again during the second heating cycle. This
is consistent with the observations of Chan et al.: PVA systems resulted in a lower degree of
amorphisation compared to PVP or copovidone [212].
Secondly, for the two lower drug loadings in PVP, the thermogram displays two Tg events
(red and brown lines). The first one, at 92.2◦C and 87.1◦C for the 20 wt% and 30 wt%
mixtures, respectively, correspond to the glass transition of the paracetamol/PVP mixture.
The second one, at 158.8◦C and 159.8◦C, belongs to pure PVP. This occurs because PVP is
so efficient at stabilising paracetamol (likely due to its strong H-bonding ability) that, at low
drug loadings, there are PVP domains remaining after dissolution of paracetamol particles.
Thirdly, not all polymers display the same degree of plasticisation when mixed with
paracetamol. The relative decrease in the Tg between the pure polymers and, for example, a
mixture with 30 wt% paracetamol, is 17% for PVA, 34% for copovidone and 44% for PVP.
This implies that paracetamol has a greater degree of dispersion in PVP and copovidone than
PVA, creating space between the chains to allow for mobility and disrupting polymer-polymer
interactions. The fact that PVP’s carbonyl group has high H-bonding capabilities, results in
strong drug-polymer interactions, that enhance the dissolution and dispersion of paracetamol.
Determination of the self-diffusion coefficient of paracetamol in polymer physical
mixtures
As was explained in chapter 3, due to the spectral overlap of these three polymers with
paracetamol in the 2 ppm (methyl) region, diffusion coefficients for paracetamol in polymer
mixtures were calculated from the signal of the aromatic and NH–/OH– resonances (6 − 10
ppm). Table 6.2 summarises paracetamol’s diffusion coefficients in 30 wt% physical mixtures at
150◦C, 160◦C and 170◦C. Paracetamol’s self-diffusivity (at 170◦C) is included for comparison
and the standard deviation errors from three measurements are quoted in parenthesis.
The results from Table 6.2, which are better visualised in Figure 6.3, show that the
diffusion coefficient of paracetamol is significantly faster in PVA than in copovidone or PVP
physical mixtures. This is likely due to the low viscosity of PVA at this temperature range,
which is over 100◦C degrees above its Tg, and possibly due to the lesser extent of drug-polymer
interactions. Nevertheless, these values are still several-fold lower than in a pure molten
state, suggesting that the diffusion of paracetamol is heavily influenced and restricted by
PVA (viscosity effects and molecular interactions are likely to play a large role). Paracetamol
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in PVP and copovidone exhibits slower diffusion coefficients, in agreement with previous
observations on Tg and polymer mobility. All three systems display a small but statistically
significant increase in diffusion coefficient over the 20◦C range studied.
Table 6.2 Diffusion coefficients of paracetamol in PVA, copovidone and PVP 30 wt% physical
mixtures. The self diffusion coefficient of paracetamol measured at 170◦C (from chapter 3) is
also included for comparison.
D × 10−12m2/s
30 wt% paracetamol in 150 ◦C 160 ◦C 170 ◦C
PVA 28.5 (±0.21) 43.7 (±0.57) 55.7 (±0.64)
Copovidone 3.85 (±0.59) 5.04 (±0.71) 7.40 (±0.73)
PVP 3.05 (±0.25)a 3.85 (±0.01) 4.83 (±0.02)
Paracetamol – – 190.0 (±20.0)
a The numbers in parenthesis indicate the standard deviation of three repeat measurements.
Fig. 6.3 Visual representation of the data in Table 6.2. Diffusion coefficients of paracetamol
in 30 wt% physical mixtures with PVA, copovidone and PVP vs temperature (error bars
represent the standard deviation of three measurements).
From the results presented in this section it can be concluded that there are both
advantages and disadvantages to formulating a system with either PVP or PVA. A parac-
etamol/PVA formulation would be easy to extrude, as the Tg is low and a high degree of
molecular dispersion is anticipated as the diffusion coefficient of paracetamol in this polymer
is considerably high. The downside of a low Tg that is barely above room temperature
(Tg = 33.3◦C at 30 wt% drug loading) is that phase separation is more likely to occur during
storage due to high molecular mobility. Furthermore, the lack of H-bonding abilities of
PVA fail to provide physical stability and the solubility of paracetamol is low, such that
only low drug loading ASDs can be achieved. On the other hand, the Tg of PVP is so high
(156◦C) that extrusion would have to be performed at temperatures on or above paracetamol’s
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melting point, which could result in thermal degradation. Additionally, the strong H-bonding
capability of PVP, facilitates the dissolution and stabilisation of much higher concentrations
of paracetamol, but it also means that it is very hygroscopic and high water content is
associated with phase separation and recrystallisation. Rask, et al. determined that solubility
of a model drug (celecoxib) in a co-polymer of PVP and PVA increased with increasing
relative VP content until 60 wt% [213]. Above this limit the solubility reached a plateau,
which was attributed to paracetamol molecules in association with PVP monomers preventing
other drug molecules from binding to neighbouring chain units. Therefore having a mixture
of PVP and PVA monomers is a good compromise on polymer characteristics, Tg, H-bonding
capabilities, hygroscopicity, physical stability and drug solubility, which is why copovidone
(co-polymer of PVP and PVA at 60:40 mass ratio) is considered the best choice.
6.3.2 Alternative drug/polymer systems: nifedipine in copovidone physi-
cal mixtures and extrudates
High-temperature characterisation via 1H NMR and DSC
The 1H spectra of nifedipine (molten, 175◦C) and copovidone (dissolved in deuterated
acetone) are shown in Figure 6.4c. The proton resonances of nifedipine (chemical structure
and nuclei labelling in Figure 6.4a) were assigned by comparison with the literature [214, 215].
The molten nifedipine spectrum is well resolved and all seven proton environments can be
identified. The inset in Figure 6.4c shows the variable-temperature spectra (150-170◦C) of
the 6 − 8 ppm region of nifedipine, which reveals the temperature dependence of peak 4 (NH
group).
Fig. 6.4 Chemical structures of (a) nifedipine and (b) copovidone with protons labelled (1-7
for nifedipine and a-g for copovidone). (c) Overlaid 1H spectra of molten nifedipine at 175◦C
and copovidone dissolved in deuterated acetone.
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Fig. 6.5 DSC high temperature characterisation
thermogram of crystalline nifedipine consist-
ing of two consecutive heat-cool cycles. Key
thermal transitions have been annotated.
To better characterise the high tem-
perature behaviour of nifedipine, a DSC
experiment where the sample was sub-
jected to two consecutive heat-cool cycles
between room temperature and 200◦C was
performed. In the first heating ramp (Fig-
ure 6.5, blue trace) nifedipine exhibits a
melting endotherm at 173.1◦C. There was
no cystallisation observed in the first cool-
ing cycle (Figure 6.5, green trace), indi-
cating that nifedipine had remained in an
amorphous glassy state. Upon the sec-
ond heating ramp, three events are clearly
defined: the glass transition at 41.9◦C, a
crystallisation exotherm at 101.9◦C and a
melt event at 171.4◦C. This type of ther-
mal behaviour classifies nifedipine as a
class II drug, the same as paracetamol.
Determination of the self-diffusion coefficient of nifedipine and nifedipine/copovidone
physical mixtures
Figure 6.6a shows the average Stejskal-Tanner plot from three PGSTE experiments for
nifedipine at 175◦C. The gradient of the line of best fit yields the molecular self-diffusivity of
molten nifedipine as 4.3·10−11(±0.1·10−11) m2/s. This is four times slower than paracetamol
at its respective melting point. Nifedipine’s slower diffusion is likely a consequence of its
significantly larger molecular radius and weight.
Table 6.3 Diffusion coefficients of 40 wt% nifedipine in copovidone physical mixtures. The
self diffusion coefficient of nifedipine measured at 175◦C is also included for comparison.
D × 10−12m2/s
Nifedipine content 150 ◦C 155 ◦C 170 ◦C 175 ◦C
40% physical mix 0.45 (±0.03)a 0.54 (±0.04) 1.06 (±0.02) –
Nifedipine – – – 42.9 (±1.4)
a The numbers in parenthesis indicate the standard deviation of three repeat measurements.
Table 6.3 summarises nifedipine’s diffusion coefficients in a 40 wt% physical mixture
with copovidone, at three different temperatures. Nifedipine’s self-diffusivity at 175◦C is
included for comparison. Consistently with the diffusometry results from paracetamol in
copovidone, PVP and PVA, the diffusion of nifedipine was over 40 times slower in mixtures
with copovidone than in its pure molten state. This is even greater than the difference
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between paracetamol and paracetamol/copovidone mixtures and it is a consequence of the
polymer hindering drug mobility through viscosity effects and the larger molecular size of
nifedipine. The data also show that there was a positive correlation between diffusivity and
temperature (Figure 6.6b).
It should be noted that results are only presented on a 40% drug loading system because
the diffusion coefficients obtained were at the limit of the measurable value with the available
equipment (maximum magnetic field gradient strength was 1,200 G/cm). A 30 wt% nifedip-
ine/copovidone physical mixture was also examined, but the SNR of the diffusion-weighted
spectra was too low to obtain sufficiently accurate diffusion coefficients to be presented in
this thesis.
Fig. 6.6 (a) Diffusion signal attenuation plot of molten nifedipine (175◦C) fitted to the
Stejskal-Tanner equation. (b) Diffusion coefficients of nifedipine in a 40 wt% drug loaded
extrudate with copovidone plotted against temperature. Error bars represent the standard
deviation of three measurements.
Comparison between physical mixtures and extrudates via DSC
The normalised reversing heat flow thermograms for 20, 30 and 40 wt% nifedipine/copovidone
physical mixtures (Figure 6.7a and b) and extrudates (Figure 6.7c and d) have been acquired
for two consecutive heat-cool cycles. The three physical mixtures display a glass transition
that corresponds to the copovidone in the system, Tg,copov=108.5◦C (page 78, chapter 3),
and a melt endotherm from crystalline nifedipine (Tm,nif =173.1◦C) in the first heating ramp.
The size of the melt peak is proportional to the amount of nifedipine in the sample. On
the second heating cycle there is no melt event observed (no crystalline nifedipine present),
indicative that nifedipine and copovidone are a miscible system at 20-40% drug loading.
The only event is a glass transition at a temperature between copovidone’s and nifedipine’s
(Tg,nif =41.9◦C). The temperature at which the glass transition occurs is correlated with
nifedipine content, such that the higher the drug loading, the lower the Tg: 103.6◦C, 99.5◦C
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and 86.3◦C for 20, 30 and 40 wt% nifedipine, respectively. This is consistent with nifedipine
acting as a plasticiser for copovidone, as paracetamol does.
Unlike for the physical mixtures, there is no melting endotherm in the first heating cycle of
the extrudates, which is indicative of an amorphous dispersion being achieved via HME. The
thermogram of the second heating ramp looks very similar as the first, but the glass transition
temperatures are slightly higher. This is likely due to the presence of water plasticising the
extrudate in the first heating. As it was observed for the physical mixtures, the Tg of the
extrudates (both in the first and second cycle) are correlated with nifedipine content. There
is some disparity between the Tg of the physical mixtures and the extrudates, but this is
likely a result of slight differences in composition.
Fig. 6.7 High temperature characterisation through DSC of 20, 30 and 40 wt% nifedip-
ine/copovidone (a), (b) physical mixtures and (c), (d) extrudates. Each thermogram consists
of two consecutive heat-cool cycles, the first heating ramp in shown in (a) and (c) and the
second heating ramp in (b) and (d).
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Solid-state NMR studies of phase separation in nifedipine/copovidone extru-
dates
The 13C CP-MAS spectra of pure copovidone and crystalline nifedipine were acquired and
are shown in Figure 6.8c. Assignment of nifedipine 13C resonances (with reference to Figure
6.8a) have been made by comparison with the literature [214, 99]. As expected, nifedipine’s
line-widths are narrow, because the sample was crystalline, and copovidone’s are wider due
to its amorphous nature.
Fig. 6.8 Chemical structures of (a) nifedipine and (b) copovidone with carbon atoms labelled
(1-17 for nifedipine and a-j for copovidone). Overlaid 13C CP-MAS spectra of (c) solid-state
pure nifedipine and pure copovidone and (d) 20 and 40 wt% nifedipine/copovidone extrudates.
(e) 1H T1 and T1ρ difference between average nifedipine and copovidone relaxation values
obtained via 13C resolved resonances for the 20 and 40 wt% nifedipine/copovidone extrudates.
The 13C CP-MAS spectra of two extruded samples at 20 and 40 wt% drug loading are
displayed in Figure 6.8d. In contrast to Figure 6.8c, all nifedipine resonances appear broad,
indicating that it has become amorphous through the HME process (in agreement with DSC
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results). Closer examination of Figure 6.8d reveals that the intensities of the resonances that
correspond to nifedipine (1-17 ) increase with drug loading and the intensities of copovidone
peaks slightly decrease at higher drug loadings, as expected. This, however, was not the
case for the paracetamol/copovidone system analysed in chapter 4 (page 76), in which both
paracetamol and copovidone signal intensity increased with drug loading. The hypothesis
presented was that, as the two components were in such close contact (molecular-level
dispersion) the CP efficiency from the 1H in paracetamol to the 13C in copovidone had
increased with drug loading, as more paracetamol molecules were in intimate contact with the
polymer chains. In contrast, nifedipine/copovidone extrudates do not display an increased
CP efficiency for copovidone resonances at increased drug loading, suggesting that perhaps
nifedipine is not as well dispersed. This hypothesis is supported by the ssNMR T1 and T1ρ
relaxometry experiments in the next paragraph.
Further characterisation of the solid-state microstructure of the nifedipine/copovidone
extrudates was achieved through CP-MAS 1H relaxometry measurements of T1 and T1ρ via
13C detection. The 13C resonances used for nifedipine 1H T1 and T1ρ calculations were the
ones resolvable in the 90-160 ppm region, as there is no copovidone signal in that frequency
range (Figure 6.8c). Four copovidone-specific resonances centred at 177 ppm, 70 ppm, 44
ppm and 34 ppm were selected for calculating copovidone’s relaxation constants.
Following the same approach as was detailed in chapter 4, a 1H T1 and T1ρ value was
calculated for nifedipine and copovidone, from the average of the individual peaks. The
absolute difference between nifedipine’s and copovidone’s T1 and T1ρ constants are shown for
a 20 and a 40 wt% nifedipine/copovidone extrudate in Figure 6.8e. Error bars represent the
standard deviation of the relaxation values for each species. The dashed line at zero represents
the position at which the T1 or T1ρ is identical for nifedipine and copovidone. The results show
conclusively that for both systems under consideration the T1 of nifedipine and copovidone is
identical, but there is a significant difference in their T1ρ. Consequently, the domain sizes
for nifedipine in these systems can be approximated (using equation 4.1, chapter 4) to be
smaller than 35 nm, but larger than 5 nm for the 20 wt% extrudate and smaller than 40 nm,
but larger than 5 nm for the 40 wt% system. The small degree of phase separation in the
nifedipine/copovidone extrudates was not observed in the paracetamol/copovidone systems
(all extrudates displayed approximate domain sizes smaller than 4 nm). This could be due to
several factors, such as poorer miscibility between nifedipine and copovidone or weaker drug-
polymer interactions failing to stabilise the molecular amorphous dispersion. Furthermore,
this would explain why the enhanced CP-effect wasn’t observed for the nifedipine/copovidone
extrudates.
124 Studies of alternative drug/polymer systems and the effect of processing variables
6.3.3 Effects of processing variables
Internal research performed by AstraZeneca was aimed at better understanding the effects
of processing parameters on the behaviour and characteristics of the resulting formulation.
A DoE matrix was built to account for four variable parameters: drug loading, processing
temperature, screw speed and copovidone commercial brand. Table 6.1 shows the samples
from the DoE that were provided and these included extrudates from two commercial brands
of copovidone (Plasdone and Kollidon), two drug loadings (20 wt% and 30 wt%), two
processing temperatures (140◦C and 180◦C) and two screw speeds (200 and 300 rpm).
The first tests conducted were aimed at ensuring that the two polymer brands used were
not significantly different. Figure 6.9a shows the 13C CP-MAS solid-state spectra of Plasdone
and Kollidon and their resonances are so similar that they are virtually indistinguishable.
High temperature characterisation was performed with two consecutive heat-cool DSC cycles
and the resulting normalised reversing heat flow thermogram (of the second heating ramp) can
be found in Figure 6.9b. The glass transition event occurs at roughly the same temperature
for both copovidone brands (Tg,Kollidon=108.6◦C and Tg,P lasdone=109.0◦C). In conclusion, in
terms of solid-state microstructure and thermal behaviour, both copovidone brands seem to
be identical.
Fig. 6.9 (a) 13C CP-MAS spectroscopy and (b) DSC thermograms of two copovidone com-
mercial brands (Plasdone and Kollidon). In the thermograms only the second heating ramp
of two consecutive heat-cool cycles is shown.
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Fig. 6.10 Diffusion coefficients of DoE 20 and 30
wt% paracetamol extrudates in Plasdone and
Kollidon vs temperature (error bars represent
the standard deviation of three measurements).
The second set of experiments per-
formed on the DoE samples consisted
on measuring the diffusion coefficients of
paracetamol in several of the formula-
tions (1B, 2A, 2B, 7A and 8A). The APG-
STE sequence was employed and measure-
ments were performed at 150◦C, 160◦C
and 170◦C. Figure 6.10 shows the tem-
perature dependence of the diffusion co-
efficients of paracetamol in the Plasdone
and Kollidon extrudates (error bars indi-
cate the standard deviation from three
measurements). No significant differences
were observed between the formulations
containing Plasdone or Kollidon, nor be-
tween the extrudates processed at 200 or
300 rpm. The only statistically significant
trend revealed by Figure 6.10 was the positive correlation between diffusivity and drug
loading, which was previously observed in chapter 3. The samples containing 30 wt% drug
loading displayed diffusivities significantly higher than the ones with 20 wt% paracetamol.
The diffusion coefficient data is consistent with the previous measurements in chapter 3.
Thermal characterisation was also performed on all ten DoE samples via two consecutive
heat-cool cycles and the resulting thermograms are shown in Figure 6.11. During the first
heating ramp (Figure 6.11a), the glass transitions occur at very low temperatures between
35◦C and 45◦C. Such a low Tg is a result of plasticisation from water, as these polymers
absorb moisture easily. Compared with the 30 wt% paracetamol/copovidone extrudate
presented in chapter 4 (page 80, Figure 4.7, Tg=56.5◦C) the range of Tg measured for DoE
samples is considerably lower, likely because of higher water moisture. A broad "bump"
centred about 105◦C is also observed for all samples. Given its position, it is likely caused
by the evaporation of water. In the second heating ramp the range of Tg’s observed rose to
70 − 85◦C, which is more representative of the paracetamol/copovidone systems than the
Tg’s from the first heating ramp, since there was no water present any more, and agreed with
results from chapter 4.
There is no significant difference in the glass transition behaviour between samples
processed at different temperatures or screw speeds, nor between the two polymer brands.
As was the case in the diffusometry experiments, the only trend identified was a negative
correlation between Tg and drug loading: the higher the drug loading the lower the Tg.
The reason for this is that paracetamol molecules plasticise copovidone by dispersing in
between the polymer chains and reducing polymer-polymer interactions. Interestingly, there
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is no melting endotherm in the first heating cycle for any of the samples. This means that,
according to DSC, paracetamol has successfully been rendered amorphous via HME, even for
the samples at higher drug loading (30 wt%) that were processed at 140◦C (2A, 2B and 8A).
This supports the hypothesis presented in chapter 3, that the viscosity at 140◦C would be
low enough for 30% paracetamol/copovidone mixtures to be processed successfully.
Fig. 6.11 High temperature characterisation through DSC (two consecutive heat-cool cycles)
of DoE 20 and 30 wt% paracetamol extrudates in Plasdone and Kollidon, where (a) shows
the first heating ramp and (b) the second heating ramp.
The fourth and final experimental approach employed to analyse the DoE sample was
high resolution 13C CP-MAS spectroscopy and relaxometry. In agreement with DSC results,
the solid-state 13C spectra of extrudates 1B, 2B, 2D, 7A, 7B, 7D and 8A (Figure 6.12a) are
all virtually identical and display broad resonances indicative of paracetamol having been
transformed to an amorphous state. No sharp (crystalline) resonances were recorded, even
for the extrudates processed at 140◦C (30◦C below paracetamol’s Tm).
CP-MAS 1H T1 and T1ρ relaxometry measurements via 13C detection was performed on
a subset of the DoE samples to determine whether there was any degree of phase separation
present in the extrudates. In the same way as in chapter 4, four peaks in the 105-165 ppm
region were used for paracetamol’s constant calculation and for copovidone, the resonances
centred at 34 ppm, 45 ppm, 70 ppm and 178 ppm were considered. From these, a 1H T1
and T1ρ value was calculated for paracetamol and copovidone and the absolute difference
between the two is plotted in Figure 6.12b. The error bars represent the standard deviation
of the relaxation value for each species and the dashed line at zero the position at which the
T1 or T1ρ is identical for drug and polymer. Figure 6.12b shows that there is no statistical
difference between the T1 or T1ρ of paracetamol and copovidone in any of the extrudates from
the DoE. This indicates that there is no phase separation since (using equation 4.1) domain
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sizes are estimated to be smaller than 4 nm. In agreement with DSC methods, the results
from this DoE sample characterisation conclude that processing at 140◦C yields amorphous
solid dispersions that are identical to those processed at 180◦C in terms of their thermal
behaviour (DSC) and homogeneity (ssNMR T1 and T1ρ).
Fig. 6.12 (a) Stacked 13C CP-MAS spectra and (b) 1H T1 and T1ρ difference between average
paracetamol and copovidone relaxation values obtained via 13C of DoE 20 and 30 wt%
paracetamol extrudates in Plasdone and Kollidon.
6.4 Conclusion
In this chapter, the techniques employed on a model paracetamol/copovidone pharmaceutical
system (in chapters 3 and 4) were applied for the characterisation of alternative formu-
lations. In particular, diffusion coefficients of API in polymer melts were measured via
high-temperature 1H diffusometry, thermal performance was characterised with DSC and
structural analysis to understand sample homogeneity was conducted through ssNMR 13C
spectroscopy and 1H relaxometry.
In the first section, copovidone was compared with PVP and PVA in physical mixtures
with paracetamol. The DSC and high-temperature (100−170◦C) NMR experiments performed
on the polymers revealed that PVA has a much lower Tg (40.2◦C) and PVP a significantly
higher one (156.0◦C) that copovidone (109.2◦C). The higher chain mobility of PVA at
temperatures higher than 100◦C was revealed in the variable temperature NMR spectra as
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sharp, resolved resonances, whereas copovidone and PVA displayed only one broad peak
in the same temperature range. When these polymers were in physical mixtures with
paracetamol, a depression in its melting point was observed (as low as 130◦C). Additionally,
DSC thermograms exhibited the plasticising effect of paracetamol in all three polymers,
resulting in lower Tg’s at the higher drug loadings. PVP experienced the highest relative
change in its Tg compared to when in paracetamol mixtures, possibly due to its strong
H-bonding capabilities and thus enhanced solubilisation of paracetamol. Finally, the lower
Tg of PVA was reflected in the significantly faster diffusion coefficient of paracetamol in
paracetamol/PVA mixtures. The diffusion of paracetamol in PVP was an order of magnitude
slower, which could be a combined effect of the higher Tg of the mixture (higher viscosity)
and the increased and stronger drug-polymer molecular interactions.
The second system examined was nifedipine/copovidone. Nifedipine, although also
considered a small molecule drug, is twice the molecular weight of paracetamol. This was
evidenced in the self-diffusion coefficient in the molten state. Nifedipine’s diffusivity at its
Tm was four times slower than paracetamol’s (at its respective Tm). PFG NMR diffusometry
experiments at high temperature for nifedipine/copovidone samples could only be conducted
on 40 wt% drug loading systems, because the diffusivities measured were at the limit of
detection of the equipment available, as was the temperature at which the measurements were
performed. With a stronger gradient set it would have been possible to determine the slower
diffusion coefficients of nifedipine in lower drug loaded samples. However, these experiments
on nifedipine/copovidone systems showed that the high-temperature PFG NMR technique
reported in this thesis is not only applicable to a model system (paracetamol/copovidone),
but also to a sample that is more representative of an industrially relevant compound for
extrusion. Through high resolution CP-MAS 13C spectroscopy, it was determined that
nifedipine was in an amorphous state in the 20 and 40 wt% drug loaded extrudates and this
was corroborated using DSC. However, 1H T1 and T1ρ via 13C measurements revealed that
there was a small degree of phase separation, with domain sizes estimated to be smaller than
40 nm and larger than 4 nm. This is probably due to a number of reasons, such as weak
drug-polymer interactions or poor miscibility.
Finally, a number of extruded paracetamol/copovidone samples formulated with different
processing parameters were analysed. From the PFG NMR diffusion coefficient measurements,
it was observed that in the 20 wt% drug loaded extrudates the diffusion coefficient of
paracetamol was significantly slower than in the 30 wt% ones, but none of the other parameters
(copovidone brand and extrusion screw speed) resulted in visible differences in the diffusion
coefficient of paracetamol. 13C NMR spectroscopy and DSC revealed that in all the DoE
samples paracetamol was in an amorphous state and ssNMR relaxometry that the drug
domain sizes were smaller than 4 nm, irrespective of drug loading, copovidone brand, screw
speed or processing temperature. This applies even for the extrudates formulated at 140◦C
(30◦C below paracetamol’s Tm). In chapter 3, it was hypothesised that 170◦C was too high
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for 30% paracetamol/copovidone extrusion, because the viscosity of the system was below
the optimal range, the material would be free flowing and would not provide a good mixing
medium; and thus lowering the temperature below 144◦C would be advantageous. This
chapter has demonstrated that extruding a 30 wt% paracetamol/copovidone system at 140◦C
results in satisfactory products, with fully amorphisised drug and no phase separation.

Chapter 7
Predicting and modelling drug
solubility in polymer mixtures
7.1 Introduction
The previous chapters have shown that NMR experimental techniques can provide valuable
information on a range of features of drug/polymer systems and ASD formulations such as
diffusion coefficients of components in the molten mixture, intermolecular associations and
homogeneity of an extruded sample. However, before preparing an extruded formulation and
conducting time and resource heavy analysis on a particular system, it would be desirable to
be able to predict some key properties of the system. These could be the solubility of the
drug in the polymer at a certain temperature condition, which would limit the drug loading;
or the time to dissolution, which would dictate how long a sample should be processed for to
yield an ASD. For an in-depth review on the application of modelling to the formation and
stability of ASDs, refer to DeBoyance et al. [216].
Determining the drug solubility in a polymer has been the focus of numerous publications
and a summary of qualitative and quantitative methods was presented in chapter 1 (section
1.2.5, page 11). One of the reasons why it has attracted so much attention is that it
is a parameter that underpins other important mechanisms such as dissolution rate or
diffusivity, however, drug solubility in a polymer at high temperature cannot be measured
directly through experimentation. Indirect experimental measurements of solubility have been
proposed, among others, by Yang et al. [155]. They determined the solubility of paracetamol
in PEO (polyethylene oxide) employing three different empirical approaches: rheology,
thermal (DSC) and microscopy (hot-stage microscopy). Although results from the three
approaches were consistent, the results had significant error bars and the experimentation
involved was time consuming, as samples of different compositions had to be analysed at
several temperatures. More recently, Bordos et al. introduced THz-Raman spectroscopy to
determine the saturation solubility of a crystalline API in polymer matrices during HME in
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real time by observation of the solid state spectrum of the drug [75]. As the drug dissolved
in the polymer, the intensity of the spectral characteristics associated with crystalline API
decreased.
Experimental approaches to estimate drug solubility, however, are not prevalent in the
literature because they are time consuming and do not provide a sufficient level of accuracy.
Instead an approach that combines experimental data with theoretical calculations is by far
the most frequently used. This is based on the Flory-Huggins (FH) lattice theory, which was
initially developed for polymer-solvent systems to take molecular size into account and is
still considered an appropriate starting point to understand polymer thermodynamics. If the
amorphous drug is considered to behave similar to a solvent, the FH model can be applied to
describe the thermodynamics of drug-polymer systems [113]. Refer to [44, 39, 35] for more
information on FH theory and its application to drug-polymer systems.
FH lattice theory defines an interaction parameter, χ, that describes the thermodynamics
of mixing through the interaction of the polymer chains with the drug molecules. χ quantifies
the relative strength of cohesive and adhesive interactions (such as Van der Waals, H-bonding
and ionic interactions) and is dependent on composition and temperature. A negative or
smaller than 0.5 value for the interaction parameter is indicative of miscibility [217]. χ can
be evaluated in two different ways:
(i) The difference in solubility parameters (δ) between the drug and polymer as a function
of the volume of the lattice site (Vsite), as defined by the FH theory:
χ = Vsite
RT
(δdrug − δpolymer)2 (7.1)















The interaction parameter can be computed in a number of ways. Among the most
popular approach is the solubility parameter group contribution method by Hansen (Equation
7.1) [42, 218]. The solubility parameter δ for the drug and the polymer is calculated from
the contribution of dispersion, hydrogen bonding and polar forces. These values have been
tabulated for many chemical groups, polymers and drugs [219].
The interaction parameter can also be calculated experimentally through the melting
point depression of the drug. If a drug and polymer are miscible, a significant melting point
depression, correlated with the composition of the system, is observed due to the exothermic
mixing, ∆Hfus (Equation 7.2) [113]. By measuring the melting temperature of the drug in
polymer system at several drug loadings (ϕdrug), equation 7.2 can be fitted to obtain a value
for χ.
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The most common way to represent the results from the interaction parameter calculations
is in the form of a phase diagram, where the solubility, miscibility and glass transition are
plotted at different composition and temperature coordinates. Miscibility and solubility curve
estimations are based on the value of χ (the mathematical expressions will be presented in
section 7.4.1). One key advantage is that a phase diagram not only indicates the saturation
concentration at a range of temperatures, but also displays the regions at which a formulation
is stable, metastable and unstable. Drug-polymer phase diagrams have been employed in
numerous articles, for some examples refer to [75, 39, 35, 104, 220, 36, 199, 37, 38].
Accurate prediction of dissolution kinetics and solubility and thus the formation of stable
ASDs has been attempted through computational modelling and simulations. Molecular
descriptors and molecular modelling have been used to account for molecular kinetics factors,
such that the greatly reduced molecular mobility in the solid state that can prevent phase
separation even if the formulation solubility limit has been exceeded [216]. However, there
are a lack of accurate models that take into account the features of HME, such as screw
speed and architecture, degree of fill or residence time distribution. One model, proposed
by Derksen et al., simulates the dissolution of spherical particles in laminar shear flow [117].
The laminar shear is a simplification of the complex shear field exerted by the rotating screws
on the drug/polymer melt. A detailed explanation of this model will be presented in section
7.2.2. Another model was proposed more recently by Schittny et al. [118]. They were the
first to explore the links between the formation of ASDs and HME process parameters by
combining calculations of time to dissolution of solid drug particles in a molten polymer with
a model of mean residence time.
This chapter will present two models for the simulation of the dissolution of a solid drug
particle in a polymer melt. One of them will be simple, as dissolution is simulated to occur
in a static medium (based upon the Berkeley Madonna mathematical modelling software),
and the second more complex model will simulate dissolution under laminar shear [117].
The modelling predictions will be compared to experimentally obtained data on time to
dissolution of a paracetamol particle in a copovidone melt. Finally, a phase diagram for the
paracetamol/copovidone model system will be constructed by calculating the solubility and
miscibility curves and measuring its Tg.
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7.2 Development of numerical methods
7.2.1 Static particle dissolution model (based on the Berkeley Madonna
model)
Fig. 7.1 Schematic of the dissolution of a spher-
ical particle.
One of the simplest approaches to model
the dissolution of a drug crystal in a
polymer melt is presented by the Berke-
ley Madonna modelling software package
(https://berkeley-madonna.myshopify
.com). This model considers a spherical
drug particle of radius r suspended in a dis-
solution medium in which the only mode
of mass transport is diffusion. This would
result in concentric shells of uniform so-
lute concentration, that decreases with
distance from the particle (refer to Figure
7.1). Applying Fick’s first law [221] to this
system and considering only the flux (F ) across the plane perpendicular to the x axis:
F = −D · A · dc
dx
(7.3)
where D is the diffusion coefficient and c is the concentration.
The surface area (A) of each of the shells depicted in Figure 7.1 is defined by:
A = 4 · πx2 (7.4)
where x is the distance from the surface of the spherical particle.




= − F4 · π · x2 · D (7.5)
which can be integrated to:
c = F4 · π · x · D + k (7.6)
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Considering as the boundary condition that a perfect sink exists after the outermost shell
(positioned at rout), then c = 0 at this point and the constant of integration (k) is given by:
k = − F4 · π · rout · D
(7.7)
Using the definition of k shown in equation (7.7), the concentration at any position x is given
by equation (7.6) as:


















Following from equation (7.7), the total flux through each layer is given by:






If rout >> r0, then equation (7.8) can be simplified to:
F = 4 · π · D · c0 · r0 (7.11)
In a non-infinite system holding several spherical drug particles, the rate of increase of
drug mass in solution (ms(t)) can be related to the radius of the drug particle (R(t)), by
taking into account the definition for flux in equation (7.11) and the difference between the
drug solubility (S) and the concentration of drug in solution:
dms(t)
dt






The total number of drug particles in the system (npart) can be calculated as:
npart =
3 · m0
4 · π · R30 · ρd
(7.13)
where m0 is the total solid drug mass (before dissolution commences), R0 is the initial radius
of the spherical drug particles, and ρd is the density of the crystalline drug.
Another equation was required to describe the rate of decrease of the drug particle
radius as the dissolution process advanced. According to the Berkeley Madonna dissolution
model, this is proportional to the difference between the saturation concentration and the
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The system of differential equations formed by (7.12) and (7.14) were solved simultaneously
using the ode23 ordinary differential equation solver in MATLAB_R2017b to obtain a
dissolution rate plot. The initial conditions imposed for the two variables were that the initial
drug particle radius was R0 (R(0) = R0) and that at the initial time there was no drug in
solution (ms(0) = 0).
7.2.2 Shear flow particle dissolution model
A key outcome of HME is to achieve homogeneous products. To ensure this, one could process
the mixture for an extended period of time, but in doing so, thermal degradation is risked.
It is therefore highly relevant to be able to predict the dissolution time of a drug/polymer
system at conditions similar to those within the extrusion barrel. In the context of HME
drug particle dissolution modelling in a polymer melt, Derksen et al. published an article in
which laminar shear flow was taken into account [117]. This is relevant because in HME, solid
polymer and drug particles are fed into an extruder, inside of which the rotation of screws
exerts shearing forces on the drug/polymer mixture. Derksen et al. performed numerical
simulations for the dissolution of spherical drug particles to model this process.
The approach they followed was to solve the convection-diffusion equation, setting the
saturation concentration as a boundary condition at the surface of the particle. The model
coupled the solid (drug particles) and liquid (molten polymer) phases so that the liquid flow
translated and rotated particles (no slip boundary condition was imposed at interface between
phases) using the lattice-Boltzmann method. As the simulation evolved drug particle size
decreased as a result of solid-to-liquid mass transfer at the particle’s surface, and in turn,
the liquid phase contained an increasing concentration of dissolved solute, which underwent
diffusion and convection by the liquid flow. Additionally, the mixture underwent simple
laminar shear, simulated by two rectangular plates moving in opposite directions. The
outcome of the simulations were plots of the decay of the solids volume fraction with respect
to time, as a function of process and material conditions such as: initial solids volume fraction,
diffusion coefficient, solubility and shearing rate. Final dissolution time was determined
as the time at which 95% of the initial solid fraction had dissolved in order to remove the
uncertainty from the last few undissolved fragments.
There are five key dimensionless parameters that govern the flow dynamics of the simula-
tion:
• Initial Reynolds number: Re0 ≡ γ̇a
2
0
ν , where γ̇ is the shear rate, ν is the kinematic
viscosity and a0 the initial particle radius.
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• Initial solids volume fraction: ϕ0 ≡ 4πNa
3
0
3HLW , where N is the total number of particles
and H, L and W is the distance between the shearing plates, their length and width,
respectively.
• Initial solid over liquid density ratio: ρsρ
• Peclet number: Pe ≡ γ̇a
2
0
Γ , where Γ is the diffusion coefficient of the solute.
• Schmidt number: Sc ≡ νΓ , where ν is the kinematic viscosity and Γ is the diffusion
coefficient of the solute. The Schmidt number is also the ratio of the Peclet number to
the Reynolds number.
Several assumptions and simplifications were made. Firstly, it is considered that the
polymer first melts and reaches the simulated temperature and only then begins the dissolution
of the drug, however in reality, the melting point of the drug could be depressed by the
presence of the polymer (as it occurred for the paracetamol/copovidone system) and in
this case drug dissolution could commence as the polymer is heating up above its glass
transition temperature, but before the processing temperature has been reached. Secondly,
the liquid phase (polymer melt) is assumed to be Newtonian (even though in chapter
3, section 3.3.4, it was shown that copovidone’s viscosity did vary at different angular
frequencies). Thirdly, the particles are assumed to be spherical and remain spherical during
dissolution; however, microscopy experiments in section 7.4.4 showed that the shape was
irregular and Moseson et al. observed under polarized light microscopy that the dissolution
patterns of drug crystals in molten polymers were highly irregular and involved the formation
of channels, holes and fragmentation [151]. Also, the liquid’s viscosity and density are
considered uniform, independent of local solute concentration, but in chapter 3 section 3.3.4
it was shown that viscosity varies greatly with drug loading, particularly as, in the case of
paracetamol/copovidone, the drug has a strong plasticising effect on the polymer. Finally,
the initial Reynolds number for the parameters used by Derksen et al. (γ̇=10 s−1, ν=0.2
m2/s, a0=100 µm) was Re0 = 5 · 10−7. This is a very low number that would either require a
very high viscosity, which would limit the accuracy of the model, or a very low plate velocity,
which would make the simulations very lengthy. Since the Reynolds number was significantly
smaller than 1, it was assumed that the dynamics of the flow were independent of it, and so
Re0 was set to a more practical value of 0.05. Table 7.1 shows the input parameters used by
Derksen et al. for the dissolution simulations.
The main conclusions drawn from the simulation runs are as follows:
- Higher initial solids volume fraction (ϕ0) leads to slower dissolution. That is because
higher solute concentration in the liquid reduces the concentration gradient between the
particles’ surfaces and the bulk liquid and thus reduces the driving force for solid-liquid
mass transfer.
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- Increasing Peclet number (Pe) (effectively decreasing diffusion coefficient, Γ) results in
slower dissolution because the mass flux at the solids’ surfaces is reduced.
- Dissolution curves exhibit a fast initial decay as the solute penetrates the liquid around
the solid with high concentration gradients and then tail off as the solute concentration
in the bulk liquid increases.
- Reducing the drug/polymer solubility parameter (S) significantly increases dissolution
time.
- Plotting dissolution time as a function of Peclet number indicates that dissolution time
is highly sensitive to diffusion coefficient but, that increasing shear rate within the
range considered, does not reduce dissolution time.
Table 7.1 Parameter values used by Derksen et al. for dissolution simulations
Parameter Value Description
ϕ0 0.2 − 0.4 Initial solids volume fraction
ρs
ρ 1.25 Solid over liquid density ratio
Re0 5 × 10−7 → 0.05 Initial Reynolds number based on a0 and γ̇
P e0 20 − 800 Initial Peclet number
Sc 300 Schmidt number
Γ 10−9 − 10−8 m2/s Diffusion coefficient of solute
S 0.4 − 0.6 wt% Solubility in 180 − 200◦C range
a0 100 µm Initial particle radius
ν 0.2 m2/s Liquid kinematic viscosity
γ̇ 1 − 100 s−1 Shear rate
7.3 Materials and methods
7.3.1 Materials and sample preparation
The API/polymer model system for the work presented in this chapter was: paraceta-
mol/copovidone. Paracetamol (mean particle diameter ∼ 300 µm, Mallinckrodt) and copovi-
done (Kollidon VA 64®, Mw=45,000-70,000, BASF), were supplied by AstraZeneca.
Paracetamol/copovidone discs were required for experiments on the Rheoscope (rheometer
coupled with a microscopy camera module, see section 7.3.2). When copovidone is heated,
bubbles are formed from moisture evaporation and compression of the powder. These air
bubbles interfere with imaging approaches, so the MeltPrep equipment was used to make
bubble-free discs. The Meltprep is able to produce bubble-free discs by creating a vacuum
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within the vacuum compression molding (VCM) insert, inside of which the sample that will
be converted into a disc is contained, while being heated (refer to Figure 7.2a).
Fig. 7.2 (a) Schematic of the MeltPrep equipment, where the different parts of the apparatus
are labelled; and (b) magnified view of the VCM (vacuum compression molding) insert (mod-
ified from https://www.meltprep.com/). Photographs of bubble-free 13 mm (c) copovidone
and (d) 30 wt% paracetamol/copovidone discs prepared with the MeltPrep.
Discs of 13 mm in diameter and approximately 2.8 mm thick were prepared from copovi-
done and 5%, 20%, 30%, 40% and 60% paracetamol/copovidone physical mixtures. 440 mg
of material was introduced in the VCM chamber, in between the non-stick separation foils,
as is shown in Figure 7.2b. The VCM insert was then attached to the vacuum unit and to
the heating unit, which was set to 130◦C. After 30 min the VCM insert was carefully moved
to the cooling unit for 20 min and then the sample disc was extracted from the VCM insert
and placed in a sealed plastic bag prior to analysis. The VCM disc insert was secured to the
heating and cooling units via vacuum to ensure good thermal contact. Figure 7.2c shows a
copovidone disc prepared in the MeltPrep, displaying a uniform glassy appearance with no
bubbles (the brighter edges are a shadow effect from the photo). Figure 7.2d displays a 30
140 Predicting and modelling drug solubility in polymer mixtures
wt% paracetamol/copovidone disc, in which paracetamol crystals are suspended in the glassy
polymer.
7.3.2 Dissolution studies under static and shearing conditions
A Haake MARS rheometer equipped with a MARS III controller and an integrated microscopy
camera module fitted with a x5 objective, known as a Rheoscope was used for observational
dissolution studies under static and shearing conditions. Zero gap calibration was performed
at the test temperature and the sample disc prepared in the MeltPrep was loaded between
the 29 mm parallel polished plates. The bottom plate had a glass opening to accommodate
the microscopy objective and light source, and the polished top plate ensured that light was
reflected so it could be detected by the microscopy camera module. The plates were brought
together until the sample filled the entire plates’ surfaces (usually resulting in a 0.7 mm gap).
The temperature, shearing rate, experiment length and imaging rate were controlled with
the Haake Rheo Win Job Manager software. The shearing rates studied were 0.1 s−1 and 1
s−1, as any higher resulted in blurry images. Imaging rate was set to one frame per 10 s and
temperature to 140◦C. As well as images, viscosity values were obtained at every sampled
time point. The cross-polarised light (aligned on a single plane) setting was used for ease of
data analysis, as paracetamol crystals (anisotropic) would split the light beam into orthogonal
components that are later reunited, while amorphous material (isotropic) would just let the
light through. Consequently, crystals are captured as high intensity pixels and amorphous
components as low intensity. By increasing image contrast, white pixels were associated with
crystals and black pixels with molten/amorphous species. DSC was performed on fragments
of the discs to ensure paracetamol was still crystalline after processing in the MeltPrep.
Image analysis and plots were generated on MATLAB_2017b.
7.3.3 DSC: melting point depression, glass transition temperature and
heat capacity calculations
Thermal analysis was conducted with a Q2000 (TA Instruments, New Castle, DE, USA)
differential scanning calorimeter. The data was processed using TRIOS software (TA Instru-
ments).
Standard DSC for Tm measurements
Approximately 3-7 mg of sample was sealed in a standard aluminium pan and heated from
20◦C to 200◦C at a rate of 1◦C/min and cooled back to 20◦C at 20◦C/min. Two controlled
sequential heat-cool cycles were performed on all samples under a nitrogen stream of 50
mL/min. Melting temperatures were determined as the inflection point of the endotherms in
the normalised total heat flow plots.
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Modulated DSC for Tg measurements
Approximately 3-7 mg of sample was sealed in a standard aluminium pan and heated from
20◦C to 200◦C at a rate of 4◦C/min, with a modulation amplitude of ±1◦C and period
of 60 s, and cooled back to 20◦C at 10◦C/min. Two controlled sequential heat-cool cycles
were performed on all samples under a nitrogen stream of 50 mL/min. Glass transition
temperatures were assigned to the stationary point of the normalised reversing heat flow
data.
Modulated DSC for Cp measurements
Approximately 3-7 mg of sample was sealed in a Tzero aluminium pan (in which the base is
almost perfectly flat for improved thermal contact with the heated discs) and heated from
0◦C to 200◦C in 10◦C steps where they were held quasi-isothermally, with a modulation
amplitude of ±0.5◦C and period of 60 s. A quasi-isothermal mode is required because it is not
possible to measure Cp data at a constant temperature, as is apparent from the relationship






+ f(T, t) (7.15)
where dHdt is the heat flow,
dT
dt is the heating rate and f(T, t) is the kinetic component of the
heat flow (which is a function of temperature and time).
Two controlled quasi-isothermal sequential heat cycles were performed on all samples
under a nitrogen stream of 50 mL/min. The heat capacity data data was extracted using
TRIOS software (TA Instruments).
7.3.4 TGA for sample stability
Thermogravimetric analysis was conducted with a Discovery TGA (TA Instruments, New
Castle, DE, USA) instrument. Approximately 5-10 mg of sample was weighed into a tared
platinum pan. Isothermal tests at 140◦C, 150◦C, 160◦C and 170◦C were conducted for
3 − 12 hours. Temperature ramps were performed at a heating rate of 5 ◦C/min from room
temperature to 170◦C. All tests were conducted under nitrogen to avoid sample oxidation.
The data was visualized using TRIOS software (TA Instruments).
7.4 Results and discussion
7.4.1 Paracetamol/copovidone solubility and miscibility
The calculation of the interaction parameter for the paracetamol/copovidone system is
presented in this section. The interaction parameter is used to compute the miscibility and
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solubility curves, which will be plotted on a phase diagram, where the stable, metastable and
unstable temperature-composition regions will be shown and discussed. Meng et al. defined
drug-polymer miscibility as the tendency of the amorphous or molten drug to disperse in the
polymer matrix, while solubility refers to the ability of the polymer to act as a solvent and
dissolve the crystalline drug [40].
Interaction parameter
The first step to calculate the solubility and miscibility curves is determining a value for the
interaction parameter. χ is temperature and composition dependent, but in polymer systems
the effects of composition are negligible compared to temperature [222]:
χ = A + B
T
(7.16)
where A and B are fitting parameters. In order to obtain the temperature-dependent value
of χ, it was evaluated at the melting point of the drug and at room temperature and then
extrapolated using equation 7.16.
Fig. 7.3 Melting point depression of paraceta-
mol in copovidone at several concentrations,
obtained from DSC thermograms. Error bars
indicate the standard deviation from three in-
dependent measurements.
The value of χ at the melting tem-
perature of paracetamol (Tm = 169.8◦C)
was obtained through the experimental
melting point depression method. This
is based on the fact that the presence
of polymer reduces the melting temper-
ature of the drug when the two are mis-
cible; the extent of the depression is re-
lated to the miscibility of the compo-
nents [101]. This method is best suited
for systems in which the Tg of the poly-
mer is significantly lower than the Tm
of the drug, because the polymer needs
to be rubbery to interact with the drug
[154].
Results from DSC experiments on the melting point depression of paracetamol are shown in












ϕpoly = χϕ2poly (7.17)
The values in Table 7.2 and 7.3 were substituted in Equation 7.17 to obtain the value of
χ. ϕpoly and ϕdrug, the volume fractions of polymer and drug, respectively, were calculated
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Fig. 7.4 Melting point depression experimental data fitted to a first order polynomial to
obtain a value for χ, the interaction parameter, at 169.8◦C for a paracetamol/copovidone
system.










ϕpoly, defined as A, versus ϕ2poly, fit to a first
degree polynomial such that the gradient corresponds to the interaction parameter.
Negative or values of χ smaller than 0.5 suggest that the adhesive forces of drug-polymer
interactions are stronger than the cohesive forces of drug-drug or polymer-polymer associations
[217, 32]. The value obtained for χ at the melting point of paracetamol was 0.47, which is
indicative of miscibility between the components in the system at this temperature.
The next step was to calculate χ at room temperature. This was done using the solubility
parameter approach, for which Equation 7.1 was adapted by Hansen to account for the effects
of dispersive, polar and hydrogen bond forces on the solubility parameters. For systems
where dispersion forces dominate over polar and hydrogen bonding ones the equation to




(δdrug,d − δpoly,d)2 + 0.25 (δdrug,p − δpoly,p)2 + 0.25 (δdrug,h − δpoly,h)2
]
(7.18)
where Vsite is the lattice site volume from the FH theory, which in this scenario corresponds
to the molar volume of the drug (νdrug). The values in Table 7.4 were substituted in Equation
7.18 to obtain an interaction parameter at room temperature of 1.14.
Coefficients A and B from Equation 7.16 can be calculated with the two values of χ
obtained: χ(T = 298.15 K) = 1.14 and χ(T = 442.95 K) = 0.47. The temperature dependent
behaviour of χ is displayed in Figure 7.5 and it will be used in the following sections for the
calculation of the solubility and miscibility curves: χ = −0.903 + 607.9T
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Table 7.2 Parameter values used to calculate the interaction parameter at the melting point
for the paracetamol/copovidone system following the melting point depression approach
Parameter Value Description
T purem 169.8 [◦C] = 442.95 [K] a Melting point of pure paracetamol
R 8.314 [ JK·mol ] Gas constant
∆Hfus 175.5 [Jg ] a Heat of fusion of paracetamol






Ratio of molecular volumes
Mw,poly 55, 000 [g/mol] b Molecular weight of copovidone
ρpoly 1.15 [g/cm3] b Density of copovidone
Mw,drug 151 [g/mol] c Molecular weight of paracetamol
ρdrug 1.35 [g/cm3] d Density of paracetamol
a Experimental value from DSC; b Value from [199]; c Value from the PubChem Compound
Databse (CID=1983); d Value from [208]
Table 7.3 Melting point depression of paracetamol in copovidone at several concentrations,
obtained from DSC thermograms.
Paracetamol [wt%] Tmixm [◦C] Paracetamol [wt%] Tmixm [◦C]
95 169.6 60 167.3
90 169.5 50 163.9
85 169.3 40 160.2
80 168.8 30 159.9
75 169.1 20 158.3
70 168.4 10 153.1
65 168.0
Solubility curve
Solubility is defined as the drug loading of saturated drug-polymer solid solution without the
tendency of re-crystallisation [32]. Therefore the solubility curve defines the stable regions of
the phase diagram. As proposed by Marsac et al., the solubility of a crystalline material in a
solvent can be described by [113]:



















where it is assumed that the polymer can take the role of a solvent.
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Fig. 7.5 Temperature dependence of the interaction parameter, χ, for the paraceta-
mol/copovidone system.
Table 7.4 Parameter values used to calculate interaction parameter at room temperature for





= 124.2 [cm3/mol] Molar volume of the drug
R 8.314 [ JK·mol ] Gas constant
T 25 [◦C] = 298.15 [K] Room temperature
δdrug,d 20.66 a Paracetamol dispersion forces
δdrug,p 11.50 a Paracetamol polar forces
δdrug,h 12.78 a Paracetamol H-bond forces
δpoly,d 18.0 b Copovidone dispersion forces
δpoly,p 7.8 b Copovidone polar forces
δpoly,h 5.8 b Copovidone H-bond forces
Mw 151 [g/mol] c Molecular weight of paracetamol
ρdrug 1.35 [g/cm3] d Density of paracetamol
a Value from [223]; b Value from [49] and [224]; c Value from the PubChem Compound
Databse (CID=1983); d Value from [208]
The activity coefficient (γ) is a factor that accounts for deviations from ideality in mixing










ϕpoly + χϕ2poly (7.20)
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All of the parameters in Equations 7.19 and 7.20 have been previously calculated or
measured, except for ∆Cp. Heat capacity (Cp) is a physical property of matter, defined as the
amount of thermal energy that produces a unit change in its temperature. ∆Cp is known as
the configurational heat capacity, which is defined as the difference between the heat capacity
in the amorphous state and the crystalline form. It was measured via DSC, following the
method presented in section ??. Figure 7.6 shows the heat capacity of paracetamol measured
by DSC on two consecutive heating cycles. The first heating ramp (red trace) represents the
Cp of the crystalline state, until 170◦C, when paracetamol melts and a jump in the Cp value
is observed. For the second heating cycle (blue trace), the data points (0-60◦C) correspond
to paracetamol in an amorphous-glassy state. At 60◦C there is a sharp decrease in the Cp,
which corresponds to a crystallisation process. The difference in Cp between the data point
at 50◦C and 70◦C were used to calculate the configurational heat capacity: ∆Cp = 0.51 Jg·◦C
(arrow in Figure 7.6). Since paracetamol crystallises during heating, it was not possible to
measure the ∆Cp for the whole temperature range and it was assumed to be constant [225].
Fig. 7.6 Heat capacity of paracetamol measured by DSC on two consecutive heating cycles.


















dT − lnγdrug − lnxdrug (7.21)
























ϕpoly + χϕ2poly − lnxdrug
(7.22)
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Fig. 7.7 Temperature-composition solubil-
ity curve of paracetamol in copovidone.
Equation 7.22 was solved using Microsoft
Excel’s Solver add-in by finding the value of
xdrug (molar fraction) that would minimise the
value of the equation, for the parameters shown
in Table 7.5. The constraint imposed was that:
0.0000001 < xdrug < 0.999999. The results are
shown in Figure 7.7 as the weight fraction of
paracetamol that is soluble in copovidone at
a temperature range between 25◦C and 170◦C.
Yang et al. experimentally estimated the solu-
bility of paracetamol in PEO (a different poly-
mer) to be 14% at 80◦C and 41% at 140◦C
[155]. In Figure 7.7 the solubility of paracetamol at 80◦C is 9.2% and 37.6% at 140◦C. The
results are similar in value, and there are reasons for solubility in PEO to be higher at those
temperatures, such as the very low glass transition temperature of PEO, -55◦C.
Table 7.5 Parameter values used to calculate the solubility curve for the paraceta-
mol/copovidone system
Parameter Value Description
∆Hfus 175.5 [Jg ] Heat of fusion of paracetamol
R 8.314 [ JK·mol ] Gas constant
T 25 ∼ 170 [◦C] = 298 ∼ 443 [K] Temperature range for which
miscibility was calculated
Tm 169.8 [◦C] = 442.95 [K] a Melting temperature of paracetamol
∆Cp 0.51 [ Jg·◦C ] a Configurational heat capacity (0-180◦C)
ϕdrug ϕdrug = mass fractionρdrug Volume fraction of paracetamol






Ratio of molecular volumes
χ χ = −0.903 + 607.9T Interaction parameter
Mw,poly 55, 000 [g/mol] b Molecular weight of copovidone
ρpoly 1.15 [g/cm3] b Density of copovidone
Mw,drug 151 [g/mol] c Molecular weight of paracetamol
ρdrug 1.35 [g/cm3] d Density of paracetamol
a Value from DSC; b Value from [199]; c Value from the PubChem Compound Databse
(CID=1983); d Value from [208]
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Miscibility curve
The degree of miscibility is important for the formation of physically stable ASDs [40].
The miscibility curve defines the metastable and unstable regions of the phase diagram.
Compositions in the metastable regions are relatively stable to small molecular fluctuations
[4].
To calculate the miscibility of a drug-polymer system, the equation for the free energy of
mixing, ∆Gmix, is considered [226]:
∆Gmix = ∆Hmix − T · ∆Smix (7.23)
where ∆Hmix and ∆Smix are the enthalpy and entropy of mixing, respectively.











ϕdruglnϕdrug + ϕpolym lnϕpoly
]
is the entropy term and [χϕdrugϕpoly] the enthalpy term.
Applying Equation 7.24 to drug-polymer systems enables the evaluation of the relative
contributions of entropy and enthalpy to the free energy of mixing. A plot of ∆Gmix against
ϕdrug would result in a concave (negative free energy of mixing) or convex (positive free
energy of mixing) for which ∆Gmix = 0 at ϕdrug = 0 and ϕdrug = 1.
The maximum drug-polymer miscibility is determined by calculating the inflection point
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Fig. 7.8 Temperature-composition misci-
bility curve of paracetamol in copovidone.
Equation 7.25 was solved using Microsoft
Excel’s Solver add-in by finding the value of
ϕdrug (volume fraction) that would zero the
value of the equation, for the parameters shown
in Table 7.6. The constraint imposed was:
0.02 < ϕdrug < 0.95. The results are shown in
Figure 7.8 as the weight fraction of paracetamol
that is miscible in copovidone at a temperature
range between 25◦C and 170◦C.
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Table 7.6 Parameter values used to calculate the miscibility curve for the paraceta-
mol/copovidone system
Parameter Value Description






Ratio of molecular volumes
χ χ = −0.903 + 607.9T Paracetamol-copovidone interaction parameter
Mw,poly 55, 000 [g/mol] a Molecular weight of copovidone
ρpoly 1.15 [g/cm3] a Density of copovidone
Mw,drug 151 [g/mol] b Molecular weight of paracetamol
ρdrug 1.35 [g/cm3] c Density of paracetamol
a Value from [199]; b Value from the PubChem Compound Databse (CID=1983); c Value
from [208]
Phase diagram
In the previous sections, the solubility and miscibility curves for the paracetamol/copovidone
system were calculated. To complete the characterisation of the system and build a phase
diagram, the glass transition temperature of systems at drug loadings between 0% and 95%
were measured with DSC. Additionally, the theoretical Tg, as predicted by the Gordon-Taylor
equation (refer to chapter 4, section 4.3.4, page 81), was also calculated for comparison.
Fig. 7.9 Temperature-composition phase diagram of paracetamol-copovidone systems.
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Figure 7.9 shows the phase diagram for paracetamol/copovidone systems in the 25−170◦C
and 0 − 100% drug loading ranges. It is composed of four curves: solubility (red), miscibility
(blue) and glass transition temperature (dark and light green for predicted and measured,
respectively).
Firstly, the Tg curve decreases with increasing drug loading because paracetamol is acting
as a plasticiser. This effect is caused by the increase in free volume around polymer chains
created by the drug molecules, which reduces polymer-polymer interaction and friction [227].
Furthermore, there is a consistent positive deviation throughout the composition range in the
measured Tg from the predicted value. This is indicative of strong drug-polymer interactions,
which result in poorer chain mobility [32, 31]. Tg depicts the transition from the glassy to
the rubbery state and, although the it does not mark a thermodynamic phase transition, it
indicates a drastic change in mobility and viscosity. Consequently, it plays an important role
in the rate of crystallization and/or phase separation and kinetic stabilisation of ASDs (even
at thermodynamically metastable conditions) [37].
Secondly, the miscibility curve, also known as the spinodal curve marks the boundary
between the metastable and the unstable formulations. That is because it was calculated from
the free energy of mixing, which provides information on the spontaneity of two components
mixing, or on the other hand, phase separating. Li et al., however, identified that for a
system extruded between the miscibility and solubility curves (metastable region), the lack
of thermodynamic forces to achieve complete drug amorphisation could be compensated for
by increasing the extrusion screw speed, as this increased the system’s entropy [71].
Fig. 7.10 Temperature-composition solubil-
ity curve of paracetamol/copovidone systems
determined experimentally via THz-Raman
spectroscopy (modified from [75]).
Finally, the solubility (or liquid-solid
transition) curve, indicates the temperature-
composition region in which an ASD is ther-
modynamically stable [37]. Bordos et al.
used THz-Raman spectroscopy to construct
an empirical solubility curve of paraceta-
mol/copovidone in the temperature range
110 − 170◦C [75]. Experiments were con-
ducted in-line during the extrusion process,
at the end of the barrel, before extrudate
ejection through the die. For this reason,
the lowest temperature studied was 110◦C,
which is just above copovidone’s Tg. The
resulting solubility curve is shown in Figure
7.10, where "Cc" denotes the critical con-
centration up to which no crystallinity was
found at 110◦C (the minimum temperature in this study). Interestingly, Figure 7.10 shows
that at 145◦C the saturated concentration ranges between 45-60 wt%, this "plateau effect"
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was hypothesised to be related to temperature-dependent structural changes of copovidone.
It has been described that PVP polymers can adopt helical conformation [228], which could
unwind to accommodate additional drug molecules.
According to Bordos et al. the solubility of paracetamol in copovidone at 140◦C is 44 wt%.
This value is slightly higher than the one obtained in this chapter (37.6 wt%). Although
these values are similar, there are two reasons why the one measured by Bordos et al. could
be higher than the value calculated here. Firstly, Bordos et al. conducted experiments in
temperature steps of 10◦C, so their solubility estimations are associated with an error of
at least ±5◦C. Secondly, there could be small residual crystalline particles that fall under
the limit of detection or paracetamol-rich amorphous domains that are undetected in the
THz-Raman spectra.
7.4.2 Static particle dissolution model
The system of differential equations formed by Equations 7.12 and 7.14 were solved simulta-
neously using the parameter values shown in Table 7.7. The outcome from the dissolution
simulation model is displayed in a plot of the decrease in particle radius [µm] as a function
of time [min]. Figure 7.11 summarises the dissolution rate results for a range of values of the
diffusion coefficient (D), initial particle radius (R0) and solubility (S).
Table 7.7 Parameter values used for solving the static particle dissolution model system of
differential equations
Parameter Value Description
D 2 · 10−12 ∼ 4 · 10−12 m2/s a Diffusion coefficient of paracetamol
ρd 1300 kg/m3 b Crystalline paracetamol density
S 350 ∼ 500 kg/m3 c Paracetamol solubility concentration
V 3.7 · 10−7 m3 d Total volume
m0 1.3 · 10−4 kg d Initial solid paracetamol mass
R0 3 · 10−5 ∼ 8 · 10−5 m e Initial paracetamol particle radius
a Value from experiments in chapter 3, section 3.3.3. b Value from [198]. c Value from phase
diagram in section 7.4.1. d Value for paracetamol/copovidone Rheoscope discs, refer to
section 7.3.1. e This value corresponds to particle sizes (diameters) of 60 − 160 µm
The parameters chosen for this model correspond to a scenario where the paracetamol
particles are suspended in a copovidone melt at 140◦C, to be consistent with the results
presented in sections 7.4.1 and 7.4.4. Figure 7.11a-c shows the dissolution rate curves for
three diffusion coefficients: 2·10−12 m2/s, 3·10−12 m2/s and 4·10−12 m2/s, and in each graph
there is a curve that corresponds to one of four initial particle sizes considered: 30 µm, 40
µm, 50 µm and 80 µm. All dissolution curves have the same shape, and there is a positive
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correlation between dissolution time and particle radius and a negative correlation with
diffusion coefficient. This correlation is stronger for particle size, as a two-fold increase in drug
crystal radius results in, roughly, four-fold increase in dissolution time, whereas a two-fold
increase in diffusion coefficient leads to a two-fold decrease in dissolution time.
Fig. 7.11 Static particle dissolution model results: decay of particle radius (R) as a function
of time. Diffusion coefficients of (a) 2·10−12 m2/s, (b) 3·10−12 m2/s and (c) 4·10−12 m2/s are
evaluated for initial particle radii of 30, 40, 50 and 80 µm, and a solubility of 447 kg/m3. (d)
Solubilities of 350, 400, 450 and 500 kg/m3 for 50 µm initial particle size and 3·10−12 m2/s
diffusion coefficient.
The effect of the solubility value on dissolution time is depicted in Figure 7.11d. Four
solubilities were modelled: 350, 400, 450 and 500 kg/m3 for an initial particle radius of 50
µm and a diffusion coefficient of 3·10−12 m2/s. The results indicate, as expected, that for
lower solubilities, time to dissolution increases. The grey trace (S = 350 kg/m3) illustrates
the case in which the solubility is lower than the total drug loading of the system, in which
case complete dissolution will not be achieved.
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As will be shown in section 7.4.4, the static dissolution of a paracetamol crystal particle
(of approximately 70 µm in radius), although in the same order of magnitude, was observed
to be faster than the predicted one. This could be due to several reasons. Firstly, the
solubility of paracetamol in copovidone was calculated theoretically (section 7.4.1) and not
substantiated experimentally, so the actual value could be higher than the estimated. Among
other simplifications in the model, it was assumed that the drug particle is a perfect sphere,
but in reality the shape is irregular, leading to a higher exposed surface area for dissolution,
which would result in a faster rate. Another explanation would be that, as it has been
repeatedly shown in this thesis (chapter 3, section 3.3.3 and chapter 6, section 6.3.3), the
diffusion coefficient is strongly dependent on drug loading. Considering the static particle
dissolution model schematic presented in Figure 7.1, it follows that the the shells closest to
the particle will have a high drug loading (in the inner-most cell, this concentration would be
the saturation concentration). Figure 7.11a has shown that the diffusion coefficient makes
a large effect on dissolution rate. Diffusivity is likely underestimated in the inner shells,
resulting in slower predicted dissolution rates.
7.4.3 Shear flow particle dissolution model
A collaborator from AstraZeneca (Gavin Reynolds, Pharmaceutical Development), who was
one of the authors of the publication described in section 7.2.2 regarding the simulations of
the dissolution of spherical particles in shear flow [117], attempted to use the parameters
measured and calculated in this thesis as inputs to the model used in the article. Table 7.8
summarises the key simulation input parameters for the paracetamol/copovidone system
studied in this work.
Table 7.8 Parameter values from paracetamol/copovidone system for dissolution simulation
model proposed by Derksen et al. (2015)
Parameter Value Description
ϕ0 0.29 Initial solids volume fraction
Γ 4 · 10−12 m2/s Diffusion coefficient of solute
S 447 kg/m3 Solubility at 140◦C
a0 100 µm Initial particle radius
γ̇ 1 s−1 Shear rate
Pe0 2500 Initial Peclet number
Sc 2.5 · 1010 Schmidt number
ν 0.1 m2/s Liquid kinematic viscosity
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To match the experimental set-up of the 30 wt% paracetamol/copovidone disc (13 mm in
diameter and 2.8 mm thick) used for the Rheoscope (section 7.3.2), the initial solids volume
fraction (ϕ0) was 0.29. This was calculated from the number of particles in the disc, which
was 2.59·104 for 100 µm particle radius and 1200 kg/m3 density; and the total volume of
the disc (3.7·10−7 m3). The diffusion coefficient was selected from Table 3.2, from the 30%
drug loaded system at 150◦C as 4·10−12 m2/s. A solubility of 38 wt% (447 kg/m3) was
calculated from the phase diagram in section 7.4.1 for paracetamol in copovidone at 140◦C.
Shear rates greater than 1 s−1 could not be used in the Rheoscope set-up, as otherwise the
images captured were too blurry for analysis. Kinematic viscosity is the dynamic viscosity
of a material divided by its density. The kinematic viscosity of copovidone was calculated
from the dynamic viscosity plot (Figure 3.8a, section 3.3.4), divided by its density (1.18·103
kg/m3).
The initial Peclet number for a 1 s−1 shearing rate, 100 µm initial particle radius and
4·10−12 m2/s diffusion coefficient was calculated as 2,500. This is higher than the range
considered by Derksen et al.: 10 ≤ Pe0 ≤ 2000. The low diffusion coefficient that resulted in
the high Peclet number, also greatly increased the simulation time. As the time steps in the
simulation where fixed by the shear rate, a very large number of time steps were required
to observe the effects in the concentration fields for such small diffusion coefficients. This
resulted in numerical noise dominating the solution, since the change in the state of the
system between time steps was so small. Similarly as with the Peclet number, the Schmidt
number obtained from the parameter values in Table 7.8 is 2.5·1010, which is much higher
than the Sc number the model by Derksen was benchmarked for (Sc = 300). These could be
some of the reasons why the simulations repeatedly failed to run until particle dissolution
was achieved.
One way the model could be adapted to cope with very low diffusion coefficients would
be to decrease the grid size of the simulation to be able to capture smaller changes in
concentration fields. The downside of this is that computational requirements would steeply
increase. However, it should be considered whether such a detailed model as the one presented
by Derksen et al. is over-complicated, knowing that the system is so diffusion-limited.
7.4.4 Dissolution studies under static and shearing conditions
In order to corroborate the predictions from the mathematical models of particle dissolution,
experimental analysis on paracetamol/copovidone discs was conducted on the Rheoscope both
under static and shearing conditions (refer to section 7.3.1 and 7.3.2 for sample preparation and
experimental setup). Imaging was performed under polarised light and high contrast in order
to ease analysis. Figure 7.12 shows a field of view from a 30 wt% paracetamol/copovidone
disc at room temperature, which was used for calibration of the camera settings. These
settings were saved and used for subsequent imaging.
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Fig. 7.12 Rheoscope calibration images under (a) normal light, (b) polarised light and (c)
polarised light and high contrast.
Figure 7.13a shows a Rheoscope image for an isolated paracetamol crystal at 140◦C. It
wasn’t trivial obtaining a good field of view, as some bubbles would appear due to copovidone
melting and obscure the images and often paracetamol particles would move within the
plasticised copovidone and disappear from the field of view, making it impossible to follow
the dissolution of a single crystal. In this case, however, the single crystal remained within
the field of view and it was possible to follow its dissolution in the polymer. The signal
intensity of each frame (acquired every 10 s) was measured as the number of white pixels.
Then the signal intensity evolution was plotted against time to determine the time elapsed
until full dissolution. The initial instability in the image intensity observed in Figure 7.13b
between 0 − 500 s, is due to the crystal moving up and down in the field of view, which made
it appear smaller and larger.
Fig. 7.13 Rheoscope (a) image and (b) image intensity evolution data for the dissolution of a
paracetamol crystal under static conditions at 140◦C.
The last white pixel was detected in frame 157 out of the 160 acquired. Taking into
account that there was a one-minute lapse (between frames 90 and 91) as a new experiment
was set up because the crystal had still not dissolved in the 15 min of the first experiment, and
that there was about a 10 min initial transition before the image acquisition was started to
156 Predicting and modelling drug solubility in polymer mixtures
allow for temperature stabilisation and choice of a satisfactory field of view (one in which the
paracetamol particle remained static), the total time to dissolution was about 37 min. This
is of the same order of magnitude, but still significantly shorter than what was predicted by
the static particle dissolution model presented above. A few reasons why this could be have
already been presented in section 7.4.2. Additionally, it is possible that the micro-environment
of the paracetamol particle imaged had a lower concentration of paracetamol than 30 wt%,
which would result in faster dissolution due to lower concentration of paracetamol in the bulk
solution and thus a higher concentration gradient between the particle’s surface and the bulk.
Another factor that might enhance dissolution time in the Rheoscope experiments is that
molten copovidone tends to bubble and these bubbles would be disrupting the concentration
gradient layer and carrying paracetamol away from the dissolving particle. This forced
convection mass transport would be much faster than the microscopic self-diffusion.
Over 20 discs were analysed under shearing conditions in the Rheoscope, ranging from
0 − 60 wt% drug loading under shearing conditions of 0.1 s−1 or 1 s−1. The Rheoscope was
set to 140◦C because higher temperatures resulted in severe leakage of the sample from the
Rheoscope plates due to its low viscosity. Viscosity values were measured throughout the
experiments and these plots were compared with the image intensity graphs resulting from
the analysis of the Rheoscope microscopy images that were acquired every 10 s.
Figure 7.14 shows the viscosity and image intensity plots for 0%, 5%, 20%, 40% and
60% paracetamol/copovidone discs at 0.1 s−1 shear. Copovidone-only discs were used as a
baseline to compare the other results against. Three trends are observed in the viscosity of
copovidone (Figure 7.14a, black trace):
i. There is first an increase in viscosity, which corresponds to the sample spreading out to
cover the entire surface of the plates. A higher area for shear results in an increase in
the measured viscosity as there is stronger resistance to the plate’s motion.
ii. Then viscosity decreases as a result of copovidone chains disentangling and aligning
with the direction of shear.
iii. Finally, there is an increase in the viscosity caused by leakage of the sample from
between the plates. As copovidone leaks, it covers the edges and outer surface of
the plates, imposing higher resistance. The viscosity measured in chapter 3, section
3.3.4, for copovidone at 140◦C was 2·104 Pa·s, which is similar to that observed in the
Rheoscope.
The image analysis of the copovidone disc (most clearly seen in Figure 7.14d, black data
points) shows that the number of white pixels is very low, particularly when compared to
the data from the higher drug loaded paracetamol/copovidone discs (Figure 7.14c). There is,
however, some signal being detected that does not correspond to amorphous polymer, and
this is probably caused by sample or instrument contamination with small fibres.
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The 5 wt% paracetamol/copovidone disc displays a considerably lower viscosity than
for copovidone alone (Figure 7.14a, grey trace). This is a result of the strong plasticisation
effect that paracetamol has on copovidone, even at such low drug loadings. Accordingly,
Figure 7.14d shows that there is an initial surge in the image intensity data above noise
level, meaning that several paracetamol crystals were captured in the field of view. However,
this quickly decreases to noise level as paracetamol dissolves in copovidone and is no longer
crystalline.
Fig. 7.14 Rheoscope (a), (b) viscosity plot and (c), (d) image intensity evolution data for the
dissolution of paracetamol crystals in a 0, 5, 20, 40 and 60 wt% paracetamol/copovidone
discs under shearing conditions (0.1 s−1) at 140◦C. (b) and (d) show an amplified view of (a)
and (c), respectively.
The viscosities of the samples at 20, 40 and 60% drug loading are shown in an am-
plified plot in Figure 7.14b. The shape of these plots is very similar to that of the 5%
paracetamol/copovidone disc, but begin at a lower viscosity value. This is because there is
some paracetamol dissolution during the setting up of the experiment (approximately 4 min
elapsed on average between the disc being introduced in the Rheoscope and data acquisition
158 Predicting and modelling drug solubility in polymer mixtures
commencing) that has already plasticised copovidone by the time the first data point for
viscosity is measured. Also, the rate of viscosity decrease is faster at higher drug loadings
during the first few minutes of the experiments. Higher drug loaded samples contain more
dispersed paracetamol particles, which plasticise the polymer more efficiently.
The 20 wt% paracetamol/copovidone disc (Figure 7.14b, blue trace) stabilises at a viscosity
value considerably lower than the 5 wt% disc, but higher than the 40% and 60% paracetamol
content samples. All paracetamol crystals are expected to dissolve during this experiment,
since 20% is well below the saturation concentration for paracetamol in copovidone at 140◦C
(refer to section 7.4.1). This is supported by the image analysis data (Figure 7.14c, blue
trace) which captured a few crystalline paracetamol particles during the first 12 min of
the experiment, and afterwards the image intensity fell within noise level, indicating that
dissolution was complete.
Similarly to the 20% disc, the 40% paracetamol/copovidone disc (Figure 7.14b, green
trace) tails off at a viscosity below those samples at lower drug loading due to the increased
plasticisation. 40% is just above the solubility limit of paracetamol in copovidone at the
experimental temperature, 140◦C, (according to the calculation from section 7.4.1). Image
analysis shows a large amount of paracetamol crystals being captured in the first 10 min. This
decreased until after 20 min (from the start of the experiment), when image intensity dropped
and only very small particles were detected, which reveals that almost all paracetamol had
solubilised.
Lastly, the 60 wt% paracetamol/copovidone sample followed a similar behaviour as the
20% and 40% ones. The key difference is that this concentration was well above the solubility
limit. Consequently, although some decrease in the average image intensity was observed
(Figure 7.14c, purple trace), by the end of the experiment, there was clear evidence of
paracetamol crystals remaining in the sample. For the viscosity plot, it meant that the
starting point was lower and the decay was faster than at the lower paracetamol concentrations
(Figure 7.14b, purple trace). However, the viscosity stabilised at a higher value than for the
40 wt% paracetamol/copovidone disc. This is in agreement with the image intensity results
and is caused by the undissolved solid paracetamol crystals increasing the viscosity of the
sample. Aho et al. made the same observation: paracetamol plasticised copovidone up to the
saturation concentration, after which the remaining solid fraction resulted in an increase in
viscosity expressed by the Krieger-Dougherty equation - undissolved drug acts as an insoluble
filler [174, 72].
It should be taken into consideration that the melting of paracetamol would also result in
the reduction of crystals observed in Rheoscope images as well as a decrease in the viscosity.
However, Figure 7.3 shows that the depression in the melting point experienced by paracetamol
when in contact with copovidone is not below the experimental temperature (140◦C) in the
Rheoscope experiments. The melting point for a 20 wt% paracetamol/copovidone mixture is
158◦C, for 40 wt% it is 160◦C, and for 60 wt% it is 167◦C.
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No significant differences were observed when the samples were sheared at 1 s−1, which is
consistent with the conclusions drawn by Derksen et al. that increasing shear rate had no
significant effect in reducing dissolution time [117]. It should be noted, however, that not
enough experiments were conducted to obtain an accurate dissolution plot by the averaging
of individual experiments.
Although the Rheoscope was highly valuable in order to visualise the dissolution of crystal
particles, providing an insight that is difficult to acquire through another technique, one
of the main disadvantages is that the imaging field of view is very small compared to the
sample size. This results in uneven sampling and noisy data, which makes results difficult to
reproduce.
TGA
TGA testing was performed on paracetamol and paracetamol/copovidone physical mixtures to
ensure there were no signs of sample degradation at the temperatures and time-scales relevant
for the Rheoscope experiments. Medeiros et al. conducted dynamic TGA on paracetamol
and identified two degradation stages, the first with an onset at 188◦C and the second one at
325◦C [229]. The degradation temperature of copovidone reported by the literature is 270◦C
[152].
The thermal analysis performed for this thesis considers temperatures up to 170◦C. Figure
7.15a shows the TGA plot of paracetamol that was held isothermally at 150◦C for 3 h, at
160◦C for 3 h and at 170◦C for 6h. The mass of paracetamol decreased at an increasing but
constant rate (k) for the three temperatures considered, down to approximately 10% of the
original sample mass. These rates were k150◦C = −0.0006 wt%/s, k160◦C = −0.0013 wt%/s
and k170◦C = −0.0031 wt%/s (all with a goodness-of-fit R2 value greater than 0.998). The
fact that the decrease in mass was gradual, instead of rapid, indicates that it is not due to
degradation. Degradation of paracetamol was observed as a decrease from 100% to 3% weight
in under 10 minutes in TGA experiments [230]. An explanation was found in an article by
Leyk et al., that visualized the sublimation of paracetamol with hot-stage microscopy at
150◦C [220]. It should be noted that these sublimation rates would be significantly lower in
NMR experiments since the sample size was large (∼100 mg) and only a small surface (5
mm diameter tube) was available for sublimation, unlike in the large surface-to-volume ratio
available in open TGA pans.
A 50 wt% paracetamol/copovidone physical mix was subjected to a very similar ther-
mal cycle (Figure 7.15b) and the resulting thermogram exhibited characteristics analo-
gous to that of paracetamol. In the same way, mass loss constant rates were obtained:
k140◦C = −0.0002 wt%/s, k150◦C = −0.0005 wt%/s, k160◦C = −0.0008 wt%/s and k170◦C =
−0.0010 wt%/s (all with a R2 value greater than 0.996), but this time the rate constants and
the extent of the mass loss were not as large. This is because paracetamol is subliming, but
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copovidone, which accounts for 50% of the sample mass, is not. Furthermore, sublimation
would be hindered by paracetamol/copovidone interactions, implied by the positive shifts in
Tg compared to the predicted values observed in DSC experiments (Figure 7.9 section 7.4.1).
Fig. 7.15 High temperature characterisation of paracetamol using TGA on (a) a paracetamol
sample held isothermally at 150◦C and 160◦C for 180 min and at 170◦C for 360 min; (b) a
50 wt% physical mix held isothermally at 140◦C, 150◦C, 160◦C and 170◦C for 180 min; and
a 30 wt% physical mix held isothermally at c) 160◦C for 720 min and (d) 170◦C for 720 min.
Figure 7.15c and d are isothermal TGA plots of 30 wt% paracetamol/copovidone physical
mixtures held for 12 h at 160◦C and 170◦C, respectively. At such long experimental times, the
mass loss gradient was no longer constant. This is because towards the end of the experiment,
there is almost no paracetamol left, as most has sublimed and the left over paracetamol
molecules are the ones attached strongest to copovidone. The fast mass decrease of about
4% at the onset of both experiments is due to the moisture in copovidone evaporating, which
is why it is also observable in Figure 7.15b, but not in Figure 7.15a. The key findings are
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that there is no indication of degradation in any of the samples even when subjected for 12 h
at 170◦C; and that no significant loss of paracetamol is expected under the test conditions
(due to the relatively large sample size and small exposed surface areas).
7.5 Conclusion
This chapter has explored different methods and models to predict drug/polymer behaviour
relevant to the formation of ASDs. In the first section, drug solubility and miscibility
was calculated using Flory-Huggins lattice theory, following the melting point depression
approach and solubility parameters to determine the interaction parameter χ. As a result,
a temperature-composition phase diagram was constructed with three curves: solubility,
miscibility and Tg, outlining the boundaries of the stable, metastable and unstable regions of
drug/polymer composition as a function of temperature, respectively. It should be noted
that this simple model does not account for all the complexities of a system. Paudel et al.
noticed that that the FH thermodynamic model does not take into account the effect of
polymer chain length on interaction and miscibility and that the solid solubility of drug in
polymer is affected by parameters other than temperature, such as moisture content [231].
Nevertheless, the results from this chapter were in agreement with an experimentally obtained
solubility curve of paracetamol in copovidone. Therefore phase diagrams are a fast and easy
method to better understand drug/polymer stable and metastable compositions and they
can be employed to make informed hypotheses of successful ASD systems and processing
temperatures.
Additionally, a simple model was presented for the simulation of the dissolution of a solid
drug particle in a polymer melt in a static medium. The parameters obtained in this and
previous chapters were used as inputs to the model and a number of simulations were ran
at varying, diffusion coefficients, initial drug particle radius and solubility. As expected, a
positive correlation was observed between time to complete dissolution and particle radius;
and there was an inverse correlation with diffusion coefficient and solubility. More importantly,
the results were in the same order of magnitude as the experimental dissolution studies.
The predicted time to dissolution was longer than the empirical one and several reasons
were presented as to why this might be: (i) inaccuracy of the calculated solubility value; (ii)
irregular shape of the real drug particle rather than spherical, resulting in larger surface area
available for dissolution; and (iii) concentration dependence of the diffusion coefficient.
Innovative experimental dissolution studies, both under static and shearing conditions
were conducted on a rheometer with an integrated microscopy module that permitted the
visualisation of particles as they underwent dissolution. To facilitate analysis, images were
acquired under polarised light and high contrast, and viscosity measurements were recorded
simultaneously. Samples at drug loadings between 0 − 60 wt% were examined under shearing
stresses at 140◦C. Interesting observations included that: (i) the initial sample viscosity
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dropped as paracetamol dissolved in and plasticised copovidone; and (ii) the steady state
viscosity value decreased with increasing paracetamol content for the 0, 5 20 and 40% drug
loadings, but slightly increased at 60% as undissolved particles acted as a filler. Reassuringly,
these findings correlated with the observations from image analysis plots. Additionally, no
significant differences were observed for examples conducted at 0.1 s−1 and 1 s−1, consistent
with findings from [117].
Chapter 8
Summary of conclusions and
proposed future work
The conclusions drawn from the experimental and numerical work performed for this thesis
are presented in a chapter by chapter basis. This section will summarise and discuss those
conclusions and explore the scope for future work.
Chapter 3 reported the first direct, non-invasive measurements of API diffusion in
paracetamol/copovidone polymer melts at temperatures relevant to HME processes (150-
170◦C). The diffusivity results for hot melt extruded paracetamol/copovidone samples
indicate, for a fixed temperature, that the diffusion of paracetamol is greatly influenced by
the copovidone polymer and that increasing the amount of drug up to 30 wt% caused only
a minor increase in drug diffusivity due to increased plasticisation of the polymer by the
API. However, a sudden increase in the drug diffusivity was observed when the concentration
of API in polymer approached the solubility limit (c.a. 40 wt%) indicating the presence of
small drug-rich, phase-separated domains exhibiting faster diffusion coefficients. The novelty
of measuring the diffusion coefficients of drug molecules in polymer melts in the absence of a
liquid solvent is a critical advancement in the understanding of HME systems. The diffusion
coefficient is a molecular parameter that underpins highly relevant processes such as mass
transport and dissolution. This chapter explored the diffusivity of paracetamol, which is
a very small molecule. It would be of interest to reproduce these experiments with more
realistic and complex API/polymer systems. In this case, there are two possible issues that
should be considered:
(i) Larger molecules will possibly exhibit lower diffusion coefficients than the ones measured
in this work. However, the diffusivities measured were close to the limit of detection
for the equipment used (capable of producing 1,200 G/cm magnetic field gradient).
Therefore, stronger gradient sets should be in place for the characterisation of larger
molecules.
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(ii) More sophisticated drugs and polymers could result in ambiguous NMR spectra, where
there are no peaks that can be unequivocally assigned to the drug and the spectrum
is too complex to deconvolute. In this case, it might be useful to consider the use of
multinuclear NMR. Fluorine, for example, is a nucleus common in drug molecules, but
not in polymers.
Chapter 3 also examined the relationship between diffusion coefficient and viscosity.
It was shown that the Stokes-Einstein model was not applicable to the variable (high)
temperature PFG-NMR diffusivity data because of the smaller size of the solute (paracetamol
molecule) than the solvent (copovidone polymer chain) and because of the large solute volume
fraction and drug-polymer interactions, which hinder Brownian diffusion. Alternatively, good
correlation was found with the Arrhenius model. The activation energy (and hence barrier
to hop diffusion) extracted from the temperature dependence of the diffusion data can be
interpreted as the energy needed to overcome drug-drug and drug-polymer interactions to
allow diffusion. Future steps would investigate whether a straightforward measurement of
the diffusion coefficient at a range of temperatures could be exploited through the Arrhenius
model and become a novel approach to probe the strength of drug-polymer interactions at
high temperature.
In Chapter 4, CP-MAS 13C spectra of paracetamol/copovidone physical mixtures and
extrudates were analysed by looking at two characteristics:
(i) The line-width of the paracetamol peaks were indicative of whether it was in a crystalline
(sharp resonances) or amorphous (broad resonances) state. All HME formulations (20,
30 and 40 wt% drug loading) revealed the presence of amorphous paracetamol.
(ii) Changes in the chemical shift of peaks in the extrudate sample when compared to the
physical mixture provided an insight into the intermolecular associations between the
drug and the polymer promoted by the HME process. In this case, and as was observed
in Chapter 5 as well as in the literature, the carbonyl in the VP monomer of copovidone
was identified as having engaged in a hydrogen bond with the phenol in paracetamol.
The presence of drug-polymer interactions was also corroborated by DSC experiments, as
the predicted Tg (by the Gordon-Taylor equation) was below the experimentally obtained
values. The rationale behind this is that drug molecules attached to the polymer chains
increase the effective molecular weight and volume and thus hinder mobility. The existence
of these interactions further supports the findings in chapter 3 regarding the invalidity of the
Stokes-Einstein diffusion prediction applied to the paracetamol/copovidone system.
1H relaxometry data obtained via 13C revealed no phase separation in any of the extrudates
analysed, which, together with the evidence of amorphisation discussed in the previous
paragraph, confirms that a successful ASD was formed upon processing via HME. This was
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not the case, however, for the physical mixture that was exposed to 170◦C (same as the
HME processing temperature). This sample exhibited both some degree of phase separation
and the presence of crystalline as well as amorphous paracetamol. This is indicative of
recrystallisation, likely as there was no active mixing to promote drug dispersion and enough
of drug-polymer interactions to stabilise the formulation. It is not surprising that active
mixing is required to yield a homogeneous preparation, since the passive mass transport rate
(diffusion coefficient) of paracetamol in copovidone melts measured in Chapter 3 is very slow.
This conclusion is of particular importance because it highlights the requirement for HME
processing to obtain ASDs, as just processing at high temperatures is not enough to produce
adequate pharmaceutical products.
The work presented in this chapter could have been extended by characterising extrudates
containing drug loadings higher than 40 wt% and at a range of processing temperatures. This
could have provided further understanding on the solubility of paracetamol in copovidone
at different temperatures as well as the stability of the formulation once it was cooled and
stored at room temperature. It would serve as a benchmark for the solubility and miscibility
predictions and the phase diagram discussed in Chapter 7.
Chapter 5 examined intermolecular associations in paracetamol/copovidone HME formu-
lations employing a range of solid-state and molten-state 2D NMR techniques. Drug-polymer
interactions are of interest because they have been determined to play an important role in the
physical stabilisation of ASD products by preventing phase separation, recrystallisation and
enhancing dissolution rate as well as solubility. 13C-1H HETCOR (heteronuclear correlation)
solid-state experiments were performed in the UK 850 MHz Facility (University of Warwick,
Coventry). Using the 850 MHz magnet made it possible to obtain enough resolution in the 1H
spectrum to identify three proton environments for paracetamol and two for copovidone. In
the widely available 400 MHz magnets, only one proton resonance is resolved for either of the
species. Results from the HETCOR acquisitions at a range of contact times revealed unam-
biguous correlations between paracetamol’s aromatic ring protons and copovidone’s aliphatic
chain carbons. In agreement with the literature, these were assigned to Van der Waals
interactions. Furthermore the increasing signal intensity and number of cross-peaks at longer
contact times were evidence of the presence of intermolecular through-space interactions
between a high proportion of paracetamol and copovidone molecules.
1H-1H solid-state experiments (NOESY and MQC BABA), were not only performed at high
field (850 MHz), but also at fast spinning rates (60 kHz), which resulted in further enhancement
in the 1H resolution such that five paracetamol peaks were resolvable. These advanced
experimental conditions allowed the assignment of cross-peaks to specific paracetamol protons.
In agreement with HETCOR results, paracetamol aromatic and copovidone aliphatic chain
proton coupling via Van der Waals interactions were identified. Additionally paracetamol’s
hydroxyl proton displayed a cross-peak with copovidone aliphatic groups. These were most
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likely a result of H-bonding, but lack of resolution in copovidone’s 1H spectrum, prevented
from making unambiguous assignments.
In this chapter molten-state 2D NMR 1H-1H COSY experiments were, to the extent of my
knowledge, performed for the first time. The main advantage of molten-state NMR is that the
spectral resolution is significantly increased due to averaging out of anisotropic contributions.
In this case, the 1H spectrum of copovidone was enhanced from two distinct resonances in the
high-field fast-MAS solid-state to five resolvable peaks in the molten-state. Results from the
COSY experiments corroborated the observations from solid-state HETCOR, NOESY and
MQC BABA in regards to the presence of Van der Waals interaction and H-bonds between
paracetamol and copovidone. However, in the molten-state it was possible to assign the
H-bond to paracetamol’s hydroxyl proton and copovidone’s PVP monomer carbonyl oxygen.
To ensure that the cross-peaks in the COSY spectra were in fact so, and not noise or artifacts,
several spin-echo delays were introduced. The longer the delay, the more attenuated the
cross-peaks identified as paracetamol-copovidone interactions appeared. The explanation for
this is that rigid bonds (reduced mobility) lower the T2 relaxation constant of the protons
involved, such that their signal is lost at longer spin-echo delays.
Paracetamol/copovidone has been a good model system with which to develop the NMR
techniques presented in this chapter. However, to validate them further, it would be of interest
to apply them to more industrially relevant compounds, such as the nifedipine/copovidone
system used in Chapter 6.
In Chapter 6, alternative formulations to paracetamol/copovidone were characterised
employing the analytical techniques presented in Chapters 3 and 4. These alternative formu-
lations included two different polymers (PVP and PVA), a more industrially relevant drug
for HME (nifedipine) and ten samples from a paracetamol/copovidone design of experiments
run to study the effect of processing parameters (temperature, screw speed, drug loading and
copovidone commercial brand).
Copovidone, PVP and PVA were compared and the results indicated that:
(i) Due to PVA’s low Tg, paracetamol/PVA formulations would be easy to extrude and it
would be likely that processing below paracetamol’s melting point should be viable,
reducing risk of thermal degradation and lowering costs. However a very low Tg, that is
barely above room temperature, is not an advantageous characteristic, since above the
glass transition molecular mobility significantly increases. This, combined with the lack
of H-bonding capabilities of PVA, greatly reduces physical stabilisation and prevention
of drug recrystallisation.
(ii) On the other hand, PVP has a high Tg, but strong H-bonding capability. PVP would
perform better in physically stabilising the amorphous drug, but it is also highly
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hygroscopic. Increased moisture content is associated with increased likelihood of phase
separation and recrystallisation.
(iii) Copovidone, which is made up of a mixture of the monomers that constitute PVA and
PVP, presents a good compromise on polymer characteristics in terms of Tg, H-bonding
capabilities, hygroscopicity, physical stability and drug solubility.
Nifedipine is a more industrially relevant compound for HME because it suffers from
low water solubility. It is also a larger and more complex molecule than paracetamol.
The NMR and complementary techniques developed in Chapters 3 and 4 were used on
nifedipine/copovidone systems. Due to its larger molecular volume and higher molecular
weight than paracetamol, the diffusion coefficients measured in the polymer melt were almost
an order of magnitude slower. The slow diffusion restricted the quality of the measurements,
particularly at lower drug loadings. Future work should consider using stronger magnetic
field gradients to determine the diffusivity at a range of drug loadings and temperatures, as
well as for alternative drug candidates for HME processing. Solid-state 13C spectroscopy
of nifedipine/copovidone extrudates determined that nifedipine was amorphous in 20 wt%
and 40 wt% samples, however relaxometry experiments revealed a small degree of phase
separation. This was probably due to weaker drug-polymer interactions and perhaps lack of
miscibility. For scenarios like this one, the modelling and predictions presented in Chapter 7
are valuable to assess whether the API and polymer combination selected for processing are
likely to produce ASDs.
In Chapter 6, paracetamol/copovidone extruded samples from a design of experiments
(DOE) run were studied. They were prepared at different conditions to analyse the effect of
process parameters on several formulation characteristics. The variables considered included
polymer commercial brand, processing temperature and screw speed, and drug loading. Key
findings were:
(i) In diffusometry experiments, only the drug loading variable resulted in a perceptible
difference in the measured diffusion coefficient of paracetamol. The 20 wt% formulation
exhibited slower diffusivities than the 30 wt% ones, consistent with the observations
from chapter 3.
(ii) 13C spectroscopy and DSC revealed that paracetamol was in an amorphous state in
all samples. Interestingly, this included the 20 wt% and 30 wt% samples processed at
140◦C, well below the melting point.
(iii) Similarly as in (ii), solid-state 1H relaxometry indicated that there was no phase
separation in any of the samples.
These results are relevant because in chapter 3, it was suggested that extrusion at
temperatures lower than the melting point would be advantageous with regards to the
168 Summary of conclusions and proposed future work
viscosity of the system. However, the question stood whether lower temperatures would
yield amorphous and homogeneous products. The experiments presented in chapter 6 show
that at processing temperatures as low as 140◦C, satisfactory extrudates were obtained
for 20 and 30% drug loaded systems. Future work could be conducted to expand on the
DOE study, particularly to produce extruded samples at higher drug loadings and lower
temperatures, and use solid-state NMR spectroscopy and relaxometry to determine where the
temperature-composition limits of the system are and validate the phase diagram presented in
chapter 7. The DOE study could also be extended to include a more relevant drug candidate
for HME processing. The key advantages of processing at lower temperatures are the lower
heating costs and the reduced risk of thermal degradation.
In Chapter 7 paracetamol solubility and miscibility in copovidone were calculated using
the Flory-Huggins lattice theory. A phase diagram was presented, which outlined the bound-
aries of the stable, metastable and unstable temperature-composition formulations. Although
calculations for the phase diagram represent a simplified view of the system, it is a valuable
resource to determine whether a specific system is likely to produce desirable extruded prod-
ucts. The work presented in this section could have been extended to experimentally validate
the phase diagram for the paracetamol/copovidone system. This would have been done by
extruding at different temperature and composition combinations, particularly those close to
the curves in the phase diagram. Scope for future work could also involve the construction of
a phase diagram for a more relevant HME system, such as nifedipine/copovidone, as was
presented in Chapter 6.
Chapter 7 also explored mathematical models for prediction and simulation of drug/polymer
system behaviour relevant to the formation of ASDs. A simple static dissolution model for
a spherical drug particle in a polymer melt was presented. The model was populated with
the measured and calculated values obtained in this and previous chapters for the diffusion
coefficient and solubility. Interestingly, the results were of the same order of magnitude as
the dissolution studies performed on the Rheoscope. The predicted time to dissolution was
longer than the empirical one and this may be due to:
(i) Inaccuracies in the calculated solubility value of paracetamol in copovidone.
(ii) The irregular shape of the paracetamol crystal rather than the spherical modelled one,
resulting in a larger available area for dissolution.
(iii) The solute concentration dependence of the diffusion coefficient.
Furthermore, the experiments conducted on the Rheoscope to visualise dissolution and
measure viscosity revealed that:
(i) The initial drop in the viscosity of the sample correlated with paracetamol crystals
dissolving in and plasticising copovidone
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(ii) The steady state viscosity value decreased with paracetamol content for the 0−40 wt%
drug loadings, but slightly increased for the 60 wt% sample, as undissolved particles
acted as a filler. This agreed with the phase diagram presented in this chapter in that
60 wt% is above the solubility limit for the paracetamol/copovidone system at 140◦C.
(iii) No significant differences were observed for the two considered shear rates: 0.1 s−1 and
1 s−1.
This work did not consider shear rates larger than 1 s−1, because the images captured
were too blurry for analysis. Future work could study whether higher shear rates have an
effect on the dissolution rate employing strobe illumination to yield sharp images. Strobe
illumination consists on pulsing the light source for a short period of time, which results in
the “freezing” of a fast moving object for image capturing purposes.
Several attempts were made at running the simulations proposed by Derksen, et al. using
the parameters calculated in this thesis [117]. Unfortunately they failed to complete and
there were several reasons for this:
(i) The Peclet and Schmidt numbers that resulted from the parameter values proposed in
this thesis fell outside the benchmarked range in Derksen’s work.
(ii) The low diffusion coefficient meant that the change in the state of the system between
time steps was so small that numerical noise was prominent, which caused the simulations
to fail.
(iii) The system appears to be highly diffusion-limited, which questions whether applying
such a detailed model as the one presented by Derksen is reasonable.
A more recent model proposed by Schittny et al. is based on two large-scale variables: time
to dissolution and the average residence time of the material in the extruder [118]. Schittny
et al. took into account specific process parameters for HME such as extruder sections
(powder transport, melt transport and pressurised flow) and screw geometry. Schittny’s
model assumes that drug dissolution is mainly diffusion-controlled due to the low diffusion
coefficients and high viscosity of the polymer melt; however, in their publication, diffusion
coefficients were estimated by molecular dynamics, which is a complex and computationally
intensive method. There is scope to extend the simulation work presented in chapter 7 of this
thesis to consider a model similar to Schittny’s, which is less detailed than the one discussed
in chapter 7 (by Derksen), together with the experimentally obtained values for diffusion
coefficient and time to dissolution as an approach to simulate the hot-melt extrusion process.

References
[1] Li Di, Edward H Kerns, and Guy T Carter. Drug-like property concepts in pharmaceu-
tical design. Current Pharmaceutical Design, 15(19):2184–94, 2009.
[2] Christian Leuner and Jennifer Dressman. Improving drug solubility for oral delivery
using solid dispersions. European Journal of Pharmaceutics and Biopharmaceutics,
50(1):47–60, 2000.
[3] Ketan T. Savjani, Anuradha K. Gajjar, and Jignasa K. Savjani. Drug solubility:
Importance and enhancement techniques. ISRN Pharmaceutics, 2012:1–10, 2012.
[4] H. D. Williams, N. L. Trevaskis, S. A. Charman, R. M. Shanker, W. N. Charman, C. W.
Pouton, and C. J. H. Porter. Strategies to address low drug solubility in discovery and
development. Pharmacological Reviews, 65(1):315–499, 2013.
[5] Abu T.M. Serajuddin. Solid dispersion of poorly water-soluble drugs: Early promises,
subsequent problems, and recent breakthroughs. Journal of Pharmaceutical Sciences,
88(10):1058–1066, oct 1999.
[6] Teófilo Vasconcelos, Bruno Sarmento, and Paulo Costa. Solid dispersions as strategy
to improve oral bioavailability of poor water soluble drugs. Drug Discovery Today,
12:1068–1075, dec 2007.
[7] Feng Qian, Jun Huang, and Munir A. Hussain. Drug–polymer solubility and misci-
bility: Stability consideration and practical challenges in amorphous solid dispersion
development. Journal of Pharmaceutical Sciences, 99(7):2941–2947, jul 2010.
[8] Duncan Q.M M Craig. The mechanisms of drug release from solid dispersions in
water-soluble polymers. International Journal of Pharmaceutics, 231(2):131–144, 2002.
[9] S.B. Murdande, M.J. Pikal, R.M. Shanker, and R.H. Bogner. Solubility advantage of
amorphous pharmaceuticals: I. A thermodynamic analysis. Journal of Pharmaceutical
Sciences, 99(3):1254–1264, 2010.
[10] Gordon L. Amidon, Hans Lennernäs, Vinod P. Shah, and John R. Crison. A theoretical
basis for a biopharmaceutic drug classification: The correlation of in vitro drug product
dissolution and in vivo bioavailability. Pharmaceutical Research: An Official Journal
of the American Association of Pharmaceutical Scientists, 12(3):413–420, 1995.
[11] Mark G Papich and Marilyn N Martinez. Applying biopharmaceutical classification
system (BCS) criteria to predict oral absorption of drugs in dogs: Challenges and
pitfalls. Americal Association of Pharmaceutical Scientists, 17(4):948–964, 2015.
[12] Council of Europe. European pharmacopoeia - Dissolution test for solid dosage forms.
In European Pharmacopoeia, chapter 2.9.3, pages 228–230. EDQM, 5th edition, 2005.
172 References
[13] Keiji Sekiguchi and Noboru Obi. Studies on absorption of eutectic mixture. I. A
comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary
sulfathiazole in man. Chemical Pharmaceutical Bulletin, 9:866–872, 1961.
[14] Win Loung Chiou and Sidney Riegelman. Preparation and dissolution characteristics
of several fast-release solid dispersions of Griseofulvin. Journal of Pharmaceutical
Sciences, 58(12):1505–1510, dec 1969.
[15] Eman A. Ashour, Soumyajit Majumdar, Abdulla Alsheteli, Sultan Alshehri, Bader
Alsulays, Xin Feng, Andreas Gryczke, Karl Kolter, Nigel Langley, and Michael A.
Repka. Hot melt extrusion as an approach to improve solubility, permeability and
oral absorption of a psychoactive natural product, piperine. Journal of Pharmacy and
Pharmacology, 68:989–998, 2016.
[16] Nicole Wyttenbach and Martin Kuentz. Glass-forming ability of compounds in marketed
amorphous drug products. European Journal of Pharmaceutics and Biopharmaceutics,
112:204–208, 2017.
[17] Arthur A. Noyes and Willis R Whitney. The rate of solution of solid substances in
their own solutions. Journal of the American Chemical Society, 19(12):930–934, 1897.
[18] Aristides Dokoumetzidis and Panos Macheras. A century of dissolution research: From
Noyes and Whitney to the Biopharmaceutics Classification System. International
Journal of Pharmaceutics, 321(1-2):1–11, 2006.
[19] Boris Shekunov and Eda Ross Montgomery. Theoretical analysis of drug dissolution: I.
Solubility and intrinsic dissolution rate. Journal of Pharmaceutical Sciences, 105(9):2685–
2697, 2016.
[20] VG Levich. Physicochemical hydrodynamics. Prentice-Hall, (Englewood Cliffs, NY),
1962.
[21] Hemlata Patil, Roshan V. Tiwari, and Michael A. Repka. Hot-melt extrusion: From
theory to application in pharmaceutical formulation. AAPS PharmSciTech, 17(1):20–42,
2016.
[22] Abhishek Singh and Guy Van den Mooter. Spray drying formulation of amorphous
solid dispersions. Advanced Drug Delivery Reviews, 100:27–50, 2015.
[23] Bhavesh B. Patel, Jayvadan K. Patel, Subhashis Chakraborty, and Dali Shukla. Reveal-
ing facts behind spray dried solid dispersion technology used for solubility enhancement.
Saudi Pharmaceutical Journal, 23(4):352–365, 2015.
[24] Catherine Potter, Yiwei Tian, Gavin Walker, Colin McCoy, Peter Hornsby, Conor
Donnelly, David S. Jones, and Gavin P. Andrews. Novel supercritical carbon dioxide
impregnation technique for the production of amorphous solid drug dispersions: A
comparison to hot melt extrusion. Molecular Pharmaceutics, 12(5):1377–1390, 2015.
[25] Osama Mahmah, Rami Tabbakh, Adrian Kelly, and Anant Paradkar. A comparative
study of the effect of spray drying and hot-melt extrusion on the properties of amor-
phous solid dispersions containing felodipine. Journal of Pharmacy and Pharmacology,
66(2):275–284, 2014.
References 173
[26] Michal Beneš, Tomáš Pekárek, Josef Beránek, Jaroslav Havlíček, Lukáš Krejčík, Michal
Šimek, Marcela Tkadlecová, and Pavel Doležal. Methods for the preparation of
amorphous solid dispersions - A comparative study. Journal of Drug Delivery Science
and Technology, 38:125–134, 2017.
[27] Sanjay Verma and Varma S. Rudraraju. A systematic approach to design and prepare
solid dispersions of poorly water-soluble drug. AAPS PharmSciTech, 15(3):641–657,
2014.
[28] Shrawan Baghel, Helen Cathcart, and Niall J. O’Reilly. Polymeric amorphous solid
dispersions: A review of amorphization, cystallization, stabilization, solid-state charac-
terization, and aqueous solubilization of biopharmaceutical classification system Class
II drugs. Journal of Pharmaceutical Sciences, 105(9):2527–2544, 2016.
[29] Manfred Gordon and James S. Taylor. Ideal copolymers and the second-order transitions
of synthetic rubbers. i. Non-crystalline copolymers. Journal of Applied Chemistry,
2(9):493–500, may 1952.
[30] Robert Simha and R. F. Boyer. On a general relation involving the glass temperature
and coefficients of expansion of polymers. The Journal of Chemical Physics, 37(5):1003–
1007, 1962.
[31] Ioannis M. Kalogeras. A novel approach for analyzing glass-transition temperature vs.
composition patterns: Application to pharmaceutical compound + polymer systems.
European Journal of Pharmaceutical Sciences, 42(5):470–483, 2011.
[32] Yongcheng Li, Huishi Pang, Zhefei Guo, Ling Lin, Yixuan Dong, Ge Li, Ming Lu,
and Chuangbin Wu. Interactions between drugs and polymers influencing hot melt
extrusion. Journal of Pharmacy and Pharmacology, 66(2):148–166, 2014.
[33] Khushboo Kothari, Vishard Ragoonanan, and Raj Suryanarayanan. The role of
drug–polymer hydrogen bonding interactions on the molecular mobility and physical
stability of nifedipine solid dispersions. Molecular Pharmaceutics, 12(1):162–170, jan
2015.
[34] Jared A. Baird, Bernard Van Eerdenbrugh, and Lynne S. Taylor. A classification
system to assess the crystallization tendency of organic molecules from undercooled
melts. Journal of Pharmaceutical Sciences, 99(9):3787–3806, 2010.
[35] Krishna Bansal, Uttam Singh Baghel, and Seema Thakral. Construction and validation
of binary phase diagram for amorphous solid dispersion using Flory–Huggins theory.
AAPS PharmSciTech, 17(2):318–327, 2016.
[36] Esther S. Bochmann, Dirk Neumann, Andreas Gryczke, and Karl G. Wagner. Micro-
scale prediction method for API-solubility in polymeric matrices and process model
for forming amorphous solid dispersion by hot-melt extrusion. European Journal of
Pharmaceutics and Biopharmaceutics, 107:40–48, 2016.
[37] Christian Luebbert, Fabian Huxoll, Gabriele Sadowski, Guy Van Den Mooter, and Hol-
ger Grohganz. Amorphous-amorphous phase separation in API/polymer formulations.
Molecules, 22(296):1–17, 2017.
[38] Malte Bille Rask, Matthias Manne Knopp, Niels Erik Olesen, René Holm, and Thomas
Rades. Comparison of two DSC-based methods to predict drug-polymer solubility.
International Journal of Pharmaceutics, 540(1-2):98–105, 2018.
174 References
[39] Yiwei Tian, Jonathan Booth, Elizabeth Meehan, David S. Jones, Shu Li, and Gavin P.
Andrews. Construction of drug-polymer thermodynamic phase diagrams using flory-
huggins interaction theory: Identifying the relevance of temperature and drug weight
fraction to phase separation within solid dispersions. Molecular Pharmaceutics,
10(1):236–248, 2013.
[40] Fan Meng, Vivek Dave, and Harsh Chauhan. Qualitative and quantitative methods
to determine miscibility in amorphous drug-polymer systems. European Journal of
Pharmaceutical Sciences, 77:106–111, 2015.
[41] M. K. Cheung, J. Wang, S. Zheng, and Y. Mi. Miscibility of
poly(epichlorohydrin)/poly(vinyl acetate) blends investigated with high-resolution
solid-state 13C NMR. Polymer, 41(4):1469–1474, 2000.
[42] Charles M Hansen. The three dimensional solubility parameter and solvent diffusion
coefficient. Their importance in surface coating formulation. J. Paint Technology, page
104, 1967.
[43] Ritesh Fule, Vivek Paithankar, and Purnima Amin. Hot melt extrusion based solid
solution approach: Exploring polymer comparison, physicochemical characterization
and in-vivo evaluation. International Journal of Pharmaceutics, 499(1-2):280–294, 2016.
[44] Paul J. Flory. Thermodynamics of high polymer solutions. The Journal of Chemical
Physics, 9:660–661, aug 1941.
[45] Maurice L. Huggins. Solutions of long chain compounds. The Journal of Chemical
Physics, 9:440, 1941.
[46] A. Newman, D. Engers, S. Bates, I. Ivanisevic, R. C. Kelly, and G. Zografi. Characteri-
zation of amorphous API:polymer mixtures using X-ray powder diffraction. Journal of
Pharmaceutical Sciences, 97(11):4840–4856, 2008.
[47] X Yuan, D Sperger, and E J Munson. Investigating miscibility and molecular mobility
of nifedipine-PVP amorphous solid dispersions using solid-state NMR spectroscopy.
Molecular Pharmaceutics, 11:329–337, 2014.
[48] Julie L. Calahan, Stephanie C. Azali, Eric J. Munson, and Karthik Nagapudi. Inves-
tigation of phase mixing in amorphous solid dispersions of AMG 517 in HPMC-AS
using DSC, solid-state NMR, and solution calorimetry. Molecular Pharmaceutics,
12(11):4115–4123, 2015.
[49] M. Maniruzzaman, M. M. Rana, J. S. Boateng, J. C. Mitchell, and D. Douroumis.
Dissolution enhancement of poorly water-soluble APIs processed by hot-melt extrusion
using hydrophilic polymers. Drug Development and Industrial Pharmacy, 2012:1–10,
2012.
[50] Dana E. Moseson, Naila A. Mugheirbi, Andrew A. Stewart, and Lynne S. Taylor.
Nanometer-Scale Residual Crystals in a Hot Melt Extruded Amorphous Solid Dispersion:
Characterization by Transmission Electron Microscopy. Crystal Growth and Design,
18(12):7633–7640, 2018.
[51] Yuejun Song, Lianyan Wang, Ping Yang, Robert M. Wenslow, Bo Tan, Hailu Zhang,
and Zongwu Deng. Physicochemical characterization of Felodipine-Kollidon VA64
amorphous solid dispersions prepared by hot-melt extrusion. Journal of Pharmaceutical
Sciences, 102(6):1915–1923, 2013.
References 175
[52] Francesco Tres, Steven R Coombes, Andrew R Phillips, Leslie P Hughes, Stephen
A C Wren, Jonathan W Aylott, and Jonathan C Burley. Investigating the dissolution
performance of amorphous solid dispersions using magnetic resonance imaging and
proton NMR. Molecules, 20:16404–16418, 2015.
[53] Shrawan Baghel, Helen Cathcart, and Niall J. O’Reilly. Understanding the generation
and maintenance of supersaturation during the dissolution of amorphous solid disper-
sions using modulated DSC and 1H NMR. International Journal of Pharmaceutics,
536(1):414–425, jan 2018.
[54] J. S. Papanu, D. S. Soane (Soong), A. T. Bell, and D. W. Hess. Transport models for
swelling and dissolution of thin polymer films. Journal of Applied Polymer Science,
38(5):859–885, 1989.
[55] Nikolaos A. Peppas, J. C. Wu, and Ernst D. von Meerwall. Mathematical modeling
and experimental characterization of polymer dissolution. Macromolecules, 27(20):5626–
5638, 1994.
[56] I. Devotta, V. D. Ambeskar, A. B. Mandhare, and R. A. Mashelkar. The life time of a
dissolving polymeric particle. Chemical Engineering Science, 49(5):645–654, 1994.
[57] A. C. Ouano and J. A. Carothers. Dissolution dynamics of some polymers: Solvent-
polymer boundaries. Polymer Engineering and Science, 20(2):160–166, jan 1980.
[58] P. D. Krasicky, R. J. Groele, and F. Rodriguez. Measuring and modelling the transition
layer during the dissolution of glassy polymer films. Journal of Applied Polymer Science,
35(3):641–651, feb 1988.
[59] I. Devotta, M. V. Badiger, P. R. Rajamohanan, S. Ganapathy, and R. A. Mashelkar.
Unusual retardation and enhancement in polymer dissolution: Role of disengagement
dynamics. Chemical Engineering Science, 50(16):2557–2569, aug 1995.
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A.1 T1 and T2 temperature dependence of samples
Table A.1 T 1 and T 2 temperature dependence of paracetamol, copovidone and a 30 wt%
physical mix acquired with the inversion recovery and CPMG sequences, respectively (Figure
2.3 and 2.4). The paracetamol signal at 130◦C and 140◦C from the inversion recovery
experiments was too low for T 1 measurement.
Paracetamol Copovidone 30 wt% physical mix
T1 [s]
130◦C – 4.9±0.1 2.6±0.2
140◦C – 5.1±0.3 2.0±0.2
150◦C 0.3±0.1 4.7±0.1 2.0±0.3
160◦C 0.6±0.1 3.4±0.1 1.7±0.3
170◦C 1.2±0.1 3.0±0.1 1.0±0.1
T2 [ms]
130◦C 17±1.4 1.5±0.2 3.6±0.5
140◦C 43±1.1 0.4±0.1 11±0.6
150◦C 97±1.5 0.3±0.1 37±0.5
160◦C 177±34.1 0.6±0.1 59±0.5
170◦C 435±36.1 1.4±0.2 43±0.2

